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ephrin-B signaling has been reported to modulate these processes, but the molecular mechanisms
remain poorly understood. Our laboratory has previously shown that EphBs organize the formation of
both pre- and postsynaptic specializations, and interact directly with NMDA-type glutamate receptors.
Therefore, I sought to investigate the molecular mechanisms for formation of presynaptic specializations
and the interaction domain between EphBs and NMDA receptors. I found that EphBs can induce the
formation of presynaptic specializations by trans-synaptic interactions with both ephrin-B1 and ephrin-B2.
These ephrin-Bs can then recruit the machinery for neurotransmitter release through the multiple PDZdomain containing adaptor protein syntenin-1. Furthermore, ephrin-B1 and ephrin-B2 act independently
for formation of presynaptic specializations, but together to recruit syntenin-1 to synaptic sites. Based on
this work and that of other laboratories, I was able to define the molecular pathway from postsynaptic
EphBs to presynaptic glutamatergic vesicles. Furthermore, on the postsynaptic side of the synapse, I
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novel molecular mechanism, I show that extracellular phosphorylation of this residue after ephrin-B
binding is sufficient to induce the EphB-NMDAR interaction. Furthermore, I show that in the mature brain,
the EphB-NMDAR interaction preferentially regulates NR2B-subunit containing NMDA receptor
localization, function, and downstream gene transcription. Together, these findings impact our
understanding of synapse formation and function, and highlight the EphB-NMDAR interaction as a
potential target to treat neurological disease.
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ABSTRACT

Molecular mechanisms of pre- and postsynaptic EphB/ephrin-B
signaling in synapse formation and function

Sean Isaac Sheffler-Collins
Matthew B. Dalva

Proper function of the central nervous system relies on precise and coordinated
cell-cell interactions and communication via synaptic transmission to assemble
neuronal networks. Aberrant synaptic transmission is a hallmark of neuronal
disease. The EphB family of receptor tyrosine kinases and their ephrin-B ligands
play critical roles in the central nervous system in axon guidance, formation of
pre- and post-synaptic specializations, localization of glutamate receptors,
synaptic plasticity, and disease. EphB/ephrin-B signaling has been reported to
modulate these processes, but the molecular mechanisms remain poorly
understood.

Our laboratory has previously shown that EphBs organize the

formation of both pre- and postsynaptic specializations, and interact directly with
NMDA-type glutamate receptors.

Therefore, I sought to investigate the

molecular mechanisms for formation of presynaptic specializations and the
interaction domain between EphBs and NMDA receptors. I found that EphBs
can induce the formation of presynaptic specializations by trans-synaptic
iii

interactions with both ephrin-B1 and ephrin-B2. These ephrin-Bs can then recruit
the machinery for neurotransmitter release through the multiple PDZ-domain
containing adaptor protein syntenin-1. Furthermore, ephrin-B1 and ephrin-B2 act
independently for formation of presynaptic specializations, but together to recruit
syntenin-1 to synaptic sites. Based on this work and that of other laboratories, I
was able to define the molecular pathway from postsynaptic EphBs to
presynaptic glutamatergic vesicles. Furthermore, on the postsynaptic side of the
synapse, I define a single amino acid that is necessary and sufficient to mediate
the EphB-NMDAR interaction. In a novel molecular mechanism, I show that
extracellular phosphorylation of this residue after ephrin-B binding is sufficient to
induce the EphB-NMDAR interaction. Furthermore, I show that in the mature
brain, the EphB-NMDAR interaction preferentially regulates NR2B-subunit
containing NMDA receptor localization, function, and downstream gene
transcription.

Together, these findings impact our understanding of synapse

formation and function, and highlight the EphB-NMDAR interaction as a potential
target to treat neurological disease.
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Abstract
Assembly and function of neuronal circuits rely on selective cell-cell interactions
to control axon targeting, generate pre- and postsynaptic specialization, and
recruit neurotransmitter receptors. In neurons, EphB receptor tyrosine kinases
mediate excitatory synaptogenesis early in development, and then later
coordinate synaptic function by controlling NMDAR synaptic localization and
function. EphBs direct synapse formation and function to regulate cellular
morphology through downstream signaling mechanisms and by interacting with
glutamate receptors. In humans, defective EphB-dependent regulation of
NMDAR localization and function is associated with synaptopathies such as
neuropathic pain, anxiety disorders, and Alzheimer’s disease. Here, we propose
that EphBs act as a central organizer of excitatory synapse formation and
function, and as a key regulator of diseases linked to NMDAR dysfunction.
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Introduction
Synapses are the fundamental unit of information flow within the central
nervous system. Early in development there is a period of new synapse addition
followed by synapse maturation (Fu et al., 2011; Shen and Cowan, 2010; Shen
and Scheiffele, 2010; Tallafuss et al., 2010). Formation of excitatory synapses
requires precise coordination between two contacting neurons to organize a
presynaptic terminal capable of neurotransmitter release, and a postsynaptic
specialization equipped with the proper neurotransmitter receptors (Fu et al.,
2011; Jin and Garner, 2008; McMahon and Diaz, 2011; Shen and Scheiffele,
2010; Siddiqui and Craig, 2010; Tallafuss et al., 2010). Maturation of synapses
involves the pruning of inappropriate connections, stabilization of pre- and
postsynaptic

components,

and

formation

of

appropriate

morphological

specializations. Finally, maintenance and plasticity are required at sites of
contact for proper function (Fu et al., 2011; Shen and Scheiffele, 2010). The
improper

formation

and

function

of

synapses

can

have

devastating

consequences for the adult brain. Malformations in synaptic formation and
maturation are implicated in a wide variety of disease including Angelman
syndrome, autism spectrum disorders, neuropathic pain, anxiety disorders, and
Alzheimer’s disease (Mabb et al., 2011; Penzes et al., 2011; Sloniowski and
Ethell, 2011; Sudhof, 2008; van Spronsen and Hoogenraad, 2010) (see Glossary
for definitions).
Excitatory synaptic transmission is mediated by α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA)-type (Bredt and Nicoll, 2003; Kessels
3

and Malinow, 2009) and N-Methyl-d-aspartate (NMDA)-type (Lau and Zukin,
2007; Perez-Otano and Ehlers, 2005) glutamate receptors. AMPARs and
NMDARs are directed to the cell surface and synaptic sites by both neuronal
activity and intermolecular interactions. At synaptic sites, glutamate receptors are
dynamically regulated and changes in the size and number of AMPARs and
NMDARs at synaptic sites are thought to underlie the expression of synaptic
plasticity (Groc et al., 2009; Henley et al., 2011; Kerchner and Nicoll, 2008; Lu
and Roche, 2011; Yashiro and Philpot, 2008). Many of the molecular
mechanisms

governing

glutamate

receptor

trafficking,

retention,

and

maintenance at synaptic sites are well characterized. Especially important are
associations of glutamate receptors with scaffolding proteins such as PSD-95
and GRIP, and with synaptic adhesion molecules such as EphBs, neuroligins,
and ErbBs (McMahon and Diaz, 2011; Siddiqui and Craig, 2010; Tallafuss et al.,
2010). Dynamic glutamate receptor trafficking is not only important for normal
brain function, but deficits in trafficking are associated with diseases including
Alzheimer’s disease, addiction and schizophrenia (Lau and Zukin, 2007; Opazo
and Choquet, 2010).
Numerous cell signaling and adhesion molecules coordinate the
differentiation, morphological changes, and precise organization of proteins
required to generate a functional synapse (Dalva et al., 2007; McMahon and
Diaz, 2011; Shen and Scheiffele, 2010; Siddiqui and Craig, 2010; Tallafuss et al.,
2010). An important member of these multifunctional synaptogenic molecules are
the EphBs (Chen et al., 2011; Klein, 2009; Lai and Ip, 2009; Sloniowski and
4

Ethell, 2011). The EphBs are part of the larger Eph (erythropoietin-producing
hepatocellular carcinoma) family of receptor tyrosine kinases (RTKs), which is
the largest family of RTKs in the human genome. The Eph receptors are divided
into two classes (A and B) by their ability to bind their membrane-attached ephrin
ligands. In mammals there are nine members of the EphA class (A1-A8, A10)
and five members of the EphB class (B1-B4, B6) (Klein, 2009). Ephrin-As (A1A5) are attached by a Glycophosphatidylinositol (GPI) anchor, whereas ephrinBs (B1-B3) contains a short intracellular signaling domain (Egea and Klein,
2007). For the most part, EphAs specifically bind ephrin-A ligands, and EphBs
bind ephrin-B ligands. However, EphA4 has a high binding affinity for ephrin-B
ligands, and EphB2 binds ephrin-A5 (Flanagan and Vanderhaeghen, 1998;
Himanen et al., 2004). Generally, Ephs act to coordinate signaling events that
occur between cells including: axon guidance, synaptogenesis, dendritic filopodia
motility, neural crest cell and stem cell migration, angiogenesis, cell sorting at
compartmental boundaries, bone formation, and synaptic plasticity (Genander
and Frisen, 2010; Klein, 2009; Lai and Ip, 2009; Pasquale, 2008; Suetterlin et al.,
2011).
This review will focus on the role of EphB/ephrin-B signaling mechanisms
that control NMDAR function and localization. We will highlight how EphBdependent misregulation of NMDARs contributes to synaptic diseases such as
neuropathic pain, anxiety disorders, and Alzheimer’s disease.
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EphBs and Synapse Formation
In vivo and in vitro evidence suggest that there is a rapid phase of
synapse addition early in neuronal development followed by a plateau phase,
and later synaptic loss as contacts begin to mature (Kayser et al., 2008; Papa et
al., 1995; Ziv and Smith, 1996). During the phase of rapid synaptogenesis,
dendrites and axons have motile filopodia that appear to search for contacts.
Different molecules control specific aspects of new synapse accumulation:
SynCAM1 restricts the number of filopodia at axonal growth cones (Stagi et al.,
2010), neuroligin stabilizes dendritic filopodia (Chen et al., 2010), and EphBs
controls dendritic filopodia motility enabling synapse formation (Kayser et al.,
2008). EphB-dependent synapse formation driven by filopodia motility requires
ephrin-B binding, EphB kinase activity, and p21 activated kinase (PAK) (Kayser
et al., 2008). These data are consistent with a model (Figure 1) in which filopodia
find appropriate target axons, and motility subsequently decreases leading to
stabilized synaptic contacts. Next, through transynaptic interactions with ephrinBs, EphBs initiate a program of pre- and postsynaptic maturation through both
extracellular protein-protein interactions and intracellular signaling.
EphBs organize functional presynaptic specializations by binding specific
ephrin-B ligands at sites of contact between dendrites and axons (Kayser et al.,
2006; McClelland et al., 2009). The number of presynaptic specializations is
decreased by knockdown of postsynaptic EphB2 or presynaptic ephrin-B1 or
ephrin-B2 (Ethell et al., 2001; Kayser et al., 2006; McClelland et al., 2009).
Ephrin-B1 and ephrin-B2 organize presynaptic terminals through interactions with
6

presynaptic scaffolding molecules containing PDZ-binding domains. Specifically,
ephrin-Bs recruit the adaptor protein syntenin-1 to new presynaptic sites
(McClelland et al., 2009). Mixed culture assays indicate that the syntenin-1 is
required in contacting axons for EphB-dependent presynaptic specializations
(McClelland et al., 2009). Syntenin-1 could then recruit synaptic vesicles by
interacting with ERC2/CAST1/RM1 (Ko et al., 2006). Together, these results
provide a direct link (Figure 1.1) from postsynaptic EphB through presynaptic
ephrin-B1/2 and syntenin-1 to formation of functional presynaptic specializations.
EphBs regulate maturation of postsynaptic sites by inducing spine
morphogenesis and recruiting neurotransmitter receptors. Consistent with their
importance in these functions, in EphB1−/−, 2−/−, 3−/− triple knockout (TKO) mice
there is a significant reduction in excitatory synapse density (~40% cortex, ~25%
hippocampus) (Henkemeyer et al., 2003; Kayser et al., 2006). The effects of
EphBs on spine development appear similar in cortex and hippocampus. Spine
density and postsynaptic density size are reduced in the hippocampus of EphB
TKO animals (Henkemeyer et al., 2003). Similarly, synapse and spine density
are decreased in the cortex of EphB TKO, but not DKO animals (Kayser et al.,
2006). In the cerebellum it appears that EphBs may act differently because EphB
TKO mice have increased numbers of spines (Cesa et al., 2011). However, these
may be so called “naked” spines that lack presynaptic specializations and are
associated with defective synaptogenesis in the cerebellum (Hendelman and
Aggerwal, 1980). More work will be need to resolve the mechanisms mediating
these differences in EphB function.
7

Changes in spine and synapse density in the cerebral cortex are likely due
to the decreases in dendritic filopodia motility (Kayser et al., 2008). Filopodia
motility is impaired in cortical slices from EphB TKO, but not DKO animals
(Kayser et al., 2008). Interestingly in cultured hippocampal neurons, expression
of any EphB is sufficient to rescue defects in synapse development (Henkemeyer
et al., 2003). This finding suggests that any EphB is sufficient to initiate EphBdependent synaptogenesis. Similarly, re-expression of EphB2 in EphB TKO
slices rescues deficits in synapse density and spine formation (Kayser et al.,
2006). Although EphBs may play redundant functions, individual EphBs appear
to exert their effects on specific circuits or domains of neurons. The pattern of
EphB expression in the hippocampus reflects the possibility of localized function:
EphB2 and EphB3 are expressed in CA1, and EphB2 and EphB1 are expressed
in CA3 (Henderson et al., 2001; Henkemeyer et al., 2003; Liebl et al., 2003). In
the cortex, EphBs appear to preferentially affect dendritic protrusions in basal
dendrites of pyramidal neurons (Kayser et al., 2011). Together, these finding
suggest that in addition to regulating synapse formation, specific EphB family
members may have selective functions in different brain regions.
EphBs control neuronal morphology and motility by modulation of the actin
cytoskeleton. EphBs exert these effects through GTPases such as Rho, Rac1,
and Cdc-42 (Klein, 2009; Sloniowski and Ethell, 2011), by activation of the actinsevering protein cofilin (Shi et al., 2009; Simon et al., 2009), and by the
phosphorylation of the cell surface proteoglycan syndecan-2 (Ethell et al., 2001).
A principle mechanism enabling EphBs to signal to the actin cytoskeleton is by
8

interacting with guanine exchange factors (GEFs), which accelerate the
exchange of GDP for GTP (Klein, 2009; Sloniowski and Ethell, 2011). EphBs
interact directly with GEFs such as Rho/Rac1-GEF Kalirin-7(Penzes et al., 2003),
Rac1-GEF Tiam1 (Tolias et al., 2005; Tolias et al., 2007), and with Rho-GEF
intersectin-1 through the adaptor protein Numb (Irie and Yamaguchi, 2002;
Nishimura et al., 2006) recruiting these proteins to synapses and spines. In
addition to their interaction with EphBs, intersectin-1 and Tiam1 can associate
directly with NMDARs at synaptic sites to modulate receptor function (Irie and
Yamaguchi, 2002; Nishimura et al., 2006; Tolias et al., 2005; Tolias et al., 2007).
By linking to both Rac1 and Rho/Cdc-42 signaling pathways, EphBs can prevent
depolymerization of the actin cytoskeleton. Preventing depolymerization drives
synapses to mature and form mushroom shaped spines.
In addition to coupling with positive regulators of synapse development,
the synaptogenic activities of EphBs are subjected to a specific negative
regulatory pathway. EphB activity is inhibited by binding the RhoA-GEF called
Ephexin5 (Margolis et al., 2010). Ephexin5’s inhibition of EphB is released by
ephrin-B activation of EphBs (Margolis et al., 2010). EphB activation causes
phosphorylation of Ephexin5 on tyrosine-361 that enables the E3 ligase Ube3A
to bind and ubiquitinate Ephexin5 (Margolis et al., 2010). Then ubiquitinated
Ephexin5 undergoes proteasomal degradation, which allows EphBs to initiate
synapse formation (Margolis et al., 2010). Notably, Ephexin5 knockout mice have
increased synapse number (Margolis et al., 2010). Consistent with a negative
regulatory function, overexpression of Ephexin5 reduces the number of excitatory
9

synapses (Margolis et al., 2010). Intriguingly, these findings link EphBs to human
cognitive disorders: Angelman syndrome (AS) and Autism Spectrum Disorders
(ASDs). Mutations or deletions of Ube3A are a cause of AS and duplications in
the 5q11–q13 locus, which includes Ube3A, are found in genetic forms of ASDs
(Mabb et al., 2011). Whether these diseases result from a misregulation of
Ube3a function during synapse maturation (Yashiro et al., 2009), or regulation of
AMPAR trafficking (Greer et al., 2010) remains to be elucidated. However, these
findings place EphB signaling pathways in a key position to regulate diseases of
cognitive dysfunction.
As neurons mature, synapse addition slows while synaptic function
becomes more stable and reliable (Papa et al., 1995; Ziv and Smith, 1996).
EphBs also act as central organizers to coordinate these events. In the mature
cerebral cortex and hippocampus, both immuno-electron microscopy and
biochemical fractionation experiments indicate that EphBs are localized to the
pre- and postsynaptic terminal suggesting that EphBs continue to play a role at
mature synapses (Bouvier et al., 2008; Buchert et al., 1999; Nolt et al., 2011).
However, EphBs are not critical to maintain synapse density once synapses have
formed (Kayser et al., 2008). Thus, if EphB2 expression is reduced with shRNA
knockdown at mature synapses (DIV14-21), there is no effect on synapse density
(Kayser et al., 2008). Moreover, overexpression of EphB2 in neurons from TKO
mice rescues synapse density early in development (DIV3) but fails to rescue
synapse formation when expressed later (DIV10) (Kayser et al., 2008). These
findings suggest that EphBs control synaptogenesis selectively during the rapid
10

phase of synapse addition (DIV0-14) (Kayser et al., 2008). Interestingly,
Ephexin5 expression is down regulated as EphBs begin to function to control
synaptogensis (DIV7-8) (Margolis et al., 2010; Sahin et al., 2005) suggesting a
possible restrictive mechanism. After synapses begin to mature (>DIV14), EphBs
are not required for synapse maintenance and function of EphBs appears to shift
to the regulation of synaptic function. While it remains to be determined what
causes this change in EphB function, the role of EphBs in the mature brain is the
focus of the next two sections of this review.

EphB Trafficking and Regulation of AMPARs
Receptors undergo regulated delivery to the plasma membrane and
removal from the cell surface (Andersson, 2011; Conner and Schmid, 2003). For
EphBs, receptor trafficking is critical to coordinate pre- and postsynaptic
formation, and to regulate glutamate receptor function, while EphB receptor
cleavage and internalization may mediate detachment of contacts and repulsion
(Cowan et al., 2005; Egea and Klein, 2007; Lin et al., 2008; Litterst et al., 2007;
Marston et al., 2003; Pitulescu and Adams, 2010; Zimmer et al., 2003). Although
the mechanisms controlling EphB delivery to the membrane are poorly
understood, work from non-neuronal and neuronal systems demonstrate that
EphB membrane localization is tightly regulated (Egea and Klein, 2007; Fasen et
al., 2008; Pitulescu and Adams, 2010). The key points of regulation are EphB
receptor cleavage, internalization, and degradation (Pitulescu and Adams, 2010).
Activated EphBs undergo proteolytic processing by ADAM10 and matrix
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metalloproteinases (MMPs) (Lin et al., 2008; Litterst et al., 2007). To enable
events such as growth cone collapse, the EphB2 receptor can be endocytosed
via clathrin-mediated mechanisms, ubiquitinated, and targeted for degradation in
the proteasome (Andersson, 2011; Fasen et al., 2008; Margolis et al., 2010;
Pitulescu and Adams, 2010). Interestingly, the entire EphB-ephrin-B receptorligand complex can be trans-endocytosed bidirectionally into the EphB or ephrinB expressing cell (Marston et al., 2003; Zimmer et al., 2003). Although what
differentiates amoung these various modes of receptor trafficking is poorly
understood, receptor trafficking is clearly important for regulation of synaptic
proteins.
EphBs can regulate both surface localization and function of AMPAtype glutamate receptors (Figure 1.2). In cultured neurons, EphB2 and AMPARs
associate by each binding to the PDZ-adaptor proteins PICK1 and GRIP1
(Contractor et al., 2002; Torres et al., 1998). Both PICK1 and GRIP1 bind directly
to AMPARs and are thought to act in opposition: GRIP1 promotes AMPAR
surface retention, while PICK1 acts to remove AMPARs from the cell surface (Lu
and Roche, 2011). However, a link between PICK1, EphB2 and AMPAR
trafficking has not been shown (Calo et al., 2006). Instead, PICK1 appears to
cluster EphB/ephrin-Bs at synaptic sites (Torres et al., 1998). In neurons, GRIP1
appears to help localize both EphB2 and GluA2-containing AMPARs to the
dendritic plasma membrane (Hoogenraad et al., 2005). Consistent with a role for
EphBs in control of AMPAR trafficking, EphBs are important for retention of
AMPARs in the receptor recycling pool (Kayser et al., 2006). This control of
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AMPAR trafficking requires ephrin-B activation, the PDZ-binding domain, and
kinase activation of EphB2 receptors (Kayser et al., 2006). EphB-dependent
internalization

of

AMPARs

likely

relies

on

synaptojanin-1,

which

is

phosphorylated by EphB2, promoting its activation (Irie et al., 2005). Since
GRIP1 and PICK1 preferentially interact with the GluA2 subunits, which regulate
calcium influx through AMPARs (Bredt and Nicoll, 2003; Kessels and Malinow,
2009; Lu and Roche, 2011), these findings suggest that EphB receptors may be
an important regulator of AMPAR subunit composition at synaptic sites.
Physiological evidence demonstrates that EphBs modulate AMPAR
function at synapses. The AMPAR-dependent component of mEPSC in mature
(DIV21-23) neurons can be increased by EphB2 overexpression, and reduced by
knockdown of EphB2 (Nolt et al., 2011). However, consistent with the different
developmental functions of EphB2, knockdown of EphB2 in younger neurons has
no effect on mEPSC amplitude (Kayser et al., 2006). The changes in AMPAR
currents may be explained by the observation that levels of GluA2 in EphB TKO
mice are unchanged at cortical synapses compared to wild-type mice (Nolt et al.,
2011). These observations suggest that EphBs may act to regulate synaptic
AMPAR subunit composition rather than overall number. However, additional
work is required to demonstrate the overall impact of EphB-dependent regulation
of AMPARs.

13

EphBs and NMDA Receptors
EphB receptors regulate multiple facets of NMDAR surface localization,
function, and downstream signaling. EphBs and NMDARs colocalize at synaptic
sites, and mice lacking EphB2 have reduced levels of NMDARs at synapses in
the hippocampus and cortex (Dalva et al., 2000; Henkemeyer et al., 2003;
Kayser et al., 2006). Upon ephrin-B binding, EphBs interact directly with
NMDARs through their extracellular domains (Attwood et al., 2011; Dalva et al.,
2000; Grunwald et al., 2001; Slack et al., 2008). However, the specific region of
the extracellular domains involved in this interaction for both EphB2 and the
NMDAR remains to be identified. Ephrin-B activation of EphBs not only induces
the EphB-NMDAR interaction, but also potentiates NMDAR function (Dalva et al.,
2000; Takasu et al., 2002). Ephrin-B activation of the EphB-NMDAR interaction
causes src kinase-dependent phosphorylation of the NR2B subunit of the
NMDAR at tyrosines 1226, 1336 and 1472 (Takasu et al., 2002). Phosphorylation
at tyrosine 1472 of NR2B-containing NMDARs blocks binding of the AP-2
complex preventing clathrin-mediated endocytosis (Chen and Roche, 2007).
Thus, the EphB-NMDAR interaction can increase the surface retention of NR2Bcontaining NMDARs. Additionally, EphB2 can increase calcium influx through
NR2B-containing NMDARs by decreasing calcium-dependent inactivation rates
(Nolt et al., 2011; Takasu et al., 2002). Notably, EphB2 does not appear to act
similarly on calcium inactivation of NR2A-containing NMDARs (Nolt et al., 2011).
The enhanced calcium influx through the NMDAR also results in enhanced
downstream gene transcription (Takasu et al., 2002). In EphB TKO mice there is
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a reduction in NR2B at synaptic sites in cerebral cortex and cultured
hippocampal neurons (Henkemeyer et al., 2003; Kayser et al., 2006). At the
mature synapse, knockdown of EphB2 causes a reduction in mEPSC amplitude
and NMDAR-dependent decay time (Nolt et al., 2011). Similarly, overexpression
of EphB2 causes an increase in mEPSC amplitude and NMDAR-dependent
decay time (Nolt et al., 2011). This study specifically implicated NR2B-containing
NMDAR being trafficked onto the surface at synaptic sites after ephrin-B
activation in the mature brain (Nolt et al., 2011). Interestingly, a recent report
suggests that EphBs may also interact with and regulate the function of nAChRs
(Liu et al., 2008), suggesting the possibility that EphBs play a larger role in the
regulation of neurotransmitter function than previously appreciated. Regardless,
these data support a model (Figure 1.2) where EphBs are not required for
synapse maintenance, but are instead critical regulators of NMDAR localization,
function, and signaling in the mature brain.
The extracellular domain mediated EphB-NMDAR interaction has also
been implicated in NMDAR-dependent forms of hippocampal synaptic plasticity,
particularly for EphB2. EphB2−/− null mice have reduced synaptic NMDAR, but
not AMPAR currents, reduced long-term potentiation (LTP), and long-term
depression (LTD) (Grunwald et al., 2001; Henderson et al., 2001). Importantly,
these effects are rescued by transgenic expression of a truncated EphB2
receptor lacking its kinase domain (Grunwald et al., 2001). These data suggest
that EphB-dependent regulation of synaptic plasticity requires the extracellular
domain-mediated interaction between EphB and the NMDAR. Consistent with
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these deficits in synaptic plasticity, EphB2−/− mice perform poorly in behavioral
learning tasks such as the Morris water maze (Grunwald et al., 2001). Taken
together, these data imply that the EphB-NMDAR interaction is required for
proper synaptic function, synaptic plasticity, and behavior.

EphB-NMDAR Interaction in Disease
There is a growing body of evidence that suggests a synaptic origin for
diseases of neuronal development and in the aging brain. Proper NMDAR
synaptic localization and function has long been placed at the epicenter of these
synaptopathies. By direct interaction and functional modulation of the NMDAR,
EphBs and ephrin-Bs appear to be key synaptic regulators implicated in many of
these diseases. Specifically, we will discuss three examples of EphB/ephrin-B
signaling in disease: neuropathic pain, anxiety disorders and Alzheimer’s disease
(AD).

Neuropathic pain and hyperalgesia
Control of NMDAR function by EphBs plays a critical role in the
enhancement of pain. In the spinal cord and periphery, neuropathic pain (chronic
pain caused by injury) and hyperalgesia (increased sensitivity to painful stimuli)
are linked to EphB1/ephrin-B signaling through modulation of NMDAR function.
Remarkably, in four different models of pain - thermal hyperalgesia,
spontaneous, crush, and mechanical allodynia - EphB1 functions similarly
(Figure 1.3). Despite differences in models, neurons, and brain regions
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mediating pain, downstream signaling mechanisms are well conserved.
Therefore, EphB-dependent modulation of NMDAR function may be an important
target for the control of pain.
Induction of neuropathic pain in the spinal cord is mediated by
dysregulation of excitatory glutamatergic synapses between the axons from
sensory neurons in the dorsal root ganglia (DRG) and second-order neurons in
the dorsal horn (DH) (Kuner, 2010). At the DRG-DH synapses, induction of
neuropathic pain depends on NMDAR function (Kuner, 2010). Specifically,
NMDAR dependent LTP-like changes in synaptic strength are suggested as the
cellular mechanism for pain amplification and hyperexcitability of the DRG-DH
circuit (Kuner, 2010).
The levels of ephrin-B1, ephrin-B2, and EphB1 expression are
upregulated after injury in the DRG and spinal cord suggesting that these
proteins are involved in the response to pain (Kobayashi et al., 2007; Song et al.,
2008a; Song et al., 2008b). Indeed, intrathecal injection of EphB1/B2-Fc or
shRNA against ephrin-B2 prevents EphB/ephrin-B signaling, and decreases
hyperalgesia and mechanical allodynia suggesting a role for EphB signaling in
regulation of pain after injury (Kobayashi et al., 2007; Song et al., 2008b).
Moreover, injection of ephrin-B2-Fc to activate EphBs induces pain (Battaglia et
al., 2003; Conover et al., 2000; Slack et al., 2008; Song et al., 2008b).
EphB-dependent modulation of NMDAR function appears to drive EphBs’
function in pain responses (Figure 1.3). Similar to the cerebral cortex, injury
induced upregulation of EphB1 and ephrin-B expression appear to directly
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modulate

the

function

of

NR2B-containing

NMDARs.

EphB-dependent

hyperalgesia depends upon tyrosine phosphorylation of NR2B in the spinal cord
(Guo et al., 2002), while blocking NMDARs and src kinase activity is sufficient to
prevent hyperalgesia (Battaglia et al., 2003; Slack et al., 2008; Song et al.,
2008b). As expected from work on the EphB-NMDAR interaction, src kinase
exerts its effects by phosphorylating NR2B at Y1472 (Dalva et al., 2000; Slack et
al., 2008; Takasu et al., 2002). EphB-dependent regulation of NMDAR function
also appears to regulate the changes in synaptic strength thought to underlie
induction and maintenance of hyperalgesia. In the spinal cord, EphB activation
lowers the threshold for LTP induction and increases phosphorylation of NR2Bcontaining NMDARs (Battaglia et al., 2003; Song et al., 2008b). Moreover,
inhibition of EphB signaling blocks pain-induced activity-dependent gene
transcription of the immediate early gene c-Fos (Battaglia et al., 2003; Song et
al., 2008b). These findings suggest that EphB/ephrin-B signaling is critical for
suppressing the injury-induced hyperexcitability of the DRG-DH circuit.
EphB-dependent neuropathic hyperalgesia appears to be mediated
specifically by EphB1. EphB1 is expressed at high levels in the spinal cord, and
EphB1-/- and EphB1+/- mice have significantly reduced thermal hyperalgesia and
pain-induced hyperexcitablity of DH neurons (Han et al., 2008; Liu et al., 2009).
Consistent with the importance of EphB1 in control of pain sensitivity, EphB1-/mice show defects in enhancement of pain after morphine-induced withdraw
(Han et al., 2008). EphB1 appears to be the only EphB receptor required for
ephrin-B1 induced hyperalgesia because treatment with ephrin-B1-Fc has no
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effect on pain sensitivity in EphB1-/- or EphB1+/- mice (Han et al., 2008). These
changes in hyperalgesia in EphB1-/- mice are linked to NMDAR-dependent
increases in p-CaMKII, p-ERK and p-CREB and the induction of c-fos expression
(Han et al., 2008; Liu et al., 2009). Interestingly, EphB1 upregulation after injury
appears to be dependent on MMP-2/9, although the specific signaling
mechanisms remain to be determined (Liu et al., 2011).
The EphB-dependent modulation of NMDAR function is also critically
important in pain sensitivity outside of the spinal cord in the periphery. As in the
spinal cord, in the peripheral nervous system injection of ephrin-B1-Fc, which
activates EphBs, induces hyperalgesia dependent on NMDARs (Cao et al., 2008;
Guan et al., 2010; Ruan et al., 2010). This leads to increased c-fos expression
and activation of NMDAR-dependent phosphorylation of two pathways: MAPKs
(p-p38, pERK and pJNK) (Cao et al., 2008; Ruan et al., 2010) and PI3K, Akt, and
ERK (Guan et al., 2010). Taken together, these results suggest that in the
periphery a similar mechanism for hyperalgesia occurs with EphB1 upregulation,
NMDAR-dependent phosphorylation of targets required for synaptic plasticity,
and changes in gene transcription.
Similar to the central and peripheral pain mechanisms, the EphBdependent modulation of NMDAR function is implicated in cancer-induced pain
for both bone and pancreatic cancer. In models of cancer-induced pain,
expression of ephrin-B1 and EphB1 are upregulated (Dong et al., 2011; Liu et al.,
2011; Orikawa et al., 2010). Here, the EphB-NMDAR interaction is also
specifically implicated because blocking EphB1 signaling alleviates mechanical
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allodynia (Liu et al., 2011). The mechanism for this alleviation is decreased
activation of NR2B-containing NMDARs, which reduces the phosphorylation of
downstream targets pSrc (Tyr418), pERK1/2, pCaMKII, and pCREB, and gene
transcription of c-fos (Liu et al., 2011). The changes in EphB and ephrin-B1
expression in cancer-induced pain are likely to be downstream of the
inflammatory cytokines IL-1β, IL-6 and TNF-α (Dong et al., 2011). Consistent
with this, inhibiting the CCK2/gastrin receptor with a drug (Z-360) reduces IL-1β
levels, prevents upregulation of ephrin-B1 expression, and reduces NR2B
phosphorylation in models of cancer pain (Orikawa et al., 2010). The observation
that blocking EphB1 with EphB receptor bodies also alleviates morphine
tolerance in models of bone cancer pain (Liu et al., 2011) suggests that
modulating EphB receptor signaling may be a promising avenue for treating
chronic pain. More broadly, there is extensive evidence linking EphB-dependent
regulation of NMDAR function to the induction and expression of chronic pain.

Anxiety
Emerging evidence links both regulation of EphB receptor cleavage and
EphB-dependent regulation of NMDAR function to anxiety (Figure 1.4). Severe
or sustained stress can result in changes to synaptic architecture and function
mirroring those found after induction of synaptic plasticity, and lead to behavioral
changes associated with fear and anxiety disorders (Lupien et al., 2009). The
pathogenic plasticity involved in these changes requires NMDAR activation and
increases neuronal activity in the hippocampus and amygdala (Lupien et al.,
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2009). Antagonists of NMDAR receptors can produce anxiolytic effects in animal
models of anxiety like the elevated plus maze (Barkus et al., 2010). Several lines
of evidence suggest that changes in the extracellular matrix mediated by
proteolysis promote an anxiety response (Lohman et al., 2009; Matys et al.,
2004; Pawlak et al., 2003; Pawlak et al., 2005). The serine protease neuropsin
(also known as kalikrein-related peptidase 8) is highly expressed in the
hippocampus and amygdala (Chen et al., 1995). Furthermore, genetic variations
in human neuropsin are associated with bipolar disorder and cognitive functions
(Izumi et al., 2008). Neuropsin-deficient mice have defects in spatial working
memory, impaired ability in the Morris water maze assay, and reduced longlasting LTP (Chen et al., 1995; Ishikawa et al., 2008b; Matsumoto-Miyai et al.,
2003; Tamura et al., 2006). In the amygdala, EphB2 and neuropsin colocalize
and neuropsin expression is upregulated after stress (Attwood et al., 2011; Izumi
et al., 2008). Furthermore, neuropsin upregulation and colocalization with EphBs
in the amygdala result in cleavage of the EphB2 ectodomain (Attwood et al.,
2011; Izumi et al., 2008). Neuropsin-dependent cleavage of EphB2 decouples
the EphB-NMDAR interaction, likely explaining the changes in NMDAR currents
observed in neuropsin null mice (Attwood et al., 2011). Furthermore, injection of
function blocking antibodies to EphB2 or neuroposin can prevent behaviorally
stress-induced anxiety in the elevated plus maze task (Attwood et al., 2011).
Taken together, these data suggest that targeting neuropsin-dependent cleavage
of EphB2 is a potential strategy for treating stress-related and anxiety disorders.
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In models of stress, EphBs appear to increase the amount of NMDAR
currents at the synapse after neuropsin-dependent cleavage (Attwood et al.,
2011). One potential explanation for the molecular mechanism of these findings
comes from the studies on γ-secretase cleavage of EphB2 (Litterst et al., 2007;
Xu et al., 2009). Intriguingly, after MMP-dependent cleavage of the EphB2
extracellular domain, the γ-secretase releases a kinase-active fragment in nonneuronal cells (Xu et al., 2009). Expression of a soluble kinase active intracellular
fragment was shown to phosphorylate NR2B subunits of NMDARs, resulting in
increased NMDAR surface localization (Xu et al., 2009). Whether a similar
mechanism plays a role in neurons remains to be determined. However, these
non-neuronal experiments raise the possibility that EphBs may regulate NMDAR
function both through direct interactions and by indirectly phosphorylating the
NMDAR. It will be important to determine whether direct or indirect interactions
between EphBs and the NMDAR are important for anxiety.

Alzheimer’s disease
EphB-dependent modulation of NMDAR function appears to play a role in
the

pathogenesis

of

Alzheimer’s

disease

(AD).

AD

is

a

progressive

neurodegenerative disorder characterized by declarative memory defects and
dementia (Walsh and Selkoe, 2004). Among the many pathological changes
seen in patient brains is the loss of excitatory synapses and increased neuronal
death (Penzes et al., 2011; Selkoe, 2002). The reduction in synapse density in
the cortex and hippocampus is found early during the onset of AD and correlates
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with the level cognitive impairment (Penzes et al., 2011; Selkoe, 2002). These
observations suggest that elucidating the underlying mechanisms causing
deficits in synaptic function will be important to understanding the disease. AD
patient data links EphBs and NMDARs with the observation that both EphB and
NMDAR subunit expression is reduced early in AD progression (Ikonomovic et
al., 1999; Simon et al., 2009; Sze et al., 2001). In addition, there are reduced
levels of NR2 subunit phosphorylation in AD patient brains (Sze et al., 2001).
Building on these observations in patients, work has focused on whether
these effects on NMDAR expression are linked to prominent disease
mechanisms such as amyloid-β (Wilcox et al., 2011). In patients with AD, the
level of a 40- or 42-amino acid peptide called amyloid-β (Aβ) in the brain
correlates with disease onset and progression (Wilcox et al., 2011). In mouse
models and in cell culture, the presence of Aβ can cause NMDAR endocytosis,
reduced surface expression of NMDARs, and reduced NMDAR currents (Snyder
et al., 2005). Also in mouse models of AD, the Aβ-dependent reduction in EphB2
expression levels occurs prior to detectable behavioral impairments (Simon et al.,
2009). Interestingly these effects appear more pronounced on NR2B-containing
NMDARs (Snyder et al., 2005).
Recently, a strong link has emerged between EphB2, Aβ, and Alzheimer’s
disease through NMDAR phosphorylation and regulation at the plasma
membrane (Figure 1.4). Consistent with experiments demonstrating reduced
EphB2 expression levels in AD (Simon et al., 2009), Aβ binds to the extracellular
FnIII domains of EphB2, causing receptor internalization and degradation (Cisse
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et al., 2011). The functional consequence of the removal of EphB2 from the cell
surface by Aβ appears to be reduced NMDAR surface expression (Cisse et al.,
2011). Furthermore, EphB2 depletion by knockdown or knockout, can phenocopy
the Aβ-dependent reduction in NMDAR surface localization (Cisse et al., 2011;
Nolt et al., 2011). Similarly, targeted knockdown of EphB2 in the dentate gyrus
causes deficits in LTP and NMDAR (but not AMPAR) currents (Cisse et al.,
2011). These findings are consistent with previous observations on the effects on
LTP in mice lacking EphB2 and on synaptic function following the knockdown of
EphB2 in cortical neurons (Dalva et al., 2000; Grunwald et al., 2001; Henderson
et al., 2001; Nolt et al., 2011). The effects of targeted knockdown of EphB2 in the
dentate gyrus are mirrored in the hAPP overexpressing mouse (Cisse et al.,
2011). Not only does knockdown of EphB2 cause defects in LTP, but viral
overexpression of EphB2 in the dentate gyrus of hAPP overexpressing mice
rescues LTP and NMDAR current deficits to wild-type levels (Cisse et al., 2011).
Remarkably, targeted overexpression of EphB2 in the dentate gyrus rescues
hippocampal-dependent cognitive deficits in the Morris water maze in hAPP mice
(Cisse et al., 2011). These effects were seen despite infection of a relatively low
percentage of neurons in the dentate gyrus, suggesting that functional
modulation of synapses for only a subset of neurons in a network can have
significant effects on behavior. In summary, increasing neuronal EphB2 levels in
hAPP mice reversed cognitive and behavioral defects associated with AD, while
EphB2 knockdown appears to mimic many of the defects in NMDAR function in
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these mice. Therefore, these findings suggest that Aβ may principally
dysregulate synaptic and NMDAR function in AD.

Conclusions and future directions
EphBs regulate excitatory synapse development and function at
mammalian synapses by controlling dendritic morphology and excitatory
neurotransmitter receptor content. Dysfunction of EphB-dependent control of
synaptic NMDAR function and surface localization appears to lead to profound
synaptopathy including AD and pain. In each of these diseases, the role of
EphBs is linked to direct extracellular interaction between EphB and the NMDAR.
However, the domain mediating this interaction has yet to be identified (see
Outstanding Questions). In anxiety, EphB-dependent regulation of NMDAR
function is also important, but may be regulated by a different mechanism
governed by the release of the EphB intracellular domain. However, in these
three cases, EphB-dependent regulation of NMDAR function and surface
localization has profound consequences. Given the potential significance for
modulation of the EphB-NMDAR in treating human disease, understanding the
mechanisms enabling these proteins to interact will be of significant importance.
It will be especially important for future work to understand the
extracellular nature of the EphB-NMDAR interaction. One intriguing idea is that
since the EphB-NMDAR interaction occurs in the extracellular space, the
interaction may be dependent on an extracellular modification to either protein
such as extracellular phosphorylation. Phosphorylation of residues destined to
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be extracellular has been shown to be critical to Drosophila limb and wing
development in vivo (Ishikawa et al., 2008a). Soluble and membrane-attached
protein kinases have been found in neurons to regulate synaptic plasticity and
aggregation of Aβ in AD patients (Chen et al., 1996; Fujii et al., 2000; Kumar et
al., 2011; Redegeld et al., 1999).

Furthermore, the extracellular domain of

EphB2 receptors is phosphorylated after ligand binding (D.S.S., T.A.N., S.I.S-C,
and M.B.D., unpublished observations).

Thus, extracellular phosphorylation

appears to an underappreciated mechanism for disease, and a potential modifier
of the EphB-NMDAR interaction.
In addition to EphBs, a number of other regulators of synapse
development have developmental shifts in function. Focal adhesion kinase
(Moeller et al., 2006; Shi et al., 2009), synCAM (Robbins et al., 2010), SALM1/2
(Ko et al., 2006; Wang et al., 2006), and neuroligin/neurexin (Sara et al., 2005;
Varoqueaux et al., 2006) all regulate synaptic function in more mature neurons,
while controlling synaptogenesis early in development. These findings suggest
that synaptic organizing proteins play dual functions, first to generate synapses
and later to control their function. The dual function of these proteins could
explain some of their complex linkage to disease. We propose that there may be
sufficient redundancy in synaptogenic factors that most synapses are still able to
form normally after malfunction of any one of these organizers. Once the circuitry
begins to mature, however, each of these proteins is required for proper mature
synaptic function and breakdowns in these molecules might then manifest as
neuronal or cognitive dysfunction. Thus, a better understanding of these synaptic
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organizing proteins is needed in three broad areas: 1) to investigate their
functions in organizing synapses, 2) to appreciate how the activity of these
molecules changes during development, and 3) to determine their different roles
in controlling synaptic function. Exploring these three areas will be critical to
discerning brain function and treating synaptopathies.
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Outstanding Questions Box:
•

What are the domains on EphBs and the NMDAR that mediates the EphBNMDAR interaction?

•

How do EphBs differentially regulate downstream GEF signaling
pathways?

•

Does Ephexin-5 signaling contribute to autism spectrum disorders?

•

What is the mechanism for EphBs in regulating the function of NR2Bcontaining NMDARs?

•

Do EphBs regulate AMPARs at mature synapses?

•

How is the activity of EphBs switched from synaptogenesis to synaptic
maintenance?

•

Are there pharmacological agents that can block the EphB-NMDAR
interaction for neuropathic pain?

•

What is the specific domain for Aβ binding to EphB2?

•

Are there pharmacological agents that can potentiate the EphB-NMDAR
interaction for human cognitive disorders?

28

Glossary Box:
Adaptor protein: A protein with multiple protein-protein interaction domains that
recruits other proteins to a signaling complex.
Allodynia: Pain caused by an innocuous stimulus.
Alzheimer’s disease (AD): The most common form of dementia and a fatal
neurodegenerative disease characterized by progressive memory loss, deficits in
cognitive ability, and aberrant behavior.
AMPA receptor: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type
ionotropic glutamate receptor.
Amyloid precursor protein (APP): Neuronal integral membrane protein
concentrated at synaptic sites. Proteolysis of APP first extracellular by Betasecretase 1 (BACE1) then subsequently γ-secretase generates the 40-42 amino
acid β-amyloid (Aβ) found in amyloid plaques of AD patients.
Angelman syndrome (AS): Neuro-genetic disorder characterized by intellectual
and developmental delay, lack of speech, seizures, and disorders in walking and
balance.
Crush pain model: Under deep anesthesia a spinal nerve distal to the dorsal
root ganglions (DRG) is crushed. Thermal hyperalgesia or mechanical allodynia
are then tested.
Dendritic filopodia: Thin, motile dendritic process seeking axonal contact and
thought to be the precursor of dendritic spine synapses.
Dendritic spine: Mushroom-shaped extension from the dendrite equipped with
neurotransmitter receptors to review local axonal input.
29

DH neuron: Integration of DRG inputs occurs in deep layers of spinal dorsal
horn (DH) neurons. Output is carried to projection sites in the brain.
DRG neuron: Nocioceptive afferents carrying noxious stimuli (heat, noxious
cold, pressure, or chemicals) have glutamatergic synapses onto relay neurons in
the dorsal root ganglion (DRG).
GTPase: Small momeric G-proteins which binds and hydrolyzes guanosine
triphosphate (GTP) to guanosine diphosphate (GDP) to stimulate downstream
effectors.
Guanine Nucleotide Exchange Factor (GEF): A protein which activates small
monomeric GTPase activity by accelerating the exchange of guanosine
diphosphate (GDP) for guanosine triphosphate (GTP).
Hyperalgesia: Increased sensitivity to pain.
Hyperexcitability of DRG neurons: This is characterized by lower current
threshold for action potentials, an increase in spontaneous activity, and repetitive
discharge.
Intraplantar injection: Injection into the plantar surface of the paw.
Intrathecal injection: Injection into the arachnoid membrane of the spinal cord.
Long-term Depression (LTD): Prolonged weakening of synaptic inputs.
Long-term Potentiation (LTP): Prolonged strengthening of synaptic inputs.
Mechanical Allodynia model: The plantar surface of each hind paw with a
sharp, cylindrical probe. Incidence of foot withdraw is measured.
Miniature synaptic current: Postsynaptic current evoked by single vesicle (or
quanta) of neurotransmitter.
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Neuropathic pain: Chronic pain caused by injury to the central or peripheral
nervous system.
NMDA receptor: N-Methyl-d-aspartate-type ionotropic glutamate receptor.
PDZ-domain: A carboxy-terminal protein binding domain named after its three
indentifying member proteins (PSD-95, Drosophila discs large protein and Zona
Occludens-1).
Receptor Trafficking: Active process by which receptor proteins are moved
between regions of the cell, and on and off of the plasma membrane.
Receptor

tyrosine

kinase

(RTK):

Cell-surface

localized

single-subunit

transmembrane protein with intracellular catalytic activity to autophosphorylate
and phosphorylate tyrosine residues on signaling substrates.
RNA Interference (RNAi): A method using small hairpin RNAs (shRNAs) to bind
the mRNA encoding a protein of interest to suppress its expression.
Spontaneous pain model: Formalin is subcutaneously injected into a hind paw.
Amount of time licking, biting, and flinching on the injected paw is assessed.
Synaptic cell adhesion molecules (SAMs): Pairs of molecules that interact
across adjacent cells to stabilize the initial contacts between axon and dendrite to
form a synapse. SAMs also regulate function of existing synapses through
protein-protein interactions and intracellular signaling cascades.
Thermal hyperalgesia pain model: Animals are placed in a testing box with a
temperature-controlled floor. A heat source is then focused on the hind paw
flushed to the floor and foot withdraw latency is measured.
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Figure Legends:

Figure 1.1. EphBs regulate excitatory synapse development. (a) The domain
structure of the EphB receptor: G - Gobular domain (purple). C - Cistine Rich
domain (yellow), F – Fibronectin type III domains (light blue), K – Kinase domain
(red), S – SAM domain (green), and P – PDZ binding domain (orange).

(b)

Early in neuronal development (DIV0-10), EphB receptors direct formation of
excitatory synapses by regulating motility of filopodia via p21 activated kinase
(PAK) and receptor tyrosine kinase activity. (c) During the rapid phase of
synapse addition (DIV7-14), EphBs interact in trans with ephrin-B1 or ephrin-B2
expressed on axons of adjacent cells. This EphB/ephrin-B interaction activates
EphB kinase activity, which removes inhibition of synapse formation by the
specific negative regulator Ephexin-5. EphB activation phosphorylates Ephexin5,

inhibiting

RhoA-GTPase

activity,

and

promoting

ubuiqitination

and

proteasomal degradation of Ephexin-5 by the E3 ligase Ube3A. To promote
synapse maturation, EphB kinase activation recruits GEFs to hydrolyze GDP into
GTP, activating Rho-GTPases that enable synapse formation through PAK. (d)
Postsynaptically, EphBs directly cluster NMDA-type glutamate receptors (green)
through an extracellular interaction, and cluster AMPA-type glutamate receptors
(purple) via a PDZ-domain dependent interaction with GRIP1. Furthermore,
EphBs modulate the change in morphology of the actin cytoskeleton into mature
mushroom-shaped dendritic spines. Presynaptically, EphBs direct presynaptic
differentiation by clustering ephrin-B1 and ephrin-B2 at presynaptic terminals.
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The EphB/ephrin-B1/2 interaction recruits the adaptor protein syntenin-1 to these
signaling complexes through the PDZ-binding domain of ephrin-Bs. Syntenin-1
enables EphBs to recruit the machinery required for neurotransmitter release to
presynaptic specializations.

Figure 1.2. EphBs regulate glutamate receptor trafficking and function. (a)
EphBs regulate AMPAR trafficking through a PDZ-dependent interaction with
GRIP1 and indirect interactions with synaptojanin-1 (Stj1), a phosphatidylinositol
5'-phosphatase. If an EphB receptor is interacting with GRIP1, kinase activation
by ephrin-Bs promotes AMPAR insertion into the membrane from the recycling
pool. Alternatively, EphB kinase activation by ephrin-Bs can also promote
AMPAR internalization by phosphorylation of synaptojanin-1, which activates
clathrin-mediated endocytotic mechanisms. (b) After binding ephrin-B ligand,
EphBs directly interact with NMDARs to regulate their synaptic surface
localization and function. Activation of EphBs promotes insertion of NR2Bcontaining NMDARs into the synaptic membrane of mature neurons.
Furthermore, after activation, EphBs recruit src kinase to phosphorylate NR2Bconstaining NMDARs at Y1472 blocking binding of the AP-2 complex and
clathrin-mediated endocytosis. Functionally, EphB activation decreases calciumdependent desensitization, mEPSC amplitude, and decay time of NR2Bcontaining NMDAR. This increased calcium influx through NMDARs also leads to
EphB-dependent increases in gene expression of c-fos.
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Figure 1.3. EphBs and neuropathic pain.

(a) Under physiological pain

conditions, ephrin-B and EphB1 expression remains low and NR2B-containing
NMDAR signaling remains normal. (b) For pathological central pain, both ephrinBs and EphB1 are upregulated. Activation of EphBs leads to recruitment and
activation

of

src,

insertion

of

NMDARs

into

the

membrane,

NR2B

phosphorylation at Y1472, and increased calcium influx leading to c-fos gene
transcription. (c) Pathological peripheral pain shares common mechanisms with
central pain. However, three parallel signaling pathways have been well
characterized leading to gene transcription of c-fos and CRE. First, src
phosphorylates

CamKII,

which

phosphorylates

CREB

causing

nuclear

translocation and CRE gene transcription. Second, PI3K is phosphorylated,
which phosphorylates Akt, which phosphorylates ERK, which translocates to the
nucleus to activate c-Fos gene transcription. Finally, JNK gets phosphorylated
and activated, which phosphorylates p-38 and converges to activate ERK. (d)
Pathological cancer-induced pain shares a remarkable number of the same
mechanisms as pathological central and peripheral pain. Unique to cancerinduced pain is that src kinase directly phosphorylates ERK to activate gene
transcription of c-fos. Additionally, inflammatory cytokines TNFα, IL-6, and IL-1β
are upregulated leading to hyperalgesia, and hyperexcitability of nerve afferents.

Figure 1.4. EphBs and Synaptic Disease. (a) Physiological EphB signaling
affects both synaptic plasticity and synapse maturation. Ephrin-B activation of
EphBs promotes the direct EphB- NMDAR interaction. This interaction modulates
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NMDAR function by increasing calcium influx, inserting new NR2B-containing
NMDARs

into

the

membrane,

and

activating

calcium-dependent

gene

transcription required for LTP. In anxiety disorders, there is a stress-induced
upregulation of the serine protease neuropsin (also known as kalikrein-related
peptidase 8). At the membrane, neuropsin cleaves the EphB receptor
ectodomain, releasing the intracellular domain into the cytosol. This intracellular
kinase may be active and able to phosphorylate downstream intracellular targets
including NMDARs. Cleavage of the EphB ectodomain dissociates the EphBNMDAR interaction, leading to NMDAR internalization and activation of Fkbp51
gene transcription in the nucleus. (b) In Alzheimer’s disease, there is an
overabundance of soluble Aβ oligomers, which appear to bind directly to EphB2.
The EphB2-Aβ interaction inhibits receptor activation and causes internalization
and degradation of both EphBs and NMDARs. Degradation of EphB receptors
inhibits their ability to retain NMDARs on the membrane potentially though the
EphB-NMDAR interaction. Fewer NMDARs on the cell surface leads to
decreased calcium influx and none of the changes in gene transcription required
for LTP.
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Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic
development via syntenin-1
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Abstract
The development of central nervous system synapses requires precise
coordination between presynaptic and postsynaptic components. The EphB
family controls postsynaptic development by interacting with glutamate receptors
and regulating dendritic filopodia motility, but how EphBs induce the formation of
presynaptic specializations is less well understood. Here, we show that
knockdown of presynaptic ephrin-B1, ephrin-B2, or syntenin-1, but not ephrin-B3,
prevents EphB-dependent presynaptic development. Ephrin-B1, ephrin-B2, and
syntenin-1 are clustered together with presynaptic markers, suggesting that
these molecules function jointly in presynaptic development. Knockdown of
ephrin-B1 or ephrin-B2 reduces the number of synaptic specializations and the
colocalization of syntenin-1 with synaptic markers. Simultaneous knockdown of
ephrin-B1 and ephrin-B2 suggests that they function independently in the
formation of synaptic contacts, but act together to recruit syntenin-1 to
presynaptic terminals. Taken together, these results demonstrate that ephrin-B1
and ephrin-B2 function with EphB to mediate presynaptic development via
syntenin-1.
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Introduction
The EphB family of receptor tyrosine kinases directs postsynaptic
development by interacting with NMDA- and AMPA-type glutamate receptors,
controlling dendritic filopodia motility, and regulating spine formation (Dalva et al.,
2000; Kayser et al., 2006; Kayser et al., 2008). EphBs can also signal transsynaptically to induce presynaptic development, suggesting that EphB receptors
are capable of coordinating the development of both presynaptic and
postsynaptic compartments (Kayser et al., 2006). However, the mechanisms by
which EphBs induce presynaptic development are not well described. The
ligands for EphBs are the ephrin-Bs, a family of three (ephrin-B1–B3)
transmembrane molecules that, in addition to “forward” signaling through the
activation of EphBs, can also signal in the “reverse” direction through intracellular
phosphotyrosines and a C-terminal PDZ-binding domain. Ephrin-Bs have
recently been shown to regulate presynaptic development in the Xenopus tectum
(Lim et al., 2008) and are expressed in mouse cortex (Lein et al., 2007; Migani et
al., 2007, 2009; Tang et al., 1997). Although it is thought that ephrin-Bs might
have unique functions at the synapse (Aoto and Chen, 2007; Essmann et al.,
2008; Grunwald et al., 2004), whether particular ephrin-Bs interact with
postsynaptic EphBs to regulate synapse development in the mammalian CNS,
and what the downstream mechanisms are that mediate this process, are not
known.
The syntenin family consists of two (syntenin-1 and syntenin-2) tandem
PDZ domain-containing proteins implicated in a number of cellular processes
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such as trafficking, signaling, and cancer metastasis (Beekman and Coffer,
2008). Initially identified as binding partners for the heparan sulfate proteoglycan
syndecan (Grootjans et al., 1997), syntenins are comprised mainly of two PDZ
domains that enable self-association and interactions with a number of
synaptically localized transmembrane molecules such as glutamate receptors, βneurexin, SynCAM, and ephrin-Bs (Biederer et al., 2002; Grootjans et al., 2000;
Hirbec et al., 2002; Koroll et al., 2001; Lin et al., 1999; Torres et al., 1998). In
addition, syntenin-1 may regulate the organization of presynaptic active zones
through interactions with the ERC/CAST family of active zone molecules (Ko et
al., 2006).
Here, we show that two members of the ephrin-B family (ephrin-B1 and
ephrin-B2) function to mediate EphB-dependent presynaptic development via
PDZ-binding domain-dependent interaction with syntenin-1. Simultaneous
knockdown of ephrin-B1 and ephrin-B2 suggest that these molecules function
independently in the formation of synapses, but function together in the
localization of syntenin-1 to synaptic specializations.
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Results

Ephrin-B Family Members Are Required for EphB2-Dependent Presynaptic
Development.
A presynaptic role for ephrin-Bs has been suggested by the finding that
EphB-expressing non-neuronal cells can induce presynaptic development
(Kayser et al., 2006). To determine whether EphB-dependent presynaptic
induction is mediated by specific presynaptic ephrin-B family members, we asked
whether non-neuronal cells expressing EphB2 could induce presynaptic
specializations when ephrin-B expression is reduced in axons by RNAi-mediated
knockdown. We generated constructs encoding 19-nt shRNAs targeting
individual ephrin-B family members and confirmed that these constructs were
capable of reducing the expression of the target molecule (Figure 2.1F and
Supplementary Figure 2.1). We transfected shRNA constructs into days in vitro
(DIV) 3 cortical neurons along with a GFP-tagged version of the presynaptic
vesicle marker synaptophysin (syn-GFP) to label transfected axons. At DIV9,
transfected neurons were cocultured with HEK293T cells expressing either FLAG
epitope-tagged EphB2 (fEphB2) or red fluorescent protein (RFP) and fixed 16–18
h later. Because our transfection efficiency in neurons was low (<1%), expression
of syn-GFP revealed easily identifiable stretches of axons with discrete puncta of
syn-GFP that colocalized with the excitatory presynaptic marker VGlut1. Labeled
HEK293T cells were scattered throughout the culture and occasionally found to
be contacting a syn-GFP-expressing axon. To determine the effect of transfected
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HEK293T cells on presynaptic development, we compared the linear density of
syn-GFP in the stretch of axon contacting the HEK293T cells to the density in the
adjacent axon region (see SI Text).
In control neurons coexpressing syn-GFP with the shRNA vector control,
the density of syn-GFP in axon regions contacting RFP-expressing HEK293T
cells was similar to that in adjacent regions, resulting in a density ratio near 1.0
(Figure 2.1A and B). However, consistent with our previous findings (Kayser et
al., 2006), syn-GFP puncta density increased by ≈1.5-fold underneath EphB2expressing HEK293T cells (Figure 2.1A and B). These results confirm that
EphB2-expressing HEK293T cells can induce presynaptic differentiation in
segments of single axons.
To test whether this process is mediated by presynaptic ephrin-Bs,
neurons were cotransfected with syn-GFP and shRNA constructs targeting each
ephrin-B family member (Figure 2.1F and Supplementary Figure 2.1). In axons
from neurons transfected with shRNA targeting ephrin-B3, HEK293T cells
expressing EphB2 caused a significant increase in syn-GFP density similar to
that seen in control neurons (Figure 2.1A and B). However, in axons from
neurons expressing shRNA targeting ephrin-B1 or ephrin-B2, HEK293T cells
expressing EphB2 failed to induce presynaptic vesicle clustering (Figure 2.1AC). To confirm that the effect of these shRNAs are specific, we determined that
blockade of EphB2-induced presynaptic differentiation can be rescued by
coexpressing ephrin-B1 or ephrin-B2 shRNAs with constructs encoding the
appropriate molecule rendered insensitive to knockdown (Figure 2.1A and E).
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These results suggest that EphB-dependent presynaptic differentiation is
controlled by ephrin-B1 and ephrin-B2.
Presynaptic assembly is mediated in part by protein–protein interactions
with multidomain scaffolding molecules, many of which contain multiple PDZ
domains (Bresler et al., 2004). To test whether the ephrin-B PDZ-binding domain
is required for EphB-dependent presynaptic development, we coexpressed synGFP with HA-tagged ephrin-B1 lacking the PDZ-binding domain (HAeB1ΔPDZ)
in DIV3 neurons. Because the known intracellular signaling domains are highly
conserved, overexpression of intracellular mutants such as HAeB1ΔPDZ are
thought to act as dominant negatives and block PDZ-binding domain-dependent
signaling through all ephrin-B subtypes (Segura et al., 2007; Zimmer et al.,
2003). In DIV9 axons coexpressing HAeB1ΔPDZ and syn-GFP, EphB2expressing HEK293T cells failed to induce an increase in syn-GFP density
similar to that seen with knockdown of ephrin-B1 or ephrin-B2 (Figure 2.1D).
These results indicate that, similar to other molecules that mediate presynaptic
development (Dalva et al., 2007; Jin and Garner, 2008), EphB-dependent
presynaptic differentiation likely relies on protein–protein interactions with the
ephrin-B PDZ-binding domain.
Syntenin-1 Is Required for EphB-Dependent Presynaptic Development.
Interactions between the ephrin-B PDZ-binding domain and the tandem PDZ
domain-containing protein syntenin-1 have been demonstrated by GST pull-down
(Grootjans et al., 2000; Lin et al., 1999), yeast two-hybrid assay (Ko et al., 2006;
Terashima et al., 2004; Torres et al., 1998), and X-ray crystallography
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(Grembecka et al., 2006). Because a recent report (Ko et al., 2006)
demonstrated that syntenin-1 participates in the organization of presynaptic
terminals through interactions with ERC/CAST family members, we hypothesized
that ephrin-B may recruit presynaptic vesicles downstream of EphB by interacting
with syntenin-1. To test whether EphB-dependent presynaptic induction is
caused by syntenin-1 PDZ domain interactions, we generated a syntenin-1
molecule lacking the second PDZ domain (syntenin-1ΔPDZ2). The second PDZ
domain of syntenin-1 is required to bind ephrin-B (Grembecka et al., 2006;
Grootjans et al., 2000; Ko et al., 2006; Lin et al., 1999), and we confirmed that
syntenin-1ΔPDZ2 cannot bind ephrin-B1 by coimmunoprecipitation. Because this
mutant cannot interact with ephrin-Bs, we predicted that it might act in a
dominant negative fashion, similar to ephrin-B1ΔPDZ. We found that
overexpression of syntenin-1ΔPDZ2 blocked the ability of EphB2-expressing
HEK293T cells to induce an increase in syn-GFP in underlying axons (Figure
2.2A and B), suggesting that EphB-dependent presynaptic recruitment depends
on PDZ domain interactions between ephrin-Bs and syntenin-1.
To confirm the role of PDZ proteins in EphB-dependent presynaptic
induction, we generated shRNA constructs targeting syntenin-1 and GRIP1
(Figure 2.2D), a synaptically localized PDZ protein that can also interact with
ephrin-B (Bruckner et al., 1999; Lin et al., 1999). Although GRIP1 is primarily
thought to function postsynaptically, GRIP1 protein has also been identified in
axons (Wyszynski et al., 1999). In axons expressing GRIP1 shRNA, EphB2expressing HEK293T cells induced a significant increase in syn-GFP density,
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suggesting that GRIP1 is not involved in this process (Figure 2.2A and B).
However, in axons expressing either of two unique syntenin-1-targeting shRNAs,
fEphB2-expressing HEK293T cells failed to induce an increase in syn-GFP
density (Figure 2.2A and B). Knockdown of syntenin-1 had no effect on the
ability of ephrin-B1 or ephrin-B2 to bind exogenously applied EphB2-Fc,
suggesting that ephrin-Bs were still found at the cell surface (Supplementary
Figure 2.2). However, syntenin-1 knockdown did cause a decrease in the
colocalization of both ephrin-B1 and EphB2-Fc with syn-GFP, consistent with a
model in which syntenin-1 links ephrin-Bs to the presynaptic complex
(Supplementary Figure 2.2). The effects of syntenin-1 knockdown were rescued
by transfecting an shRNA targeting syntenin-1 together with a knockdowninsensitive syntenin-1 molecule (Figure 2.2A and C), demonstrating that the
effects of syntenin-1 shRNA constructs are specific. Taken together, these
results demonstrate that EphB-dependent presynaptic development is likely
mediated by ephrin-B1 and ephrin-B2, which can recruit presynaptic machinery
through PDZ domain interactions with syntenin-1.

Localization of Ephrin-B Subtypes and Syntenin-1 in Cultured Cortical
Neurons.
To begin to address how ephrin-Bs and syntenin function together to
regulate synapse development, we immunostained mature DIV21–30 cultures for
ephrin-B1, ephrin-B2, and syntenin-1 along with synaptic markers to determine
the distribution of these molecules in cortical neurons. We have previously
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reported that ephrin-B1 and ephrin-B3 are colocalized with excitatory presynaptic
and postsynaptic markers (Kayser et al., 2006). To determine how this
localization compares for ephrin-B2, we stained DIV21 cortical neurons for
ephrin-B2 and the presynaptic and postsynaptic markers VGlut1 and SynGAP
(Rao et al., 1998). Ephrin-B2 staining was found throughout cortical neuron
cultures. However, in contrast to the highly synaptic staining observed for ephrinB1 and ephrin-B3, the pattern of ephrin-B2 staining consisted of smaller puncta,
some of which were colocalized with synaptic puncta (Figure 2.3A). Consistent
with a previous report (Bundesen et al., 2003), we also observed a few cells with
intense ephrin-B2 staining that were positive for the glial marker GFAP (Figure
2.3B). We next directly compared the synaptic localization of ephrin-B1 and
ephrin-B2 by costaining DIV30 cultures for these molecules and VGlut1. Similar
to previous observations, ephrin-B1 was highly colocalized with VGlut1 (≈45%),
whereas ephrin-B2 was found in small puncta that were also colocalized with
VGlut1

(≈23%;

see

Supplementary

Table

2.1,

Figure

2.3C,

and

Supplementary Figure 2.3). In addition, many synaptic puncta colocalized with
both ephrin-B1 and ephrin-B2, and there was a significant association of these
two molecules at presynaptic sites (P < 0.0001; Pearson's χ2 test) (Figure 2.3C
and Supplementary Table 2.1). Interestingly, we often observed several small
ephrin-B2 puncta surrounding and adjacent to ephrin-B1-positive VGlut1 puncta
(Figure 2.3C Insets). Thus, both ephrin-B1 and ephrin-B2 colocalize with
synaptic markers, but the staining pattern is different from that for each ephrin-B
protein.
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The ephrin-B PDZ-binding domain can bind the tandem PDZ protein
syntenin-1 (Grembecka et al., 2006; Grootjans et al., 2000; Ko et al., 2006; Koroll
et al., 2001; Lin et al., 1999; Terashima et al., 2004; Torres et al., 1998), and our
findings that knockdown of syntenin-1 blocks EphB-dependent presynaptic
development suggests a model in which ephrin-Bs interact with the presynaptic
machinery via syntenin-1. To further address the relationship between syntenin,
ephrin-Bs, and the presynaptic machinery, we coimmunostained mature DIV21–
30 neurons for syntenin-1, the excitatory presynaptic marker VGlut1, and either
ephrin-B1 or ephrin-B2. Consistent with previous studies (Ko et al., 2006; Torres
et al., 1998), we found that syntenin-1 is localized to presynaptic specializations
(Figure 2.3D and E). In addition, we found that syntenin-1 is enriched at VGlut1positive presynaptic puncta containing ephrin-B1 or ephrin-B2 (P < 0.0001;
Pearson's χ2 test) (Figure 2.3D and E and Supplementary Table 2.1). These
results demonstrate that ephrin-B1, ephrin-B2, and syntenin-1 are associated at
presynaptic specializations.

Presynaptic Ephrin-B1 and Ephrin-B2 Are Required for the Development of
Synapses and Recruitment of Syntenin-1.
To

test

whether

ephrin-Bs

regulate

the

formation

of

synaptic

specializations, we examined the density of synapses in single axons after
knockdown of ephrin-B1 or ephrin-B2 in the absence of exogenous stimulation
with EphB2-expressing HEK293T cells. EphB-dependent synapse formation
occurs between DIV7–14, and robust decreases in synapse number can be seen
51

by knocking down EphB2 from DIV3–21 (Kayser et al., 2008). Therefore, to
identify the effects of ephrin-Bs on EphB-dependent synapse development,
neurons were cotransfected with ephrin-B shRNA and syn-GFP constructs at
DIV3, fixed at DIV21–23, and immunostained for GFP and the postsynaptic
marker PSD-95. Synapses were identified as colocalization between syn-GFP
and endogenous PSD-95 puncta. Our low transfection efficiencies allowed us to
selectively examine the presynaptic role of ephrin-Bs during synapse
development. Knockdown of ephrin-B1 or ephrin-B2 with either of two unique
shRNA constructs for each led to a significant decrease in the density of both
syn-GFP puncta and colocalized synaptic puncta (Figure 2.4A-E and
Supplementary Figure 2.4). Together, these results demonstrate that reducing
the expression of ephrin-B1 or ephrin-B2 results in fewer synapses.
To begin to investigate whether ephrin-B1 and ephrin-B2 function
independently in the formation of synaptic contacts, we compared the effects of
individual ephrin-B knockdown to simultaneous knockdown of ephrin-B1 and
ephrin-B2 in the same axon. This approach is designed to mimic genetic
experiments in which a single functional pathway is demonstrated by a more
severe phenotype in double hypomorphic mutants than in the single mutants
((Boone et al., 2007; Mani et al., 2008) and see SI Text). To achieve this we used
partial shRNA knockdown for both ephrin-B1 and ephrin-B2 in tandem.
To interpret double-knockdown experiments, knockdown of each molecule
must be sufficient to create a sensitized background but not to an extent that
further changes cannot be observed. Because shRNA-mediated knockdown is
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incomplete, and the effects we observe on synapse number is partial, it is likely
that the effects of single knockdown can be modified by double knockdown.
Nevertheless, to ensure that knockdown levels were moderate, we first identified
reduced amounts of ephrin-B1 and ephrin-B2 shRNA that generated similar, but
decreased, levels of knockdown in non-neuronal cells (Supplementary Figure
2.5 and SI Text). The expression of this reduced amount of ephrin-B1 shRNA
resulted in a small, but significant, reduction in the number of syn-GFP puncta
without a change in the number of colocalized synaptic puncta (Figure 2.4F-H),
suggesting that this level of ephrin-B1 knockdown creates a sensitized
background. The expression of ephrin-B2 shRNA at this reduced level resulted in
a significant effect on the number of both syn-GFP puncta and colocalized
synaptic puncta, which is also consistent with a sensitized background.
Interestingly, the differences between the effects of ephrin-B knockdown suggest
that synaptic specializations are more susceptible to changes in the expression
level of ephrin-B2 than ephrin-B1. These findings suggest that knockdown of
ephrin-B1 and ephrin-B2 with reduced levels of shRNA is suitable for the
evaluation of double knockdown.
We next asked whether coexpression of these shRNAs might potentiate
the effects on synapse density. When expressed together at these reduced
levels, simultaneous knockdown of both ephrin-B1 and ephrin-B2 caused a
decrease in synapse density similar to knockdown of ephrin-B2 alone (Figure
2.4F and H). Thus, the effects of ephrin-B1 and ephrin-B2 shRNAs do not
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appear to be additive, consistent with ephrin-B1 and ephrin-B2 functioning
nonredundantly in the formation of synaptic contacts.
Because

syntenin-1

is

required

for

EphB-dependent

presynaptic

development, and ephrin-Bs are enriched at synaptic specializations containing
syntenin-1, we next asked how knockdown of ephrin-Bs specifically affects the
localization of syntenin-1 to synapses. To address this question, we expressed
ephrin-B1 and ephrin-B2 shRNA, alone or together, and determined the number
of synapses that contain syntenin-1. We found that expression of reduced levels
of ephrin-B2 shRNA, but not ephrin-B1 shRNA, led to a significant decrease in
the number of synaptic puncta containing syntenin-1 (Figure 2.4F). However,
simultaneous knockdown of ephrin-B1 and ephrin-B2 together resulted in a
further significant reduction in the number of synapses containing syntenin-1
compared with either ephrin-B1 or ephrin-B2 alone (Figure 2.4F). These results
suggest that both ephrin-B1 and ephrin-B2 are involved in normal syntenin-1
localization, and that ephrin-B1 and ephrin-B2 may function together during the
formation of syntenin-1-containing synapses. Because decreases in the density
of syntenin-1-containing synapses after ephrin-B knockdown might be caused by
the overall loss in synapses number (Figure 2.4H), we asked how knockdown of
ephrin-B1 and/or ephrin-B2 affected the ability of syntenin-1 to localize to the
remaining synaptic contacts. For each axon, we determined the proportion of
synapses that contain syntenin-1 by dividing the density of syntenin-1-containing
synapses (Figure 2.4I) by the overall density of synaptic contacts (Figure 2.4H).
We found that neither knockdown of ephrin-B1 nor ephrin-B2 led to a decrease in
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the percentage of synaptic contacts containing syntenin-1 (Figure 2.4F and J),
suggesting that ephrin-B1 and ephrin-B2 each can compensate for the loss of the
other at the remaining synapses. However, simultaneous knockdown of ephrinB1 and ephrin-B2 together resulted in a significant reduction in the percentage of
synaptic puncta that contain syntenin-1 (Figure 2.4F and J). Thus, simultaneous
knockdown of both ephrin-B1 and ephrin-B2 results in a synergistic effect on the
ability of syntenin-1 to localize to synaptic contacts. Taken together, these results
suggest that ephrin-B1 and ephrin-B2 are required for normal numbers of
excitatory synapses and appear to function in a partially redundant fashion in the
recruitment of syntenin-1 to synaptic specializations.
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Discussion
In this study we show that ephrin-B1 and ephrin-B2 are key regulators of
EphB-dependent

presynaptic

development,

likely

through

PDZ

domain-

dependent interactions with syntenin-1. Ephrin-B1, ephrin-B2, and syntenin-1
colocalize at synaptic contacts, and knockdown of ephrin-B1 or ephrin-B2 leads
to a reduction in the number of synaptic contacts. Simultaneous knockdown of
both ephrin-B1 and ephrin-B2 suggests that these molecules are required for the
synaptic localization of syntenin-1, but function independently in the control of
synapse formation. In sum, these results support a model in which excitatory
synapse

development

occurs

via

a

trans-synaptic

interaction

between

postsynaptic EphB and specific presynaptic ephrin-Bs (Supplementary Figure
2.6).
Further study will be necessary to elucidate the mechanisms that
determine specificity among different ephrin-B family members. Potential
mechanisms include differences in signaling, localization, or affinity for EphBs.
Differences in signaling or localization could be mediated by domains of the wellconserved juxtamembrane regions of ephrin-B1 and ephrin-B2, which diverges in
ephrin-B3; affinity differences are possible given that ephrin-B3 has a slightly
lower binding affinity for EphBs than ephrin-B1 or ephrin-B2 (Flanagan and
Vanderhaeghen, 1998).
To study the role of ephrin-Bs in EphB-dependent presynaptic
development, we have developed an assay that allows us to simultaneously
manipulate both members of a trans-synaptic interaction pair. In previous
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experiments using coculture assays (Biederer and Scheiffele, 2007), a single
molecule of a potential interaction pair was expressed in heterologous cells, and
the trans-synaptic binding partner was inferred. In contrast, our modified
coculture system allows us to evaluate the effects of molecular interactions
between pairs of cells that may occur in vivo. In addition, our assay allows us to
study the intracellular events downstream of trans-synaptic interactions that
induce presynaptic maturation. By coculturing heterologous cells expressing
fEphB2 with neurons expressing shRNA constructs targeting ephrin-B family
members, we provide direct evidence simultaneously implicating both members
of a receptor–ligand pair in the trans-synaptic control of synapse formation.
These findings are validated by our long-term knockdown experiments.
Presynaptic organization is supported by multidomain scaffolding
molecules that regulate both structure and signaling at presynaptic terminals,
including the PDZ domain-containing proteins Mint, CASK, Piccolo, RIM, and
syntenin-1 (Jin and Garner, 2008). Syntenin-1 binds directly to the ephrin-B PDZbinding domain (Grembecka et al., 2006; Grootjans et al., 2000; Ko et al., 2006;
Koroll et al., 2001; Lin et al., 1999; Terashima et al., 2004; Torres et al., 1998)
and is linked to presynaptic maturation via ERC2/CAST1 (Ko et al., 2006).
ERC2/CAST1 associates with a number of other presynaptic molecules,
including RIM, Piccolo, Bassoon, and liprin-α. RIM1 binds the synaptic vesicle
protein Rab3A, and ERC2/CAST1 interacts with RIM1 and Piccolo/Bassoon to
regulate synaptic transmission (Jin and Garner, 2008). Thus, syntenin-1 provides
a directly link by which ephrin-B can associate with a protein complex involved in
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the recruitment and regulation of presynaptic vesicles (Supplementary Figure
2.6).
The degree to which presynaptic development is mediated by specific
interactions between synaptogenic factors and particular scaffolding proteins is
not well established. The finding that disruption of syntenin-1 blocks EphBdependent presynaptic development suggests that presynaptic development can
be mediated by specific interactions between ephrin-Bs and syntenin-1. This
pathway is likely distinct from those involving other PDZ domain interactions such
as that between neurexin and Mint/CASK (Jin and Garner, 2008). Thus, these
results suggest that presynaptic terminals may be organized by independent
pathways.
Knockdown of ephrin-B1 or ephrin-B2 alone disrupts EphB-dependent
presynaptic development and results in a decrease in the number of synaptic
contacts. To test whether ephrin-B1 and ephrin-B2 function together or
independently in synaptogenesis, we transfected neurons with shRNAs targeting
both of these proteins to induce a partial loss in single neurons. Because we
selected shRNA levels that generated a partial loss of function, results from
these experiments are interpreted as analogous to genetic experiment using
trans-heterozygous animals (Boone et al., 2007). However, while knockdown
using shRNAs has often been described as generating a hypomorphic condition,
it remains possible that simultaneous use of two shRNAs results in unexpected
effects. Therefore, to fully resolve the roles of these proteins additional complex
genetic experiments will be needed. Regardless, our simultaneous knockdown
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experiments suggest that ephrin-B1 and ephrin-B2 likely function independently
to control EphB-dependent synapse development. There are several possible
explanations that account for these findings. While ephrin-B1 and ephrin-B2
share functional domains, they may coordinate synapse development through
distinct pathways. Consistent with this idea, neurons display different sensitivities
to the knockdown of ephrin-B1 versus ephrin-B2 for the formation of synaptic
contacts, and the staining pattern of ephrin-B1 and ephrin-B2 is different at the
level of individual synaptic puncta (Figure 2.3C). This specificity may be
mediated by differences in trans-synaptic interactions or by distinct, currently
unidentified, functional domains. Alternatively, while ephrin-B1 and ephrin-B2
colocalize at many synapses, they are often found alone. Thus, one mechanism
for the function of the ephrin-Bs in synapse formation might be their localization
to different synaptic puncta.
Ephrin-B1 and ephrin-B2 do appear to function together to recruit
syntenin-1 to synapses. Evidence for this synergy comes from our findings that
combined knockdown of ephrin-B1 and ephrin-B2 lead to a significant further
reduction in density and percentage of synaptic specializations that colocalize
with syntenin-1. One likely mechanism is the identical PDZ-binding domains
found on ephrin-B1 and ephrin-B2, suggesting that they can both bind syntenin-1
with equal affinity. Although more work will be needed to resolve the different
roles of ephrin-B1 and ephrin-B2 in synaptic development, our results provide
evidence that ephrin-B1 and ephrin-B2 function to mediate EphB-dependent
presynaptic maturation via syntenin-1.
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Materials and Methods
For detailed methods see SI Text.

Cell Culture and Transfection.
Primary dissociated cortical neurons were prepared from embryonic day 17 (E17)
to E18 rats and transfected at DIV0 or DIV3 as described (Kayser et al., 2006;
Kayser et al., 2008). See SI Text for details on the culture conditions for the
heterologous cell culture assay.

Expression and shRNA Constructs.
Nineteen-nucleotide RNAi sequences were identified for ephrin-B1, ephrin-B2,
and ephrin-B3. Sequences used for shRNAs and details for HA-ephrin-B1, HAephrin-B2, and FLAG-syntenin-1 constructs are in SI Text. Except when noted,
0.75 μg of shRNA construct per well (of 24-well plate) was transfected into
neurons.

Western Blot Analysis.
See SI Text for more details.

Imaging and Analysis.
Cultures were fixed and immunostained using methods similar to those described
in (Dalva et al., 2007). Significance between experimental conditions was
determined by ANOVA, except where noted. Statistical measures were
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conducted on a per-cell basis, collected from a minimum of three independent
experiments. See SI Text for details.
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Figure Legends

Fig. 2.1. Ephrin-B1 and ephrin-B2 are required for EphB2-dependent
presynaptic development. (A) Representative images of DIV10 cortical neuron
axons transfected with syn-GFP and shRNA constructs at DIV3 and cocultured
with HEK293T cells transfected with RFP or FLAG-EphB2 (fEphB2). Arrowheads
indicate syn-GFP puncta colocalized with HEK293T cells. (Scale bar: 3 μm.) (B)
Quantification of fold increase in syn-GFP puncta density in axon segments
contacting HEK293T cells expressing fEphB2 or control constructs compared
with adjacent axon segments (syn-GFP induction) for neurons transfected with
indicated shRNA constructs: vector control (RFP: n = 19; fEphB2: n = 29),
ephrin-B1 shRNA#1 (RFP: n = 14; fEphB2: n = 29), ephrin-B3 shRNA (RFP: n =
21; fEphB2: n = 30). (C) Quantification of axonal syn-GFP induction: vector
control (n = 40), ephrin-B1 shRNA#2 (n = 47), ephrin-B2 shRNA#1 (n = 24), or
ephrin-B2 shRNA#2 (n = 20). (D) Quantification of axonal syn-GFP induction:
vector control (n = 25), ephrin-B1 shRNA#1 (n = 26); HA-ephrin-B1ΔPDZ (n =
24). (E) Quantification of axonal syn-GFP induction: vector control (n = 50),
ephrin-B1 shRNA#1 (n = 25), ephrin-B1 shRNA#1 + rescue (n = 27), ephrin-B2
shRNA#1 (n = 30), or ephrin-B2 shRNA#2 + rescue (n = 28). (F) Western blots of
lysates from HEK293T cells transfected with HA-ephrin-B1 or HA-ephrin-B2 plus
vector control, ephrin-B1 shRNA#1, ephrin-B1 shRNA#2, ephrin-B2 shRNA#1, or
ephrin-B2 shRNA#2 and probed for HA and β-tubulin. Error bars indicate SEM. *,
P < 0.04.
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Figure 2.2. Syntenin-1 is required for EphB-dependent presynaptic
development. (A) Representative images of DIV10 cortical neuron axons
transfected with syn-GFP and indicated constructs and cocultured with HEK293T
cells transfected with RFP or fEphB2. Arrowheads indicate syn-GFP puncta
colocalized with HEK293T cells. (Scale bar: 3 μm.) (B) Quantification of axonal
syn-GFP induction for neurons transfected with the indicated shRNA constructs:
vector control (RFP: n = 76; fEphB2: n = 76), ephrin-B1 shRNA#2 (RFP: n = 26;
fEphB2: n = 33), syntenin-1ΔPDZ2 (RFP: n = 32; fEphB2: n = 35), syntenin-1
shRNA#1 (RFP: n = 30; fEphB2: n = 29), syntenin-1 shRNA#2 (RFP: n = 27;
fEphB2: n = 30), or GRIP1 shRNA (RFP: n = 43; fEphB2: n = 47). (C)
Quantification of axonal syn-GFP induction: vector control (RFP: n = 27; fEphB2:
n = 31), syntenin-1 shRNA#1 (RFP: n = 31; fEphB2: n = 32), or syntenin-1
shRNA#1 + rescue (RFP: n = 27; fEphB2: n = 30). (D) Western blots of lysates
from HEK293T cells transfected with FLAG-syntenin-1 or myc-GRIP1 plus vector
control, syntenin-1 shRNA#1, syntenin-1 shRNA#2, or GRIP1 shRNA and probed
for FLAG or myc and β-tubulin. Error bars indicate SEM. **, P < 0.002; *, P <
0.04.

Figure 2.3. Localization of ephrin-B1, ephrin-B2, and syntenin-1 in cultured
cortical neurons. (A) Representative image of DIV21 neurons stained for
ephrin-B2 (green), SynGAP (blue), and VGlut1 (red). (Scale bar: 3 μm.) (B)
Representative image of DIV21 neurons stained for ephrin-B2 (green) and GFAP
(red). (Scale bar: 10 μm.) (C) Representative image of DIV30 neurons stained for
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ephrin-B1 (green), ephrin-B2 (red), and VGlut1 (blue). See SI Text for staining
details. Mask of merge is RGB image created from binary masks of the three
individual channels. Image shown is of only the colocalized pixels with all other
pixels removed. Colocalization in masks is indicated by: ephrin-B1 and ephrinB2, yellow; ephrin-B1 and VGlut1, cyan; ephrin-B2 and VGlut1, magenta. (Scale
bar: 3 μm.) (Inset) High-magnification image of boxed region. (Scale bar: 1 μm.)
(D and E) Representative image of DIV21 neurons stained for syntenin-1 (green),
VGlut1 (blue) and either ephrin-B1 (D) or ephrin-B2 (E) (red). Arrowheads
indicate triple colocalization. (Scale bar: 3 μm.)

Fig. 2.4. Presynaptic ephrin-B1 and ephrin-B2 are required for synapse
formation and synaptic localization of syntenin-1. (A) (Left and Center)
Representative images of DIV21–23 axons transfected at DIV3 with syn-GFP
and indicated shRNA construct costained for GFP (green) and PSD-95 (red).
(Scale bar: 3 μm.) (Right) Mask of colocalization created by identifying
colocalized puncta in binary masks from syn-GFP and PSD-95 images. (B–E)
Quantification of density of syn-GFP puncta (B and D) and synaptic puncta
defined by colocalized syn-GFP and PSD-95 (C and E) for vector control (n = 21)
or ephrin-B1 shRNA#1 (n = 24) (B and C) and vector control (n = 19), ephrin-B1
shRNA#2 (n = 19), ephrin-B2 shRNA#1 (n = 12), or ephrin-B2 shRNA#2 (n = 19)
(D and E). (F) (Left and Center) Representative images of DIV21 axons
transfected at DIV3 with syn-GFP and indicated shRNA construct costained for
GFP (green), syn-GAP (red), and syntenin-1 (blue). Arrowheads indicate
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synaptic puncta identified colocalization of syn-GFP and SynGAP puncta. Arrows
indicate colocalized SynGAP and syntenin-1 puncta. (Scale bar: 3 μm.) (Right)
Schematic showing outlines of synaptic syn-GFP puncta and areas of
colocalization with syntenin-1 in blue. (G–J) Quantification of syn-GFP puncta
density (G), synaptic puncta identified by colocalization of syn-GFP and SynGAP
(H), synaptic syntenin-1 (triple colocalized syn-GFP, SynGAP, and syntenin-1)
puncta density (I), and percentage of synaptic puncta that colocalize with
syntenin-1 for neurons transfected with vector control (n = 30), ephrin-B1
shRNA2 (n = 29), ephrin-B2 shRNA1 (n = 26), and ephrin-B1 shRNA2 + ephrinB2 shRNA1 (n = 25) (J). Error bars indicate SEM. *, P < 0.05; **, P < 0.003.

65

Supporting Information
SI Text

Ephrin-B3 Knockdown Validation. To confirm that knockdown constructs
targeting ephrin-B3 are effective in reducing the expression of ephrin-B3 in
neurons, we evaluated ephrin-B3 immunostaining in neurons expressing ephrinB3 knockdown constructs. DIV0 cortical neurons were transfected with GFP and
ephrin-B3 shRNA or vector control. At DIV10, neurons were fixed and
immunostained for GFP and ephrin-B3. We then measured both the number of
endogenous

ephrin-B3

puncta

and

the

overall

intensity

of

ephrin-B3

immunostaining. We found a significant decrease in both the intensity of ephrinB3 immunostaining and the number of ephrin-B3 puncta (Supplementary Figure
2.1). Moreover, consistent with recent reports (Aoto and Chen, 2007), we found
that expression of this ephrin-B3-targeting knockdown construct leads to a
significant decrease in the number of postsynaptic specializations.

Syntenin-1 Knockdown Does Not Affect Ephrin-B Surface Localization. To
address whether the effects of syntenin-1 knockdown on EphB-dependent
presynaptic induction are caused by a role for syntenin-1in ephrin-B trafficking,
we tested whether ephrin-B1 and ephrin-B2 could localize to the cell surface in
the presence of syntenin-1 knockdown. To identify surface localized ephrin-B in
knockdown axons, we cotransfected DIV3 neurons with syn-GFP and syntenin-1
shRNA or vector control. At DIV10, we treated live neurons with the extracellular
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domain of EphB2 tagged to the human Fc fragment (EphB2-Fc) to label surface
ephrin-B. Neurons were fixed and stained for GFP, the human Fc fragment to
label EphB2-Fc, and ephrin-B1 or ephrin-B2. We then measured the percentage
of ephrin-B puncta in syn-GFP positive axons that were labeled with EphB2-Fc.
Consistent with a model in which syntenin links ephrin-Bs to presynaptic
specializations, we found that syntenin-1 knockdown led to a decrease in the
number of syn-GFP puncta colocalized with ephrin-B1 and EphB2-Fc
(Supplementary Figure 2.2C and G). Interestingly, we did not detect a change
in the density of ephrin-B2 colocalized with syn-GFP (Supplementary Figure
2.2E). When we evaluated the proportion of ephrin-B that was exposed to the
surface, we found that the percentage of ephrin-B1 or ephrin-B2 puncta labeled
with EphB2-Fc was unchanged with expression of syntenin-1 shRNA
(Supplementary Figure 2.2D and F). These results suggest that the effects of
syntenin-1 knockdown on EphB2-dependent presynaptic development are not
caused by an effect on ephrin-B surface localization.

Ephrin-B1

and

Ephrin-B2

Co-immunostaining.

To

simultaneously

immunostain with anti-ephrin-B1 and anti-ephrin-B2 primary antibodies that were
both raised in goat, we used rabbit anti-goat Fab fragments to convert the goat
IgG epitope of the antiephrin-B2 antibody to rabbit. We confirmed that ephrin-B1
and ephrin-B2 recognize the target protein expressed in HEK293T cells and not
other ephrin-B family members by Western blot, and the specificity of the ephrinB2 antibody has been confirmed in mice lacking ephrin-B2 (Grunwald et al.,
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2004). Before staining, goat antiephrin-B2 antibodies were preincubated with
rabbit anti-goat Fab fragments at a ratio of 650:1 by weight. After fixation and
blocking with standard conditions, cells were incubated with goat anti-ephrinB2/Fab conjugates for 2 h at room temperature followed by goat anti-ephrin-B1
and guinea pig anti-VGlut1 primary antibodies overnight at 4 °C. Secondary
labeling was performed with Cy2-conjugated donkey anti-goat, Cy3-conjugated
donkey anti-rabbit, and Cy5-conjugated donkey anti-guinea pig (Supplementary
Figure 2.3A). To validate the effectiveness of the Fab fragments, we evaluated
two control conditions. First, we performed the identical staining as described
above but without goat anti-ephrin-B1 primary antibody. In this condition, we
observed normal staining of the goat anti-ephrin-B2/Fab conjugates with Cy3
anti-rabbit secondary antibodies, but we did not observe any labeling with Cy2
anti-goat antibodies, demonstrating that the Fab fragment effectively blocked the
goat epitope of the ephrin-B2 antibody (Supplementary Figure 2.3B). Second,
we performed the identical staining as described above but without the goat antiephrin-B1 antibody or the rabbit anti-goat Fab fragment (Supplementary Figure
2.3C). In this condition, the staining pattern for the Cy2 anti-goat secondary is
identical to that as for the Cy3 anti-rabbit secondary in Supplementary Figure
2.3A and B, indicating that the Fab fragment accurate converts the goat epitope
of the ephrin-B2 antibody to rabbit. In addition, we did not observe any labeling
with the Cy3 anti-rabbit secondary, demonstrating that the Cy3 labeling in
Supplementary Figure 2.3A was only caused by the Fab fragment labeling of
the goat anti-ephrin-B1 antibody. Taken together, these results confirm that the
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Fab fragment effectively blocks anti-goat secondary reagents and accurately
converts the ephrin-B2 epitope into rabbit. Thus, the pattern observed with antirabbit and anti-goat secondary reagents after application of goat-ephrin-B2/Fab
conjugates with goat anti-ephrin-B1 antibody accurately represents the staining
pattern of these antibodies.

Ephrin-B Knockdown at DIV9. To confirm that the effects of ephrin-B shRNA
constructs are caused by reduction in ephrin-B expression, we conducted
experiments to determine whether the decreases in synaptic specializations
induced by ephrin-B knockdown could be rescued by coexpressing ephrin-B1
shRNA constructs with an HA epitope-tagged ephrin-B1 with silent mutations in
the region targeted by our shRNA construct (HAeB1R). In these experiments,
DIV0 cortical neurons were cotransfected with syn-GFP and ephrin-B shRNA or
vector control, and the density of syn-GFP was determined at DIV9. Compared
with control conditions, axons of neurons expressing ephrin-B1 shRNA
constructs had a ~25% decrease in the density of syn-GFP (Supplementary
Figure 2.4). Coexpression of ephrin-B1 shRNA with HAeB1R constructs rescued
the effects of ephrin-B1 knockdown, resulting in a syn-GFP puncta density similar
to control (Supplementary Figure 2.4), suggesting that the effects we observed
after transfection of shRNA are specific.
We also examined the effects of ephrin-B3 shRNA on the development of
synaptic specializations. Consistent with the effect on EphB-dependent
presynaptic induction, knockdown of ephrin-B3 did not lead to a decrease in syn69

GFP puncta density (Supplementary Figure 2.4). In contrast, knockdown of
ephrin-B3 resulted in syn-GFP puncta that were smaller and less evenly
distributed than in control conditions, resulting in an increased syn-GFP density
(Supplementary Figure 2.4). It has previously been shown that loss of ephrinB3 leads to a generalized increase in the expression of a number of synaptic
proteins (Rodenas-Ruano et al., 2006), and this effect may lead to an increase in
disorganized presynaptic clusters in ephrin-B3 knockdown conditions. In addition,
as described, ephrin-B3 shRNA does not affect EphB-dependent presynaptic
formation (Figure 2.1).

These results suggest that knockdown of ephrin-B3

presynaptically leads to a phenotype that is consistent with that observed in mice
lacking ephrin-B3, but ephrin-B3 does not appear to be required for EphBinduced presynaptic specializations. Taken together, these results demonstrate
that knockdown of ephrin-B1 or ephrin-B2 in axons leads to a reduction in
excitatory synapse number and disrupts the ability of EphB2 to induce
presynaptic differentiation. Thus, ephrin-Bs appear to mediate EphB-dependent
presynaptic development but not all ephrin-Bs participate in this process.

Identifying Reduced Amounts of Ephrin-B shRNA Constructs for Double
Knockdown. To evaluate the potential redundancy of ephrin-B1 and ephrin-B2
knockdown, we used a double-knockdown approach modeled on genetic
experiments in which interactions between genes are identified by a phenotype in
a double mutant that cannot be accounted for by the effects of the single mutants
alone (Mani et al., 2008). In these genetic experiments, the interpretation of an
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identified interaction depends on the nature of the genetic manipulation. An
interaction between two null alleles suggests that the two gene products function
in parallel pathways that converge on a shared function; in contrast, an
interaction between two hypomorphs suggests that the two gene products
function in a single pathway (Boone et al., 2007). To replicate the latter condition
in our double-knockdown experiments, we used reduced amounts of shRNA for
ephrin-B1 and ephrin-B2 that were more similar to hypomorphs than nulls. To
identify reduced amounts of ephrin-B1 and ephrin-B2 knockdown constructs that
were suitable for use in double knockdown experiments, we evaluated the
relationship between the amount of ephrin-B shRNA constructs transfected into
cells and the amount of knockdown achieved. We transfected HEK293T cells
with HA-ephrin-B1 or HA-ephrin-B2 and different amounts of ephrin-B1 shRNA2
or ephrin-B2 shRNA1, respectively. The total amount of shRNA construct
transfected was maintained at 1 µg in each condition with corresponding
amounts of empty control vector. We found that there is a steady decrease in
knockdown effect from 1 µg per well (of a six-well plate) to 0.083µg per well
(Supplementary Figure 2.5). Very little knockdown was observed at low
amounts of shRNA constructs (0.017 µg per well; Supplementary Figure 2.5).
Knockdown levels were similar at equivalent shRNA construct amount between
ephrin-B1 and ephrin-B2 (Supplementary Figure 2.5). These results suggest
that ephrin-B shRNA constructs are effective over a wide range of amounts, but
that absolute level of knockdown is proportional to the amount of shRNA
construct transfected. For double-knockdown experiments (Figure 2.4 F-J), we
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reduced the amount of ephrin-B1 shRNA2 by 50% relative to other experiments
(0.375 µg per well of a 24-well plate) and by 75% for ephrin-B2 shRNA2 (0.187
µg per well). To determine that our dual-knockdown assay could effectively
measure increasing effects of simultaneous knockdown we considered and
addressed possible limitations. As discussed in the main text, shRNA-mediated
knockdown does not completely prevent protein expression; therefore,
knockdown is likely to give a suitable background for measuring additive effects.
To help to ensure this, we determined lower amounts of knockdown that could
still generate effects (see Figure 2.4H-J and Supplementary Figure 2.5). An
important potential concern arises from the fact that ephrin-B2 knockdown
generates a larger effect on synapse number than ephrin-B1 knockdown,
because the greater effect on synapse number of ephrin-B2 shRNA may
represent the largest effect beyond which further decreases in synapse number
are difficult to detect. However, this possibility is unlikely because the reduced
level of knockdown results in only a partial knockdown of ephrin-B protein, and
our assay has the sensitivity needed to detect larger decreases in synapse
density (Figure 2.4I-J).

Cell Culture and Transfection. Neurons were cultured in neurobasal
(Invitrogen), B27 supplement (Invitrogen), glutamine (Sigma), and penicillin–
streptomycin (Sigma) on poly-D-lysine (BD Biosciences or Sigma) and laminin
(BD Biosciences)-coated glass coverslips (12 mm; Bellco Glass) in 24-well plates
(Costar). Cells were plated at 150,000 per well maintained in a humidified
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incubator with 5% CO2 at 37 °C. As indicated, neurons were transfected either
with Lipofectamine 2000 (Invitrogen) in suspension immediately before plating
(Takasu et al., 2002) or at 3 DIV using the calcium phosphate method (Xia et al.,
1996).

shRNA Constructs. Sequences used were:
ephrin-B1 shRNA#1, 5’-GTTCCTAAGTGGGAAGGGC-3’;
ephrin-B1 shRNA#2, 5’-CACTGTGCTTGATCCCAAT-3’;
ephrin-B2 shRNA#1, 5’-GCAGACAGATGCACAATTA-3’;
ephrin-B2 shRNA#2, 5’-GAGACAAATTGGATATTAT-3’;
ephrin-B3 shRNA, 5’-GCCTTCGGAGAGTCGCCAC-3’;
syntenin-1 shRNA#1, 5’-GTCTTTAAGTGAAGCTGAA-3’;
syntenin-1 shRNA#2, 5’-CAGTGGACATGTTGGCTTT-3’; and GRIP1 shRNA, 5’GAGAGTTCCGGAGCGATTA-3’. Forward and reverse oligonucleotides were
synthesized (Integrated DNA Technologies) such that, when annealed, they
generated a dsDNA insert consisting of the forward and reverse complement
RNAi sequences separated by a hairpin region and flanked by restriction site
overhangs. Inserts were subcloned into pSuper (Brummelkamp et al., 2002).

Expression Constructs. HA-ephrin-B2 was generated by cloning ephrin-B2
from mouse cDNA using sequence-specific primers and then QuikChange
(Invitrogen) to insert the HA coding sequence flanked by unique restriction sites
immediately downstream of the signal sequences. The HA-ephrin-B1, HA-ephrin73

B2, and FLAG-syntenin-1 rescue constructs were generated by creating seven to
nine silent mutations within the sequence targeted by ephrin-B1 shRNA#1,
ephrin-B2 shRNA#1, and syntenin-1 shRNA#1 sequences, respectively. HAephrin-B1ΔPDZ was created by amplifying the full-length HA-ephrin- B1 without
the four terminal amino acids. Syntenin-1ΔPDZ2 was created by QuikChange to
remove the second PDZ domain (amino acids 198–272). Synaptophysin-GFP in
pFUGW vector was a generous gift from M. Lush and J. Raper. FLAG-syntenin-1
and myc-GRIP1 were kind gifts of E. Kim (Ko et al., 2006) and R. Huganir,
respectively.

Immunocytochemistry. Cultures were fixed in 4% paraformaldehyde/2%
sucrose for 8 min at room temperature. Cells were washed three times in PBS
and blocked and permeabilized in 1% ovalbumin (Sigma)/0.2% cold water fish
scale gelatin (Sigma)/ 0.1% saponin (Sigma) for 1 h at room temperature.
Antibody incubations were conducted overnight at 4 °C for primary antibody and
1 h at room temperature in secondary antibody diluted in blocking reagents.
Dilutions of each antibody used is reported below. For double labeling for ephrinB1 and ephrin-B2, the goat IgG epitope of ephrin-B2 was converted to rabbit by
preincubation with goat anti-rabbit Fab fragments (Jackson ImmunoResearch).
Antibodies used were: chicken anti-GFP (Upstate; 1:2,500), mouse anti-FLAG
M2 (Sigma; 1:2,000), rabbit anti-ephrin-B3 (Zymed, 1:50), goat anti-ephrin-B1
(R&D Systems; 1:500), goat anti-ephrin-B2 (R&D Systems; 1:500), mouse antiPSD95 (Affinity BioReagents; 1:200), rabbit anti-SynGAP (Affinity BioReagents;
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1:1,000), guinea pig anti-VGlut1 (Chemicon; 1:5,000), mouse anti-syntenin-1
(Synaptic Systems; 1:200), and mouse anti-GFAP (Boehringer Manheim; 1:500).

Western Blot Analysis. Lysates from HEK293T cells were separated by
SDS/PAGE and transferred onto 0.45-µm PVDF membranes (Millipore).
Immunoblots were blocked in 5% milk in TBST (150 mM NaCl/10 mM Tris, pH
8.0/0.05% Tween 20) and blotted for indicated proteins. Antibodies used were
mouse anti-HA (Covance), mouse anti-Myc (DSHB; 9E10), mouse
anti-FLAG M2 (Sigma), mouse anti-β-tubulin (DSHB; E19), and rabbit anti-actin
(Sigma).

Ephrin-B Surface Labeling. Cultured cortical neurons were treated with EphB2Fc (R&D Systems) preclustered with donkey antihuman Fc antibody (Jackson
ImmunoResearch; see (Kayser et al., 2006)) for 60 min at 37 °C. Cultures were
washed once in PBS and fixed as described.

Imaging and Analysis. Images of primary neuronal cultures were acquired by
using confocal scanning microscopy (Leica). All images were acquired and
subsequently analyzed with custom designed National Institutes of Health
ImageJ

macros

blind

to

experimental

condition.

Significance

between

experimental conditions was determined by ANOVA, except where noted.
Statistical measures were conducted on a per-cell basis, collected from a
minimum of three independent experiments. For puncta analysis, images were
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converted to binary scale, and puncta were identified as continuous groups of
pixels corresponding to 0.5–7.5 µm. Colocalization between puncta was defined
as >1 pixel overlap between channels. Linear density measurements were
obtained by identifying puncta along at least 50 µm of axon per image.
For heterologous coculture experiments, synaptophysin-GFP puncta
density was determined as described above for axon regions colocalized with
HEK293T cells and for adjacent axon regions (starting >5µm away from
HEK293T cell border). Syn-GFP induction was determined by dividing puncta
density colocalized with HEK293T cells by density in adjacent regions.
To determine endogenous ephrin-B3 staining intensity in GFP-expressing
neurons cotransfected with constructs encoding ephrin-B3 shRNA, the average
intensity of pixels colocalized with a GFP mask in which the soma had been
removed was measured in nonsaturated images of ephrin-B3 staining in neurons
cotransfected with either vector control or ephrin-B3 shRNA collected with
identical microscope settings.
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Supplementary Figure Legends

Supplementary

Figure

2.1.

Validation

of

endogenous

ephrin-B3

knockdown. (a and b) Representative images of DIV10 neurons expressing
GFP plus vector control (a) or ephrin-B3 shRNA (b) and stained with anti-GFP
(green) and anti-ephrin-B3 (red) antibodies. (c and d) Endogenous ephrin-B3
staining from a and b. (Scale bar: 10 μm.) (e1–f2) High-magnification views of
boxed region of dendrite from neurons expressing GFP (green in e2 and f2) plus
vector control (e1 and e2) or ephrin-B3 shRNA (f1 and f2). (e1 and f1)
Endogenous ephrin-B3 staining (red in e2 and f2). Arrows indicate ephrin-B3
puncta in transfected cells. Arrowheads indicate puncta in adjacent cells. (Scale
bar: 3 μm.) (g and h) Quantification of ephrin-B3 staining intensity in arbitrary
units (g) or ephrin-B3 puncta/μm (h) after transfection of vector control (n = 37) or
ephrin-B3 shRNA (n = 41). Error bars indicate SEM. *, P < 0.0001.

Supplementary Figure 2.2. Syntenin-1 knockdown does not affect ephrin-B
surface localization. (a and b) Representative images of DIV10 neurons
transfected at DIV3 with syn-GFP plus syntenin-1 shRNA#2 or vector control,
treated with clustered EphB2-Fc for 60 min, fixed, and stained for anti-GFP
(green), human Fc fragment of IgG (blue), and ephrin-B1 (a) or ephrin-B2 (b)
(red). Arrowheads indicate triple colocalization. (Scale bar: 3 μm.) (c and d)
Quantification of puncta density for colocalized syn-GFP and ephrin-B1 puncta
(c) and percentage of colocalized ephrin-B1 and syn-GFP puncta that are
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positive for EphB2-Fc in neurons transfected with vector control (n = 31) or
syntenin-1 shRNA#2 (n = 28) (d). (e and f ) Quantification of puncta density for
colocalized syn-GFP and ephrin-B2 puncta (e) and percentage of colocalized
ephrin-B2 and syn-GFP puncta that are positive for EphB2-Fc in neurons
transfected with vector control (n = 30) or syntenin-1 shRNA2 (n = 30) ( f). (g)
Quantification of puncta density for colocalized syn-GFP and EphB2-Fc puncta
for vector control (n=31) or syntenin-1 shRNA2 (n=28). Error bars indicate SEM.
*, P < 0.02.

Supplementary Figure 2.3. Immunostaining controls. (a) Representative
images of DIV30 neurons stained with goat anti-ephrin-B1 antibodies recognized
with Cy2 donkey anti-goat secondary antibodies (green), goat anti-ephrin-B2
antibodies preincubated with rabbit anti-goat Fab fragment and recognized with
Cy3 donkey anti-rabbit secondary antibodies (red), and guinea pig anti-VGlut1
antibodies recognized with Cy5 donkey anti-guinea pig secondary antibodies
(blue). (b) Representative images of DIV30 neurons stained identically to a,
except anti-ephrin-B1 antibody was omitted. (c) Representative images of DIV30
neurons

stained

identically

to

a,

except

anti-ephrin-B1

antibody

and

preincubation of anti-ephrin-B2 with rabbit anti-goat Fab fragment was omitted.
Goat anti-ephrin-B2 antibodies are labeled with Cy2 donkey anti-goat secondary
antibodies (green). See SI Text for details. (Scale bar: 3 μm.)
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Supplementary Figure 2.4. Ephrin-B Knockdown at DIV9. (a) Ephrin-B in
presynaptic development Representative axons from DIV9 cortical neurons
transfected at DIV0 with syn-GFP plus indicated shRNA constructs. (Scale bar:
3μm.) (b) Quantification of syn-GFP puncta density of axons transfected with
vector control (n=77), ephrin-B1 shRNA#1 (n=93), ephrin-B1 shRNA#1 + rescue
(n = 25), or ephrin-B3 shRNA (n = 77). Error bars indicate SEM. *, P < 0.002.

Supplementary Figure 2.5. Titration of ephrin-B1 and ephrin-B2 knockdown
in heterologous cells. (a and b) Western blots of lysates from HEK293T cells
transfected with HA-ephrin-B1 (a) or HA-ephrin-B2 plus vector control (b) and the
indicated amounts of ephrin-B1 shRNA#2 (a) or ephin-B2 shRNA#1 (b). Control
plasmid was transfected as needed so that the total amount of shRNA vector
was 1 μg. Blots were probed for HA antibody, stripped, and reprobed for actin.

Supplementary

Figure

2.6.

Model

EphB-dependent

presynaptic

development.

Supplementary Table 2.1. Puncta analysis of DIV30 cortical neuron culture
immunostained for ephrin-B1, ephrin-B2, syntenin-1, and VGlut1
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CHAPTER 3
A novel extracellular interaction mechanism controls the EphBNMDAR interaction and synaptic function
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Abstract
Trafficking of NMDA receptors to synaptic sites is critical for synaptic function
and plasticity in the mature brain. The type and number of NMDARs must be
maintained and tightly regulated to enable changes in synaptic strength while
preventing excitotoxicity.

Increased content of NR2B-containing NMDARs at

synaptic sites increases synaptic plasticity and improves behavioral tasks of
learning and memory. In the mature brain, EphBs interact directly with NMDA
receptors and regulate the synaptic localization of NR2B-containing NMDARs.
EphB-dependent modulation of NMDARs promotes synaptic function, plasticity,
and its misregulation results in disease.

However, whether the interaction

between EphBs and NMDARs is important for these events have not been
tested.

Here, we identify a single amino acid in the extracellular domain of

EphB2 that is necessary and sufficient to mediate the EphB-NMDAR interaction.
We define a novel molecular mechanism, where a specific extracellular tyrosine
residue is phosphorylated after ephrin-B ligand binding, to induce the EphBNMDAR interaction. Mutations at this site enhance or reduce synaptic currents
of NR2B-containing NMDARs, receptor stabilization at the cell surface, and Ca2+dependent gene transcription. These findings indicate that in EphBs are critical
regulators of NMDAR subunit composition, function, and synaptic localization to
prevent disease in the mature brain.
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During development and in the adult brain, the NMDAR is required for the
generation of normal circuitry and synaptic function (Lau and Zukin, 2007; PerezOtano and Ehlers, 2005). NR2B subunit-containing NMDARs have longer
channel open time and increased calcium influx (Chen and Roche, 2007; CullCandy and Leszkiewicz, 2004; Prybylowski and Wenthold, 2004). Driving NR2Bcontaining NMDARs to synapses in the mature brain increases the plasticity of
synapses and improves performance on behavioral tasks of learning and
memory (Philpot et al., 2007; Tang et al., 1999). It appears that EphBs interact
directly with NMDARs through their extracellular domains and cluster NMDARs
at synaptic sites (Attwood et al., 2011; Dalva et al., 2000; Grunwald et al., 2001;
Slack et al., 2008). The EphB-NMDAR interaction is implicated in numerous
synaptopathies such as: Alzheimer’s disease (Cisse et al., 2011; Simon et al.,
2009), anxiety disorders (Attwood et al., 2011), and neuropathic pain (Liu et al.,
2011; Liu et al., 2009; Slack et al., 2008; Song et al., 2008b). In mature neurons,
EphB2 regulates synaptic localization and Ca2+-dependent desensitization of
NR2B-containing NMDARs (Nolt et al., 2011). After EphB activation, the EphBNMDAR interaction results in enhanced calcium influx, tyrosine phosphorylation,
and function of NMDARs (Dalva et al., 2000; Takasu et al., 2002). The EphBNMDAR interaction induces phosphorylation of the NR2B subunit at intracellular
Y1472, which can stabilize NR2B-containing NMDARs at synaptic sites (Dalva et
al., 2000; Prybylowski et al., 2005; Takasu et al., 2002).
EphB receptors are cell-surface localized, single-pass transmembrane
receptor tyrosine kinases that are activated by their clustered, membrane93

attached ephrin-B ligands (Egea and Klein, 2007). Ephrin-B/EphB signaling in
the CNS controls axon guidance, dendritic filopodia motility, pre-and postsynaptic
excitatory

synapse

formation,

synapse

maturation,

glutamate

receptor

localization and function, and synaptic plasticity (Egea and Klein, 2007;
Sloniowski and Ethell, 2011). For EphBs, the ability to coordinate these events
requires tight regulation of receptor trafficking including EphB receptor cleavage,
internalization, and degradation (Pitulescu and Adams, 2010).

While the

differences between these modes of trafficking are poorly understood, regulation
of EphB receptor trafficking is clearly important for regulation of NMDA receptors
at synaptic sites.
EphB1-/-, B2-/-, B3-/- (TKO) mice are defective in their ability to localize
NR2B-containing NMDARs to synaptic sites (Henkemeyer et al., 2003; Kayser et
al., 2006; Nolt et al., 2011). EphBs interact directly with NMDARs through an
undefined region of their extracellular domains (Attwood et al., 2011; Dalva et al.,
2000; Grunwald et al., 2001; Slack et al., 2008). We generated numerous EphB
expression constructs, but were unable to identify a small subregion (<100 amino
acids) that mediates the EphB-NMDAR interaction. Therefore, we undertook an
unbiased mass spectrometry based approach to identify candidate interactions
domains.

We expressed the FLAG epitope-tagged EphB2 (fB2) receptor in

NG108 cells. After 48 hours, cells were stimulated with clustered ephrin-B1-Fc
for 45 minutes to activate the receptors (for verification see Supplementary
Figure 3.1).

Ephrin-B treatment was used because induction of the EphB-

NMDAR interaction requires ephrin-Bs (Dalva et al., 2000). EphB2 receptors
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were immunoprecipitated using anti-FLAG antibodies, proteins were separated
using SDS-PAGE, digested in-gel with trypsin, and phosphopeptides were
enriched using TiO2 before LC-MS/MS (MW range 100-130kD). Three known
phosphopeptides were identified in the juxtamembrane and kinase domains
(Supplementary Figure 3.2) in addition two novel phosphorylation sites
(ELSEYNATAIK and AGAIYVFQVR) were identified that correspond to regions in
the extracellular portion of the receptor (Figure 3.1A-C). Due to the unusual
nature of the location of these peptides Mascot results and MS/MS spectra were
closely inspected.

We found that each peptide was identified on four

independent experiments and twice in each labeling state, with Mascot scores of
34 and 63 respectively and definable separation from the next peptide assigned
to that spectrum. Manual inspection of the MS/MS spectrum confirmed that the
signals present are accounted for and ions critical to localization at the site of
phosphorylation are present.
The two phosphopeptides identified, ELSEYNATAIK and AGAIYVFQVR
were each found in the C-terminal fibronectin type III repeat domains (cFN3; see
Figure 3.1C for schematic) and correspond to tyrosine residues Y481 and Y504
respectively. Y504 and neighboring residues are well conserved (>51% identity
in 15 of 18 neighboring amino acids) amongst the entire Eph family, whereas
Y481 is less well conserved (>51% identity in 2 of 16 neighboring amino acids) in
other Ephs (Figure 3.1D). These findings suggest that phosphorylation at Y504
may also be a common mechanism for regulation of other Eph family members.
EphB receptors interact directly with NMDA-type glutamate receptors through an
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undefined region of their extracellular domains (Attwood et al., 2011; Dalva et al.,
2000; Grunwald et al., 2001; Slack et al., 2008). Since, both the EphB-NMDAR
interaction and phosphorylation at Y481 and Y504 require activation by ephrin-B
ligand; we hypothesized that one or more of these sites might play a role in the
EphB-NMDAR interaction. To test this possibility, we generated phosphomimetic
(fB2 Y481E and Y504E) and non-phosphorylatable (fB2 Y481F and Y504F) point
mutants to the FLAG-tagged EphB2 receptor. We then transfected HEK293T
cells with fB2 WT, fB2 Y481E, or fB2 Y481F, along with HA-NR1-GFP and NR2B
constructs, to form a functional NMDAR that is trafficked to the cell surface.
NR2B-containing receptors were used because their trafficking and function is
specifically regulated at mature synapses by EphBs (Nolt et al., 2011). EphB2
receptors were immunoprecipitated using an anti-FLAG antibody, and then
probed for the HA-tag of NR1. We find that neither EphB2 Y481E (Figure 3.1E
lane 3; Figure 3.1F quantification) nor Y481F (Figure 3.1E lane 4; Figure 3.1F
quantification) affect the ability of EphBs to bind NR1. These data suggest that
Y481 does not play an important role in the EphB-NMDAR interaction. We next
tested whether the Y504 site might modulate the EphB-NMDAR interaction.
When co-expressed in HEK293T cells, we find that EphB2 Y504F significantly
reduced NR1 binding compared to WT (Figure 3.1G lane 4; Figure 3.1H
quantification, ANOVA test, p < 0.05), while mutation of Y504E significantly
increased binding compared to WT and Y504F (Figure 3.1G lane 3; Figure 3.1H
quantification, ANOVA test, p < 0.05). These findings suggest that Y504 may
play an important role in the EphB-NMDAR interaction.
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Next, we wanted to test whether Y504 mutant receptors affect the EphBNMDAR interaction in neurons.

Therefore, we generated lentiviruses

transducing EphB2-YFP WT, EphB2-YFP Y504E, and EphB2-Y504F constructs
into DIV2 cultured cortical neurons for co-IP experiments. At DIV7, expressed
EphB2 receptors were enriched using an anti-GFP antibody and level of NR1
pull-down was assessed. Consistent with previous reports (Dalva et al., 2000), in
neurons over-expressing WT EphB receptors the EphB-NMDAR interaction is
induced by ephrin-B stimulation (Figure 3.1I lanes 1 and 2; Figure 3.1J
quantification). Interestingly, in the phosphomimetic Y504E mutant, the EphBNMDAR interaction is induced without ephrin-B treatment (Figure 3.1I lane 3).
Furthermore, ephrin-B stimulation does not potentiate the EphB-NMDAR
interaction further in Y504E mutants (Figure 3.1I lane 4; Figure 3.1J
quantification). These data are consistent with phosphorylation at Y504 being
sufficient for the EphB-NMDAR interaction to occur.

Consistently, non-

phosphorylatable Y504F mutants have little pull-down with NR1 in absence of
ephrin-B treatment (Figure 3.1I lanes 5; Figure 3.1J quantification). Ephrin-B
stimulation did not potentiate the EphB-NMDAR interaction in Y504F mutant
receptors (Figure 3.1I lanes 6; Figure 3.1J quantification). Together, these
data suggest that phosphorylation of Y504 is necessary and sufficient for the
EphB-NMDAR interaction in neurons and HEK293T cells.
Although most protein kinases have been studied inside the cell, evidence
suggests that phosphorylation of proteins can occur in the extracellular space
(Redegeld et al., 1999). Both soluble and membrane attached kinases have
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been found in numerous cell types including neurons (Chen et al., 1996; Fujii et
al., 2000; Kumar et al., 2011). In neurons extracellular protein kinases regulate
processes including synaptic plasticity (Chen et al., 1996; Fujii et al., 2000) and
aggregation of amyloid β-peptides (Aβ) in mouse and human brain (Kumar et al.,
2011). To begin to test whether Y504 is phosphorylated extracellularly, we first
generated a polyclonal phospho-specific antibody to tyrosine 504. We tested this
antibody in lysates from HEK293T cells transfected with FLAG-EphB2 constructs
and found that full-length WT EphB2 receptors were recognized by this antibody
at

the

appropriate

molecular

weight

~120

kD,

but

not

Y504F

non-

phosphorylatable mutants nor untransfected lysates (Figure 3.2A left). To test
whether Y504 might become phosphorylated in the extracellular space we next
asked whether in HEK293T cells if a truncated fB2 construct lacking an
intracellular domain (Kayser et al., 2006) would still be phosphorylated. We have
previously shown this construct localizes to the plasma membrane and can
recruit presynaptic markers (Kayser et al., 2006). We found that the truncated
WT EphB2 receptor, but not Y504F mutant receptor was recognized by the
pY504 antibody at the appropriate molecular weight ~75kD (Figure 3.2A right).
These data suggest that the EphB tyrosine kinase is not required for
phosphorylation of Y504. Next, we wanted to test that our pY504 antibody was
phospho-specific and recognized synaptic EphB2 protein. Synaptosomes were
prepared from two WT CD1 mouse brains before being subjected to SDS-PAGE
in duplicate, and then immunoblots were cut in half. One blot was treated with
Calf Intestinal Alkaline Phosphatase (CIP, 1:500; New England BioLabs)
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overnight to de-phosphorylate all proteins.

Blots were then probed with the

pY504 antibody (Figure 3.2B top), then stripped and reprobed with an Nterminal commercial EphB2 antibody to verify non-phosphorylated protein was
present, and that the phospho-band ran at the appropriate molecular weight
(Figure 3.2B bottom).

These data suggests our antibody recognizes a

phospho-specific epitope.
Next, to test whether phosphorylation of Y504 might occur on the cell
surface,

we

asked

if

phosphorylation of Y504.

blocking

internalization

of

EphB2

might

block

Since EphBs are internalized by clathrin-mediated

mechanisms after ephrin-B stimulation (Irie et al., 2005; Litterst et al., 2007;
Pitulescu and Adams, 2010; Vihanto et al., 2006), we blocked clathrin-mediated
endocytosis using two pharmacological treatments (450mM hypertonic sucrose
or 80 μM dynasore; Sigma-Aldrich) in DIV6-7 cultured cortical neurons in the
presence or absence of ephrin-B stimulation. To examine the effects of drug
treatment on EphB2 phosphorylation, we immunoprecipitated with an N-terminal
anti-EphB2 antibody then probed with pY504 or intracellular EphB2 antibodies.
We found that treatment with either hypertonic sucrose or dynasore did not block
the induction of Y504 phosphorylation after ephrin-B2 treatment (Figure 3.2C
left). To validate that drug treatments did not block intracellular kinase activity,
we stripped and probed the same blots with an antibody against the EphB2
intracellular kinase domain (pY662; (Dalva et al., 2000)). Neither dynasore nor
hypertonic sucrose blocked the ability for the EphB2 kinase activation. These
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data supports the model (Figure 3.2D) that EphB2 pY504 gets phosphorylated in
the extracellular space by an exo- or ecto-protein kinase.
We next tested whether inhibition of extracellular phosphorylation alone
was sufficient to block the EphB-NMDAR interaction.

To do this, we took

advantage of the widely used, broad-spectrum extracellular kinase inhibitor k252b (Chen et al., 1996; Fujii et al., 2000; Nguyen et al., 2008).

In DIV6-7

cortical neurons, treatment with activated ephrin-B for 45 minutes induces the
EphB-NMDAR interaction (Figure 3.2E lanes 1 and 2; Figure 3.2F
quantification) and resulted in phosphorylation of Y504 (Figure 3.2E lanes 1
and 2; Figure 3.2G quantification). Following k-252b treatment (10µM; SigmaAldrich), ephrin-B stimulation failed to induce phosphorylation at Y504, although
the kinase activity of the EphB receptor was unaffected (Figure 3.2E lanes 3
and 4; Figure 3.2G quantification). In addition, treatment of neurons with k252b is sufficient to block the ephrin-B induced EphB-NMDAR interaction (Figure
3.2E lanes 3 and 4; Figure 3.2F quantification). Taken together, these results
suggest that ephrin-B-dependent phosphorylation of EphB2 Y504 occurs in the
extracellular space and is required for the EphB-NMDAR interaction.
The ability of EphB2 receptors to properly regulate NMDAR surface
localization at synapses is required for normal brain functioning, and dysfunction
of these events are implicated in numerous human diseases such as Alzheimer’s
disease (Cisse et al., 2011; Simon et al., 2009) and anxiety disorders (Attwood et
al., 2011). Therefore we asked whether phosphorylation at Y504 might alter the
trafficking of the EphB2 receptors (Figure 3.3A).
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We reasoned that since WT

EphB2 receptors are localized to the plasma membrane, mutation of Y504 to E
should not stop insertion of mutant receptors into the plasma membrane. In
support of this idea, we find that fB2 Y504E receptors do localize to the cell
surface, although at significantly reduced levels compared to other EphB2
constructs (Figure 3.3B; Figure 3.3C quantification).

Furthermore, when

expressed alone in HEK293T cells, total expression levels of fB2 Y504E are
reduced compared to WT or Y504F constructs (Supplementary Figure 3.3).
These data suggest that phosphorylation of Y504 may also regulate EphB
trafficking as well as the EphB-NMDAR interaction (Figure 3.3A). Furthermore,
these data suggest the possibility that in the absence of the NMDAR,
phosphorylation of Y504 may lead to the removal and proteolysis of EphB2
To test whether phosphomimetic Y504E mutant receptors were properly
localized to the plasma membrane, but prematurely degraded, we blocked
clathrin-mediated

internalization

using

hypertonic

sucrose

(Heuser

and

Anderson, 1989) in HEK293T cells transfected with fB2 WT, Y504E, and Y504F
constructs. Sucrose treatment for only 15 minutes increased total fB2 Y504E
expression back to baseline levels, but did not affect WT or Y504F constructs
(Figure 3.3D lanes 5 and 6; Figure 3.3E quantification).

Because proper

activation of the intracellular kinase domain in EphB2 is required for surface
localization (Irie et al., 2005; Zimmer et al., 2003), we wanted to test if kinase
activity was also required for Y504 surface localization.

Therefore, we used

constructs with a point mutation (fB2 K663R or fB2 KD) in the EphB2 ATPbinding domain that renders the kinase inactive (Dalva et al., 2000) to generate
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both non-phosphorylatable and phosphomimetic double-point mutants with
inactive kinases fB2 KD Y504E and fB2 KD Y504F respectively. Consistent with
this model, fB2 KD Y504E mutants were expressed at similar levels to WT and
Y504F constructs (Figure 3.3D; Figure 3.3E quantification). Together, these
findings suggest that Y504E mutant EphB2 receptors are rapidly internalized by
clathrin-mediated mechanisms that require EphB tyrosine kinase activity.
We next asked whether blocking endocytosis with dominant negative
dynamin (K44A) constructs, which block the formation of clathrin-coated pits at
the plasma membrane, might also rescue the expression level of EphB2 Y504E
constructs (Conner and Schmid, 2003). Over-expression of WT dynamin should
lead to a large increase in protein degradation in total lysates, whereas K44A
over-expression should block clathrin-mediated endocytosis. We co-expressed
these two dynamin constructs with fB2 WT, Y504E, and Y504F constructs in
HEK293T cells. We find that co-expressing K44A dynamin causes a significant
increase in EphB2 expression in the total lysate of WT and Y504E, but not nonphosphorylatable Y504F receptors (Figure 3.3F-G).

Furthermore, there is

significantly more fB2 expression in Y504E mutants than Y504F mutants (Figure
3.3G). These data support a model (Figure 3.3A) where Y504E mutants are
trafficked to the plasma membrane, but rapidly degraded via clathrin-mediated
mechanisms.
To test the idea that phosphomimetic Y504E receptors are degraded in
the proteasome, we used lactacystin (5µM; Calbiochem), an irreversible inhibitor
of the 20S proteasome, to block all protein degradation (Litterst et al., 2007;
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Margolis et al., 2010). We reasoned that in the presence of lactacystin, there
should be significantly more protein in the total lysate than under untreated
conditions. As expected, in the presence of lactacystin, the level of expression of
fB2 Y504E was rescued to control levels (Figure 3.3H lanes 5 and 6; Figure
3.3I quantification). These data is consistent with a model (Figure 3.3A) in
which Y504E mutant receptors are rapidly internalized off the plasma membrane
after ephrin-B activation.
To test whether a similar mechanism might function in neurons, we
biotinylated surface-localized, endogenous EphB2 receptors in DIV7 cultured
cortical neurons after ephrin-B activation. Consistent with previous reports (Irie
et al., 2005; Zimmer et al., 2003), we find that EphB2 receptors are internalized
after ephrin-B activation (Supplementary Figure 3.4). Furthermore, we find that
these activated receptors move from the biotin-labeled surface fraction to an
intracellular avidin fraction without affecting total expression (Supplementary
Figure 3.4). These data confirm that similar to HEK293T cells, EphB2 receptors
are internalized in neurons after ephrin-B activation.
Phosphorylation of Y504 induces the EphB-NMDAR interaction; therefore
we asked whether the presence of NMDAR receptors would affect the instability
of Y504E mutant receptors. To test this, we transfected fB2 WT, Y504E, and
Y504F constructs alone, or with HA-NR1-GFP and NR2B in HEK293T cells
before performing a steady-state cell surface biotinylation. We find that Y504E
mutants have reduced surface localization compared to WT or Y504F receptors
(Figure 3.3J; Figure 3.3K quantification). However, when co-expressed with
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NMDARs, the levels of Y504E mutant receptors are rescued back to levels
comparable to WT and Y504F receptors (Figure 3.3J lanes 3 and 4; Figure
3.3K quantification). These data suggests that the EphB-NMDAR interaction
stabilizes EphB receptors on the plasma membrane. Moreover, a cell surface
biotinylation in cultured cortical neurons infected with our EphB2-YFP lentiviruses
resulted in no significant differences in surface localization between Y504E, WT,
or Y504F receptors (Supplementary Figure 3.5). These data suggests that in
the presence of endogenous NMDARs, over-expressed Y504E mutant receptors
are stabilized on the membrane.
To test whether the EphB-NMDAR interaction might affect NR1 surface
retention, we transfected fB2 WT, Y504E, and Y504F constructs with HA-NR1GFP and NR2B, or NR1/2B alone in HEK293T cells before performing a steadystate cell surface biotinylation and probing for the HA-tag of NR1 (same lysates
as in Figure 3.3L-M). We find that co-expression of fB2 Y504E significantly
increased the fraction of NR1 receptors on the plasma membrane compared to
all other conditions (Figure 3.3L lane 3; Figure 3.3M quantification).
Interestingly, co-expression of non-phosphorylatable Y504F mutant receptors
causes a significant decrease of NR1 receptors on the cell surface compared to
WT EphB2 (Figure 3.3L; Figure 3.3M quantification). These data suggests
that the EphB-NMDAR interaction stabilizes NMDA receptors on the plasma
membrane.
Late in neuronal development (after DIV14), EphBs are not required to
maintain synapse number (Kayser et al., 2008), but are instead key regulators of
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NMDAR localization and functional at mature synapses (Nolt et al., 2011). To
test whether the EphB-NMDAR interaction is required to maintain the normal
number of NR2B-containing NMDARs at synapses, we asked if mutation to Y504
would alter the functional properties of synapses in mature cultured cortical
neurons. Neurons were transfected at DIV14 with EGFP and vector control,
EphB2-YFP-WT, Y504E, or Y504F constructs. Then at DIV21-23, spontaneous
miniature EPSCs (mEPSCs) were recorded using whole-cell patch clamp at
+50mV including tetrodotoxin and blockers of GABAergic channels to isolate
NMDAR-mediated spontaneous currents.

No changes on mEPSC frequency

were observed between conditions (Control, n=9; WT, n=10; Y50E, n=10; Y504F
n=13). However, EphB2 WT and EphB2 Y504E over-expression both caused a
significant increase in amplitude compared to control or non-phosphorylatable
Y504F mutants (Figure 3.4A).

These changes in mEPSC amplitude are

attributable specifically to NMDARs because treatment of the NMDAR antagonist
D-APV (50µM) blocked these affects (Figure 3.4A-B: Control n=5 cells, 491
mEPSCs w/o APV, 421 mEPSCs w/ APV; WT, n=7 cells, 1182 mEPSCs w/o
APV, 758 mEPSCs w/ APV; Y504E, n=6 cells, 705 mEPSCs w/o APV, 349
mEPSCs w/ APV; Y504F, n=9 cells, 912 mEPSCs w/o APV, 541 mEPSCs w/
APV: p<0.001). While there is a modest effect on Y504F mutants with APV
treatment, a much larger effect is observed for Y504E mutants (Figure 3.4B).
These data suggests that phosphorylation at Y504 is a functional regulator of
NMDAR currents at mature synapses.
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We have shown that EphB2 is a subunit-specific regulator of synapticNR2B containing NMDARs (Nolt et al., 2011) at mature synapses. Based on the
finding that Y504 regulates the function of NMDAR currents at mature synapses
(Figure 3.4A-B), we hypothesized that this change was due to recruitment of
NR2B-containing NMDARs to synaptic sites. To test this, we treated neurons
with Ro25-6981 (Ro25) the NR2B-selective antagonist (2.5 µM; Tocris
Bioscience) and then measured mEPSC amplitude. We find that treatment with
Ro25 caused a large decrease on mEPSC amplitude in cells expressing
phosphomimetic Y504E mutant receptors (Figure 3.4C; Y504E, n=7 cells, 767
mEPSCs w/o Ro25, 456 mEPSCs w/ Ro25).

However, no changes were

observed in current amplitude from cells expressing Y504F mutant receptors
after Ro25 treatment (Figure 3.4D; Y504F, n=6 cells, 457 mEPSCs w/o Ro25,
444 mEPSCs w/ Ro25).

These data demonstrate that at mature synapses,

phosphorylation of Y504 results in increased trafficking of NR2B-containing
NMDARs to synaptic sites, which alters synaptic currents.
To confirm our physiological findings, we performed immunostaining
experiments at the same developmental timepoints, using the same conditions,
and looking at NR2B staining intensity at synapses. We looked at NR2B staining
intensity at synaptic sites (positive for the presynaptic vesicle protein SV2;
Figure 3.4E-G: Control, n=539 synapses; WT, n=516; Y504E, n=527; Y504F,
n=539).

In accordance with our physiological findings, we find that synaptic

NR2B is significantly reduced in EphB2 Y504F expressing neurons compared to
EphB2 Y504E (Figure 3.4E-G; ANOVA test, p < 0.01). Furthermore, neurons
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expressing Y504F mutant receptors had significantly reduced synaptic NR2B
compared to controls (Figure 3.4E-F; ANOVA test, p < 0.05). We find similar
increases in EphB2 Y504E, as expected from our physiological experiments with
Ro25 (Figure 3.3C-D).
EphB regulates NMDAR-dependent gene transcription by modulating
calcium influx through NR2B-containing NMDARs (Takasu et al., 2002). To test
whether the ability of EphB2 to recruit NR2B receptors to synaptic sites might
impact NMDAR-dependent gene expression, we used a synaptic stimulation
paradigm and asked if our EphB Y504 mutant receptors altered CREBdependent reporter gene expression. We transfected DIV7 cultured cortical
neurons with GFP control, EphB2 WT, EphB2 Y504E, or EphB2 Y504F
constructs along with CRE-luciferase reporter construct or Renilla luciferase as a
transfection control. Neurons were stimulated with 4-AP and BIC in the presence
of nifedipine to block L-type calcium channels; and then some neurons were
treated with Ro25-6981 (2.5 µM) to block NR2B-containing receptors. We find
that expression of EphB2 Y504E constructs potentiates CREB-dependent gene
transcription (Figure 3.4H).

Furthermore, this effect is totally abolished with

treatment of Ro25 (Figure 3.4H). Taken together, these results suggest that
phosphorylation at Y504 potentiates calcium-dependent gene transcription
through NR2B-containing NMDARs.
It was previously shown that the EphB-NMDAR interaction requires the
EphB extracellular domain, but the specific residues required for this interaction
have remained elusive for over a decade. Here, we report that EphB2 Y504 is
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both necessary and sufficient for the EphB-NMDAR interaction to occur. Our
findings support a model in which phosphorylation of extracellular domains of
EphB2, in a ligand-dependent manner, alters the direct protein-protein
interactions with NMDARs. Mislocalization of NMDARs from the cell surface and
synaptic sites is a hallmark of the diseased brain. Specifically, deficits in EphBdependent regulation of NMDAR localization is associated with synaptopathies
including neuropathic pain (Slack et al., 2008; Song et al., 2008b), Alzheimer’s
disease (Cisse et al., 2011; Simon et al., 2009) and anxiety disorders (Attwood et
al., 2011).

Our data indicates that the EphB-NMDAR interaction in brain is

responsible for modulating NMDARs at the surface and altering receptor
function, signaling, and gene expression in a subunit specific manner.
Notably, we find that a broad-spectrum inhibitor of extracellular kinases, k252b can block the EphB-NMDAR interaction and phosphorylation at Y504 in
neurons. An extensive literature shows that in the spinal cord and periphery,
blocking EphB1 signaling is sufficient to block hyperalgesia and NMDARdependent hyperexcitability in neuropathic and cancer-induced pain (Liu et al.,
2011; Liu et al., 2009; Slack et al., 2008; Song et al., 2008b). Our data suggests
that k-252b inhibits the phosphorylation of Y504 and suggests that extracellular
inhibition of the EphB-NMDAR interaction could be a viable approach to treat
neuropathic and cancer-induced pain.
While extracellular phosphorylation has previously been reported on
serine and threonine residues (Chen et al., 1996; Fujii et al., 2000; Kumar et al.,
2011; Redegeld et al., 1999), this is the first example of extracellular tyrosine
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phosphorylation.

One possible kinase that might mediate these events is a

reported soluble form of the FGFR that lacks a transmembrane domain
(Johnston et al., 1995; Katoh et al., 1992; Sturla et al., 2003). Our data define a
new type of protein modification: phosphorylation of extracellular tyrosines that
can enable novel forms of interactions at sites of cell-cell contact or give cells the
ability to respond directly to their environment. Based on the conservation of
Y504 amongst the EphB family, we expect that extracellular phosphorylation is
an underappreciated mechanism for human disease. Taken together our finding
suggests that extracellular phosphorylation of EphB2 at Y504 is a critical
regulator of NMDAR synaptic localization and function with profound implications
on synaptic plasticity and disease.
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Figure Legends

Figure 3.1. Novel phosphorylation sites on the EphB2 receptor modulate
the EphB-NMDAR interaction.

(A-B) MS/MS spectra of peptides (A)

ELSEYNATAIK and (B) AGAIYVFQR are shown.

Fragments critical for

localization of phosphorylation sites are labeled in red. Most abundant signals
are accounted for by sequence specific ions as indicated by labeling.

(C)

Schematic of the known functional domains of EphB2 receptor. LBD, Ligandbinding domain; Cys, cysteine-rich domain; FN3, Fibronectin type III repeat
domain; TM, Transmembrane domain; JM, juxtamembrane domain; SAM, sterileα-motif; PDZ, PSD-95/DLG1/ZO-1 domain.

(D) Alignment of all mouse Eph

family members cFN3 domains (Uniprot database) for 40 amino acids beginning
at indicated site using ClustalW2 and Jalview software.

EphB2 Y504

corresponds to a very well conserved tyrosine residue (red) whereas Y481 is not
well conserved amongst the Eph family (yellow box). Blue color indicates %
identity score with a threshold set at greater than 51%.
correspond to the most conserved residues.

Darker blue colors

(E-F) HEK293T cells were co-

transfected with HA-NR1-GFP and NR2B alone, or NR1/2B and fB2 WT, fB2
Y481E, or fB2 Y481F.

EphB2 receptors were immunoprecipitated with anti-

FLAG antibodies, and immunoblotted with anti-HA (NMDAR1) or EphB2
antibodies.

Right Lysates from the same preparation as in E are shown

immunoblotted with the same antibodies. (F) Quantification of relative amount of
HA-NR1 immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).
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(G-H) As in E, HEK293T cells were co-transfected with NR1/2B construct alone,
or with fB2 WT, fB2 Y504E, or fB2 Y504F mutants.

EphB2 receptors were

immunoprecipitated with anti-FLAG antibodies, and immunoblotted with anti-HA
(NMDAR1) or EphB2 antibodies. Right, Lysates from the same preparation as in
G are shown immunoblotted with the same antibodies.

(H) Quantification of

relative amount of HA-NR1 immunoprecipitated compared to input (*p < 0.05,
ANOVA test; n=5).

(G-H) DIV2 cultured cortical neurons were infected with

EphB2-YFP WT, EphB2-YFP Y504E, or EphB2-YFP-Y504F constructs as
indicated. At DIV7, neurons were stimulated for 45 minutes using ephrin-B2-Fc
or Fc control as indicated. Infected EphB2 receptors were immunoprecipitated
using an anti-GFP antibody.

Resulting western blots were probed with anti-

NMDAR1 or GFP (EphB2) antibodies. (H) Quantification of relative amount of
NMDAR1 immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=6).

Figure 3.2.

Extracellular phosphorylation modulates the EphB-NMDAR

interaction and generation of a phospho-specific antibody to Y504. (A-B)
HEK293T cell lysates transfected with indicated FLAG-EphB2 constructs then
probed with a phospho-specific polyclonal antibody generated against EphB2
Y504 (EphB2 pY504). (B) Pure synaptosome fractions from WT CD1 mice were
subjected to SDS-PAGE. Resulting western blots were left untreated or were
treated overnight with gentle shaking at 37°C with calf intestinal alkaline
phosphatase (CIP; 1:500) as indicated then probed with EphB2 pY504
antibodies. Immunoblots were then stripped and reprobed with a commercial
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antibody against the N-terminal domain of EphB2. (C) DIV6-7 cultured cortical
neurons were treated as indicated with 450mM hypertonic sucrose for 15min at
37°C, or 30 min at 37°C with 80μM dynasore followed by 45 min of stimulation
with

Fc

control

or

ephrin-B2-Fc

(eB2).

EphB2

receptors

were

immunoprecipitated with an N-terminal anti-EphB2 antibody, and immunoblotted
against EphB2 pY504, EphB2, or the phosphorylated EphB2 kinase (EphB2
pY662). (D) Model of how extracellular phosphorylation at Y504 modulates the
EphB-NMDAR interaction. (E-G) DIV6-7 cultured cortical neurons were treated
as indicated with 10µM of the broad spectrum extracellular protein kinase
inhibitor K-252b for 60 minutes, before 45 minutes of stimulation with Fc control
or ephrin-B2-Fc. EphB2 receptors were immunoprecipitated with an N-terminal
EphB2 antibody and resulting western blots were probed with anti-NMDAR1,
anti-EphB2, anti-EphB2 pY504 extracellular, or anti-EphB2 pY662 intracellular
kinase antibodies.

(F) Quantification of relative amount of NMDAR1

immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).
Quantification

of

relative

amount

of

EphB2

pY504

(G)

phosphorylation

immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).

Figure 3.3. Tyrosine 504 regulates EphB2 surface localization, degradation,
and affects NMDAR surface retention.

(A) Model of how extracellular

phosphorylation at Y504 modulates EphB receptor trafficking and the EphBNMDAR interaction. (B-C) Mutation of Y504 to E causes decreased surface
localization of EphB2 Receptors. (B) Representative immunoblots of biotinylated
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EphB2 with no actin biotinylated. (C) Quantification of percent localized to the
cell surface of total lysate. (*p < 0.05, ANOVA test; n=4). (D-E) Mutation of
Y504 to E causes EphB2 internalization by a clathrin-mediated mechanism. (D)
Western blots of lysates from HEK293T cells transfected with indicated
constructs for 16-18 hours, then treated with 450mM sucrose for 15 minutes at
37°C before lysis. Lysates were probed for EphB2, or β-actin. (E) Quantification
of fold change normalized to actin in total protein lysate after sucrose treatment
(*p < 0.05, ANOVA test; n=4-5). (F-G) Expression of dominant negative (K44A)
dynamin increases WT and Y504E EphB2 receptor expression, but not Y504F.
(F) Western blots of lysates from HEK293T cells co-transfected with indicated
fB2 constructs and either wild-type (WT Dyn) or dominant-negative dynamin
K44A (DN Dyn) constructs. Blots were and probed for EphB2, dynamin-1, or βactin. (G) Quantification of relative amount of EphB2 in the presence of DN
K44A dynamin compared to when co-expressed with WT dynamin.
ANOVA test; n=5).

(*p < 0.05,

(H-I) Mutation of Y504 to E causes EphB2 increased

degradation in the proteasome. (H) Representation immunoblots from HEK293T
cells transfected with indicated constructs for 16-18 hours, then treated with 5µM
lactacystin for 4 hours at 37°C before lysis. Lysates were probed for EphB2, and
β-actin. (I) Quantification of fold change normalized to actin in total protein lysate
after lactacystin treatment. (*p < 0.05, ANOVA test; n=5). (J-M) Mutations at
EphB2 Y504 modulates EphB2 and NMDAR1 trafficking.

(J) Expression of

NMDARs rescues EphB2 Y504 to E surface localization, and (L) co-expression
of EphB2 Y504E increases NMDAR1 surface localization. (J, L) Representative
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immunoblots of biotinylated EphB2 (J) or NMDAR1 (L) with no actin biotinylated
from HEK293T cells. (K, M) Quantification of percent localized to the cell surface
of total lysate. (*p < 0.05, ANOVA test; n=5). Error bars indicate SEM.

Figure 3.4.

Tyrosine 504 regulates the function of synaptic NR2B-

containing NMDARs in mature neurons. (A-D) Phosphomimetic mutants at
Y504 regulate mEPSC amplitude in mature neurons in a subunit-specific
manner. (A) Quantification of mean mEPSCs before and after the application of
50µM APV. An increase in mEPSC amplitude was observed with overexpression
of EphB2 WT and Y504F, whereas NMDAR blockade using APV reduced
mEPSC in all conditions. Control: n=5 cells, 491 mEPSCs w/o APV, 421
mEPSCs w/ APV; EphB2 WT: n=7 cells, 1182 mEPSCs w/o APV, 758 mEPSCs
w/ APV; EphB2 Y504E: n=6 cells, 705 mEPSCs w/o APV, 349 mEPSCs w/ APV;
EphB2 Y504F: n=9 cells, 912 mEPSCs w/o APV, 541 mEPSCs w/ APV.
(ANOVA test, p < 0.001). Error bars indicate SEM. (B) Cumulative probability
histogram of mEPSC amplitude for Y504E and Y504F mutants at ~20-35 ms
before (dark shading) and after (light shading) NMDAR blockage with 50µM APV.
Inset, Mean traces of mEPSCs after NMDAR blockage with APV.

(C-D)

Cumulative probability histogram of mEPSC amplitude for Y504E (C) and Y504F
(D) mutants before and after application of NR2B-specific antagonist Ro25-6981
(2.5 µM). Inset, Mean traces of mEPSCs after treatment with Ro25. EphB2
Y504E: n=7 cells,767 mEPSCs w/o Ro25,456 mEPSCs w/ Ro25; EphB2 Y504F:
n=6 cells, 457 mEPSCs w/o Ro25, 444 mEPSCs w/ Ro25. (E-G) Distribution of
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synaptic NR2B-containing NMDARs.

(E) Representative images of DIV21-23

cultured cortical neurons expressing EGFP and vector control (n=539), EphB2YFP-WT (n=516), Y504E (n=527), or Y504F (n=539) constructs, immunostained
for GFP (green), NMDAR2B (red), and SV2 (blue).

Arrowheads indicate

measurement site (Scale bar: 5 μm). (F) Quantification of average of normalized
intensity for synaptic NR2B in spines. (*p < 0.05, **p < 0.01, ANOVA test). Error
bars indicate SEM. (G) Cumulative probability histograms of normalized intensity
of NR2B on synaptic spines for Y504E and Y504F receptors.

ANOVA test,

p<0.001 (H) CREB-dependent gene transcription is enhanced with synaptic
NMDAR stimulation in Y504E mutants and blocked by NR2B antagonist Ro25.
CRE-luciferase activity is reported as fold-induction (*p<0.05, ANOVA test), Error
bars indicate 0.05 confidence.
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Supplemental Online Material
Materials and Methods
Expression Constructs
Full length FLAG-EphB2, truncated FLAG-EphB2 (fEphB2 Tr) and FLAGtagged kinase dead (KD; K663R) EphB2 and truncated were previously
described (Dalva et al., 2000). Single amino acid point mutations to Y481 and
Y504 were introduced using sequence specific primers and site-directed
mutagenesis (Strategene, La Jolla, CA). Sequences used were: EphB2 Y504F,
5’-GCCTCAAAGCCGGTGCCATCTTTGTCTTCCAGGTGCGG-3’;
Y504E,

EphB2

5’-GCCTCAAAGCCGGTGCCATCGAAGTCTTCCAGGTGCGG-3’;

EphB2 Y481F, 5’-ATGAGAAGGAGCTAAGTGAGTTCAACGCCACGGCCATA-3’;
EphB2 Y481E, 5’-ATGAGAAGGAGCTAAGTGAGGAGAACGCCACGGCCATA3’.

Forward and reverse oligonucleotides were synthesized (Integrated DNA

Technologies, Coralville, IA).

Generation of EphB2-YFP was previously

described (Kayser et al., 2006). AgeI and MfeI sites were added to EphB2-YFP
using site-directed mutagenesis and sequence specific primers: EphB2YFP_AgeI, 5’-AAACCGGTTTACCGTGGAAGAAACCCTGATG-3’; EphB2-YFP
MfeI, 5’-TTAATCCAATTGGAGTGACAGAGCAGCAGGGAC-3’.

Then point

mutations at Y504 were introduced using site-directed mutagenesis.

PCR

products were ligated into the pFUGW vector using Age1 (bp3860) and EcoR1
(bp4609) sites.

Lentivirus were produced and purified by the Gene Therapy

Program Penn Vector Core Facility at the University of Pennsylvania.

117

Generation of a phosphorylation-specific antibody
The phosphorylated peptide Ac-CKGLKAGAI-pY-VGQVRA-NH2 was
conjugated to Keyhole Limpet Hemocynein (KLH) in position 1 (EZBiolab,
Carmel, IN). This conjugated, phosphorylated peptide was injected into rabbits
for polyclonal antibody production (Covance, Denver, PA). Antibody titer was
assessed using an ELISA (Covance, Denver, PA) with a non-phosphorylated
form of the injection peptide Ac-CKGLKAGAIYVGQVRA-NH2 (EZBiolab, Carmel,
IN). Serum from each animal was affinity purified using SulfoLink Coupling Resin
(Thermo Scientific – Pierce Biotechnology, Rockford, IL) according to
manufacturer’s instructions and the phosphorylated peptide without KLH
conjugation.

Protein concentration was calculated using a Bradford assay

(BioRad, Hercules, CA). Eluates were dialyzed overnight in Slide-A-Lyzer 10K
Dialysis Cassettes (Thermo Scientific – Pierce Biotechnology, Rockford, IL), then
aliquoted with a final concentration of 10% glycerol and stored at 4°C.

Cell Culture and Transfection
Dissociated cortical neurons were prepared from embryonic day 17 (E17)
to E18 rats as previously described (Kayser et al., 2008; Nolt et al., 2011) on
poly-D-lysine (BD Bioscience, Bedford, MA) and laminin (BD Biosciences,
Bedford, MA) coated glass coverslips (12 mm; Bellco Glass, Vineland, NJ) in 24well plates (Corning Life Sciences, Lowell, MA).

For immunostaining and

electrophysiology experiments neurons were transfected as indicated at either 7
or 14 days in vitro (DIV) using Lipofecatmine 2000 (Invitrogen, Carlsbad, CA) as
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previously described (Kayser et al., 2008; Nolt et al., 2011). For biochemistry
cortical neurons were plated at a density of 10 × 106 cells per 100 mm dishes
(BD Bioscience, Franklin Lakes, NJ) pre-coated with poly-D-lysine and laminin.

HEK293T Culture and Transfection
HEK-293T cells were maintained in DMEM (Invitrogen), 10% Fetal Bovine
Serum (Thermo Scientific – Hyclone, Logan, UT), penicillin-streptomycin (SigmaAldrich, Saint Louis, MO), and glutamine (Sigma-Aldrich, Saint Louis, MO). For
transfection, HEK293T cells were plated in 6-well or 35mm culture plates (BD
Bioscience, Franklin Lakes, NJ) and transfected with indicated EphB2, NR1, or
NR2B constructs using the calcium phosphate method (Kayser et al., 2006;
McClelland et al., 2009; Xia et al., 1996). 100 μm APV (Sigma-Aldrich, Saint
Louis, MO) was added to the culture medium after NMDAR transfection to
prevent excitotoxicity.

Immunocytochemistry
Cells were fixed in 4% paraformaldehyde/ 2% sucrose for 5 minutes
followed by 10 minutes in 0.25% Triton X-100 at room temperature. Cells were
washed three times in PBS then blocked and permeabilized in 1% ovalbumin
(Sigma-Aldrich, Saint Louis, MO) / 0.2% cold water fish skin gelatin (SigmaAldrich, Saint Louis, MO) / 0.1% saponin (Sigma-Aldrich, Saint Louis, MO) for 1
hour at room temperature. Primary antibody was incubated overnight at 4°C in
blocking reagents. Cells were again washed three times in PBS then incubated
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with secondary antibody in blocking reagents for 45-60 minutes at room
temperature. Cells were then washed three times in PBS before mounting using
Aqua-Mount (Thermo Scientific -- Lerner, Kalamazoo, MI).

Antibodies used

were: chicken polyclonal anti-GFP (1:2500; Millipore, Temecula, CA), rabbit antiNR2B polyclonal (1:1000; (Dalva et al., 2000)), mouse monoclonal anti-NMDAR1
(1:500; BD Pharmingen, San Diego, CA) and mouse monoclonal anti-synaptic
vesicle protein 2 (SV2) (1:200; Developmental Studies Hybridoma Bank,
University of Iowa, Iowa City, IA). Cy2, Cy3, and Cy5 secondary antibodies were
used 1:250 (Jackson ImmunoResearch, West Grove, PA).

Synaptosome Preparation
Synaptosomes were prepared as previously described (Nolt et al., 2011).
Briefly, whole brains from P30 WT CD1 mice were homogenized in HEPESbuffered sucrose. Centrifugation was used to remove the nuclear fraction and
generate a S1 fraction.

A crude membrane (P1) fraction was generated by

centrifugation of the S1 fraction. The P1 fraction was resuspended in HEPESbuffered sucrose and centrifuged again to generate a crude synaptosome. The
crude synaptosome was layered onto a sucrose gradient and found at the
interface of buffer and 1.2 M sucrose. The interface was diluted and centrifuged
again at 230,000 X g to obtain the final pure synaptosomal (Syn) pellet.
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Western Blot Analysis
Lysates from HEK293T cells or neurons were separated using 8% SDSpolyacrylamide gels and transferred onto 0.45µM PVDF membranes (Millipore,
Temecula, CA). Immunoblots were then blocked in 5% nonfat dry milk in TBS-T
(150mM NaCl, 10mM Tris pH 8.0, 0.05% Tween-20).

Indicated primary

antibodies were presented in blocking solution for 2 hours at room temperature
or overnight at 4°C: mouse monoclonal anti-GFP (1:1000; Roche, Mannheim
Germany),

mouse

monoclonal

anti-Dynamin

(1:1000,

BD

Transduction

Laboratories, Lexington, KY), goat polyclonal anti-EphB2 (1:500; R&D Systems;
Minneapolis, MN), mouse monoclonal anti-NMDAR1 (1:500; BD Pharmingen,
San Diego, CA), mouse monoclonal anti-FLAG (M2; 1:2500; Sigma-Aldrich, Saint
Louis, MO), rabbit polyclonal anti-EphB2 (1:500; (Dalva et al., 2000)), rabbit
polyclonal anti-EphB2 pY662 (1:1000; (Dalva et al., 2000)).

HRP-conjugated

secondary antibodies were used at 1:20,000 in blocking solution for 1 hour (EMD
Biosciences – Calbiochem, San Diego, CA or Santa Cruz Biotechnology, Santa
Cruz, CA) then visualized using ECL (PerkinElmer, Waltham, MA) and
autoradiography film (Kodak, Rochester, NY or TruMark Scientific, Edison, NJ).
Protein band immunoreactivity was quantified using NIH ImageJ software.

Cultured Neuron Biotinylation and HEK293T Cell Biotinylation
Biotinylations were preformed as previously described (Nolt et al., 2011).
Briefly, cells were washed twice in ice-cold PBS-Ca2+/Mg2+ rinsing solution then
cell surface proteins were bulk labeled using 1mg/mL Sulfo-NHS-SS-Biotin
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(Thermo Scientific – Pierce Biotechnology, Rockford, IL). Unreacted biotin was
quenched using rinsing solution with 100mM glycine. Cells were then washed
and lysed using radioimmunoprecipitation assay (RIPA) buffer. Lysates were
harvested and centrifuged to remove cellular debris. Biotinylated proteins were
extracted using monomeric avidin agarose (Thermo Scientific – Pierce
Biotechnology, Rockford, IL). Surface proteins were solubilized off the avidin
beads using 2X-SDS sample buffer.

Equal amounts of total cell lysate and

biotinylated (surface) proteins were subjected to SDS-PAGE and western blot
analysis.

Immunoprecipitation
Immunoprecipitations were performed as previously described with small
changes (Dalva et al., 2000; Takasu et al., 2002). After treatment with clustered
ephrin-B2-Fc or Fc control, cortical neuron cultures (or untreated HEK293T cells)
were lysed in radioimmunoprecipitation assay (RIPA) buffer (750µl for 100mm
dishes or 300µl per well for 6-well plates) containing protease inhibitors and
agitated at 4°C for 15 minutes. Cell lysates were harvested and centrifuged at
13,000 rpm for 25 minutes to pellet cellular debris. A fraction of the resulting
supernatant (100µl for 100mm dishes or 75 µl per well for 6-well plates) was
removed as an input control. The remaining supernatant was incubated with
appropriate antibody to conjugate on ice for 2 hours: rabbit polyclonal anti-GFP
(ab290; Abcam, Cambridge MA), goat polyclonal anti-EphB2 (R&D Systems,
Minneapolis, MN), or mouse monoclonal anti-FLAG (M2; Sigma-Aldrich, Saint
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Louis, MO).

Antibody bound proteins were then isolated using pre-blocked

protein-G agarose beads (Invitrogen, Carlsbad, CA) 75µl for 100mm dishes or 50
µl per well for 6-well plates on a rotator for 60 minutes at 4°C. Samples were
then centrifuged and beads were washed four times in RIPA lysis buffer and two
times in TBS-V. Immunoprecipitates were eluted from the agarose beads by
adding 25μl boiling 6X SDS-sample buffer and boiled for 5 minutes at 95°C.

Inhibitors and Reagents
K-252b and D(-)-2-Amino-5-phosphonopentanoic acid (D-APV) were
obtained from Sigma-Aldrich (Saint Louis, MO). Lactacystin was obtained from
Calbiochem (EMD Biosciences, San Diego, CA).

Alkaline Phosphatase, Calf

Intestinal (CIP) was purchased from New England BioLabs (Ipswich, MA).
Ephrin-B2-Fc and Fc control were obtained from R&D Systems (Minneapolis,
MN) and clustered using anti-Human IgG (Jackson ImmunoResearch, West
Grove, PA) then used as previously described (Kayser et al., 2006; Nolt et al.,
2011).

Cre-luciferase transcription
Cre-luciferase assay were performed as previously described with small
changes (Takasu et al., 2002). Briefly, neurons were transfected at DIV7 by the
lipofectamine method (Kayser et al., 2006; Nolt et al., 2011) with a ratio of 8:1 of
CRE-luciferase reporter construct and Renilla luciferase as a transfection control.
In this CRE-luciferase construct, there are four copies of somatostatine CRE
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before firefly luciferase.

EphB2-YFP-WT, EphB2-YFP-Y504E, EphB2-YFP-

Y504F, and pFUGW vector control were co-transfected with EGFP to assess
transfection efficiency, along with the CRE-luciferase reporter and the Renilla
luciferase at the ratio previously described in (Takasu et al., 2002). At DIV10,
neurons were silenced for 6 hours with TTX, before synaptic stimulation with a
mixture of 4-aminopyridine (4-AP) and bicuculline (BIC) in the presence of
nifedipine to block L-type Ca2+ channels for 3-4 hours before lysis (Kawashima
et al., 2009). Lysates were then collected and analyzed for luciferase expression
using the Dual Luciferase Reporter Assay System (Promega, Madison, WI).

Imaging and Analysis
Images of cultured cortical neurons were obtained using confocal
scanning microscopy (Leica Microsystems, Wetzlar, Germany) as previously
described (McClelland et al., 2009; Nolt et al., 2011).

Briefly, images were

acquired at 63X resolution, numerical aperture 1.4, and oil-immersion objective.
Analysis was done using MetaMorph software (Molecular Devices, Sunnyvale,
CA) blind to experimental condition. Images were collected from at least three
independent experiments.

Puncta were considered to be co-localized when

there was greater than one pixel overlap between channels.

During image

collection all gain values were held constant. Amount of NR2B intensity were
normalized to the maximum intensity observed from all three conditions for each
experiment.
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Electrophysiology
Recordings from DIV21-23 cultured rat cortical neurons were performed
using whole-cell patch methods as previously described (McClelland et al., 2009;
Nolt et al., 2011). Briefly, coverslips were moved into a recording chamber and
bathed in a HEPES-buffered artificial CSF (ACSF) solution in mM: 140 NaCl, 5
KCl, 2 CaCl2, 1 MgCl2, 20 glucose, and 10 HEPES, pH 7.2). Tetrodotoxin (TTX)
and picrotoxin were used at 1 and 10 μM, respectively (Sigma-Aldrich, St. Louis,
MO). Bicuculline was used at 50 μM, D-APV was used at 10 μM, and (αR, βS)-α(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol

maleate

(Ro25-6981) was used at 2.5 μM (Tocris Bioscience, Ellisville, MO). All data were
collected at 5 kHz and filtered at 1 kHz; events were detected in Clampfit 9.2
(Molecular Devices, Sunnyvale, CA). Event analysis and statistics were
performed using Clampfit software (Molecular Devices, Sunnyvale, CA). To
isolate the NMDAR component, neurons were held at +50 mV in the presence of
TTX (1 μM), bicuculline (50 μM), and picrotoxin (10 μM).

SILAC Assay
Cell culture, metabolic labeling and stimulation
Two NG108-15 (mouse neuroblastoma x rat glioma hybrid) cell lines were
used, a “wild type” cell line without stable transfection and another stably
overexpressing EphB2 (Holland et al., 1997). Both cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen Corporation, Carlsbad,
CA) or lysine and arginine depleted DMEM (Special Media, Philipsburg, NJ) and
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supplemented with 10% dialyzed fetal bovine serum (Invitrogen Corporation,
Carlsbad, CA), HAT (Sigma-Aldrich, St. Louis, MO), 100 units/ml of penicillin /
streptomycin, and either normal or

13

C6 lysine and

13

C6 arginine (Cambridge

Isotope Labs, Andover, MA). In experiments that employed metabolic labeling
cells were grown for at least 6 doublings to allow full incorporation of labeled
amino acids.

Transient Transfection of FLAG-EphB2
FLAG-EphB2

plasmid

was

amplified

and

purified

according

to

manufactures instructions using Plasmid Midi kit (Qiagen, Valencia, CA). Cells
were cultured to approximately 50% confluence and transiently transfected using
Superfect (Qiagen, Valencia, CA) according to manufactures instructions.
Briefly, 10µg of vector was diluted in 298µL of DMEM and incubated with 60µL of
superfect reagent for10 minutes at RT.

7mL of pre-condition media (media

removed directly from the cells that were to be transfected) was added to
superfect/plasmid mixture. Cells were then washed with sterile PBS and the
mixture was then added to cells, incubated for 3 hours at 37°C, removed and
replaced with fresh culture media. 24 hours later media was removed, cells were
washed with PBS and media was replaced with above mentioned formulation
without FBS. At 48hrs cells were stimulated and lysed.
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Starvation, ephrin stimulation, and phosphatase treatment
For all experiments that involved ephrin stimulation, cells were subjected
to 24hrs of serum starvation before treatment with 2 µg/mL pre-clustered
ephrinB1-Fc (Sigma-Aldrich, Saint Louis, MO) for 5 or 45 minutes.

The

clustering procedure consisted of incubation of 250 µg/mL ephrinB1-Fc with 65
μg/ml anti-human Fc (Jackson ImmunoResearch, West Grove, PA) at RT for 1
hr.

In a separate experiment cells received a general phosphatase inhibitor

solution (1:75 phos. inhib. solution: culture media) containing 1mM pervanadate
and 50nM calyculin A for 1 hr.

Cell lysis, anti-FLAG immunoprecipitation and Western Blot
Cells were lysed in lysis buffer containing 1% Triton X-100, 150 mM NaCl,
20 mM Tris, pH8, 0.2mM EDTA, pH8, 2 mM Na3VO4, 2mM NaF, and protease
inhibitors (Complete tablet; Roche, Mannheim, Germany).

For SILAC

experiments lysates were mixed in a 1:1 ratio (v:v) and incubated with agaroseconjugated anti-FLAG M2 antibody (Sigma-Aldrich, Saint Louis, MO) overnight.
After incubation the beads were spun down in a bench top Megafuge 1.0R
basket centrifuge (Thermo Scientific – Heraeus Instruments, Asheville, NC) at
2000 RPM for 1 min and the supernatant was removed.

Beads were then

washed in ~25mL lysis buffer 4 times in a similar fashion. Precipitated proteins
were eluted by boiling in SDS-PAGE sample buffer for 5 min.

After elution

sample volume was reduced by ½ by vacuum centrifugation.

Phosphatase

inhibitor treated cell lysates were also mixed 1 to 1 with SDS-PAGE sample
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buffer and boiled for 5 min. Samples were separated on a 7.5% (receptor IPs) or
10% (Phos. treated lysates) Tris-HCl gel (BioRad, Hercules, CA). Gels were
stained with Coomassie Blue and EphB2 band was excised (receptor IPs) or the
gel lane was cut horizontally into 6 sections (Phos. treated lysates).

In-gel and in-solution tryptic digestion
For in-gel digestions excised gel bands were cut into small pieces and
destained in 50 mM ammonium bicarbonate / 50% acetonitrile, dehydrated with
acetonitrile and dried. The gel pieces were rehydrated with 10 ng/µl trypsin
solution in 50 mM ammonium bicarbonate and incubated overnight at 37°C.
Peptides were extracted twice with 5% formic acid / 50% acetonitrile followed by
a final extraction with acetonitrile (Shevchenko et al., 1996). For in-solution
digests samples were dried in vacuum centrifuge, resuspended in 50mM
ammonium bicarbonate and denatured at 55°C for 30 minutes. Trypsin was
added at a 1:100 trypsin:sample ratio and incubated overnight at 37°C. After
either in-gel or in-solution digestion samples were dried by vacuum
centrifugation.

Enrichment by peptide-pipette tip TiO2 chromatography
TiO2 tips (NuTip, 1-10µL for affinity purified proteins and 10-100uL for
complex mixtures, (Glygen Corp., Columbia, MD) were conditioned TiO2 tips by
pipetting 10 (purified protein) or 100µL (complex mixture) of 1.0% TFA in 80%
acetonitrile loading buffer through the tip 10 times. Peptides were dissolved in 10
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or 100µL of loading buffer and loaded on to tip by pipetting peptide solution
through the tip at least 10 times. The tip was then washed with an additional 10
or 100 µL of loading buffer by pipetting the solution through the tip at least 10
times. The tip was washed a second time with 10 or 100 µL of 0.1% TFA in 80%
acetonitrile by pipetting the solution through the tip at least 10 times. Bound
peptides were eluted by pipetting 3.5-10 or 25-100µL of 500 mM NH4OH through
the tip 10 times. Solvent was removed by vacuum centrifugation and stored at 20°C until MS analysis.

Analysis of methyl esterified peptides by MALDI-TOF/TOF MS
Methanolic HCl solution was prepared by dropwise addition of 160 µl of
acetyl chloride to 1 ml of dry methanol (Ficarro et al., 2002). Phosphopeptide
standards and tryptic digests were redissolved in 50 µl of 2 M methanolic HCl
reagent.

Methyl esterification was allowed to proceed for 2–3 h at room

temperature. Solvent was removed by lyophilization, and peptide mixtures were
resuspended in 0.2% TFA, 30% acetonitrile. MALDI matrix was prepared by
dissolving 5mg/mL of α-cyano-4-hydroxycinamic acid (HCCA) in 900 uL of a
50/50 mix 0.1% TFA: ACN to which 100 uL of 0.1M solution of Ammonium
Phosphate was added. Sample was then mixed with MALDI matrix 1:1 (v/v), 1.2
µl was spotted onto MALDI sample stage and allowed to air dry. Positive and
negative ion mode MALDI MS spectra were obtained using an Applied
Biosystems 4700 Proteomics Analyzer with TOF/TOF ion optics (Applied
Biosystems, Wilmington, DE); in MS/MS mode the instrument was always
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operated with the collision gas off. A diode pumped Nd:YAG laser with a 600 ps
pulse length was used.

The instrument was controlled by ABI 4700 Series

Explorer (version 3.0). The ABI calibration mixture was used to calibrate the
instrument in MS mode and MS/MS mode was calibrated using the y-series
fragment ions of Glu-fibrinogen peptide, m/z 1570.677. An additional internal
calibrant of the N-terminal y1 fragment (either K or R) m/z 147.113 or 175.119
was applied in MS/MS mode. Spectra were obtained for each sample using 500
laser shots in MS mode and 3500 shots in MS/MS.

Precursor ions were

fragmented by accelerating to 8 keV, selecting them with the timing gate set to a
resolution of 50 and then accelerating fragment ions to 14 keV before entering
the reflector. Positive and negative ion mode MS spectra where acquired for insolution digests of 100fmol of Beta casein with or without methyl esterification.
All MS/MS spectra were acquired in positive ion mode and sequenced manually.

SILAC ratio determination and assignment of EphB2 phosphorylation Sites
Quantification was carried out using the open-source software MSQuant
(Peter Mortensen and Matthias Mann, http://msquant.sourceforge.net/).

To

identify the most likely sites of phosphorylation for EphB2 observed peptides,
spectra identified as phosphopeptides by Mascot were processed and validated
using

MSQuant

software.

MSQuant

calculated

the

probabilities

for

phosphorylation at each potential site and generated PTM scores as described
previously (Olsen et al., 2006).
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Supplementary Figure Legends

Supplementary Figure 3.1. Activity of FLAG-EphB2.

FLAG and pY99 IPs

followed by anti-FLAG and pY99 Western blotting verified that transfected
construct was tyrosine phosphorylated in an ephrin-dependent fashion.

Also

observed in a general increase in overall tyrosine phosphorylation after ligand
treatment suggesting the FLAG-tagged receptor is signaling properly.

Supplementary Figure 3.2. Phosphorylation Sites and Individual Ratios

Supplementary Figure 3.3. Mutation of amino acid Y504 to glutamic acid
(E) in HEK293T cells generates receptors with reduced expression. Left,
Western blots of lysates from HEK293T cells transfected with 1μg of indicated
fEphB2 constructs and probed for EphB2, or β-actin. Right. DNA titration for
indicated amount of fEphB2 constructs cDNA transfected into HEK293T cells and
immunoblotted for EphB2, or β-actin.

Supplementary Figure 3.4.

Clustered ephrin-B2-Fc treatment causes

internalization of EphB2 receptors in neurons. (A-C) DIV 7 cultured cortical
neurons were stimulated as indicated with either Fc control (Control), unclustered
ephrin-B2-Fc (inactivating eB2), or clustered ephrin-B2-Fc (activating eB2). (A)
Representative immunoblot of biotinylated EphB2 from DIV7 cultured cortical
neurons with no actin biotinylated. (B) Quantification of percent localized to the
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cell surface compared to Fc treated control. (C) Quantification of percent in
intracellular avidin fraction compared to Fc treated control. Error bars indicate
SEM. (*p < 0.05, ANOVA test; n=4).

Supplementary Figure 3.5.

EphB2 Y504E mutants in cultured cortical

neurons are retained on the plasma membrane. (A-B) DIV2 cultured cortical
neurons were infected with indicated YFP-EphB2 lentiviral constructs, then at
DIV7 cell surface EphB2 receptors were biotinylated.

(A) Representative

immunoblot of biotinylated infected EphB2 with no actin biotinylated.

(B)

Quantification of percent localized to the cell surface compared to YFP-EphB2
WT. Error bars indicate SEM. (p > 0.5, ANOVA test; n=3).
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CHAPTER 4
DISCUSSION

Since the identification of the EphB receptor tyrosine kinase as a regulator
of excitatory synapse formation and NMDA receptor synaptic localization, our
laboratory has been striving to understand how these processes work at a
molecular level.

Of particular interest was how postsynaptic EphBs mediate

formation of presynaptic specializations through cognate ephrin-B ligands and
how signaling occurs at the molecular level; and the specific binding domain and
mechanism for the direct EphB-NMDAR interaction.

Synaptopathies, or

disruption of synaptic structure and function, have been described as key
features of neurodevelopmental, neurodegenerative, and psychiatric diseases.
The research presented in this dissertation improves our understanding of the
roles of EphB receptor tyrosine kinases in synapse formation, function, and
mechanisms of disease.

Summary of main results
There are several main findings of these studies. First, from Chapter 2
focusing on ephrin-B-dependent presynaptic formation, it was found that: 1)
Postsynaptic EphBs induce formation of presynaptic specializations via ephrinB1 and ephrin-B2 early in neuronal development. 2) Presynaptic ephrin-B1 and
ephrin-B2 are able to recruit the machinery required for neurotransmitter release
through a PDZ-domain dependent interaction with syntenin-1. Second, Chapter
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3 of this dissertation focused specifically on the EphB-NMDAR interaction and
found that: 1) The extracellular domain of postsynaptic EphB2 receptors
undergoes phosphorylation at tyrosine residue 504 after binding ephrin-B
ligands.

2) Phosphorylation at Y504 promotes the EphB-NMDAR direct

interaction stabilizing both receptors on the plasma membrane. 3) Mutations at
Y504 affect the synaptic function of NR2B-containing NMDARs late in neuronal
development altering synaptic currents and gene transcription. In this chapter, I
will discuss the results from both Chapter 2 and Chapter 3 separately, focusing
on the consequences and future directions for the EphB research field.

EphBs in formation of presynaptic specializations
Prior to the work presented in Chapter 2 of this dissertation, it was shown
that EphBs can induce the formation of both pre- and postsynaptic
specializations (Kayser et al., 2006). This is accomplished through bi-directional
EphB signaling; both “forward” signaling in the EphB receptor expressing cell or
“reverse” signaling in the ephrin-B expressing cell (Egea and Klein, 2007). While
EphB signaling was well characterized, the roles for different membrane attached
ephrin-B (B1-3) ligands were poorly understood.

In the hippocampus, a

postsynaptic role began to emerge for ephrin-B2 (Essmann et al., 2008;
Grunwald et al., 2004) and ephrin-B3 (Aoto and Chen, 2007; Rodenas-Ruano et
al., 2006). Interestingly, it was shown in Xenopus retinotectal system that ephrinB1 controlled presynaptic formation (Lim et al., 2008). Therefore, the roles of
ephrin-B1, ephrin-B2, and ephrin-B3 on the development of EphB-dependent
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presynaptic formations were investigated in cultured cortical neurons. As this
work began, some of the known intracellular signaling domains including Grb4
and GIT1 on ephrin-Bs were reported (Segura et al., 2007). Therefore, I also
sought to identify the molecular mechanisms that mediate EphB-dependent
development of presynaptic specializations via ephrin-Bs.
This work moved the fields of synapse formation and EphB receptor
biology forward in several important ways. First, this work demonstrates that
postsynaptic EphB2 interacts trans-synaptically with presynaptic ephrin-B1 or
ephrin-B2, but not ephrin-B3, and that this interaction is necessary and sufficient
for formation of a functional synapse. Second, knockdown of the adaptor protein
syntenin-1 is sufficient to block EphB-dependent presynaptic formation. Based
on this work and others, a model emerges (Supplementary Figure 2.6) where
postsynaptic EphB binds presynaptic ephrin-B1/2, recruiting the adaptor protein
syntenin-1, through its PDZ domain 2, which binds ERC2/CAST1 (Ko et al.,
2006), that is directly linked to vesicles of neurotransmitter through Rim and the
synaptic vesicle protein Rab3a (Jin and Garner, 2008). Thus, the trans-synaptic
interaction between EphBs and ephrin-B1/2 can recruit the necessary machinery
including receptors and changes in the actin cytoskeleton for presynaptic
neurotransmitter release via syntenin-1. In support of this model, syntenin-1,
ephrin-B1, and ephrin-B2 are co-localized at synaptic sites.

However, it is

important to note that ephrin-Bs are not responsible for formation of all
presynaptic specializations. Therefore, our data are consistent with EphB/ephrinB signaling directing a subset (~45% co-localization with VGLUT1 for ephrin-B1
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and ~23% for ephrin-B2; Supplementary Table 2.1) of excitatory presynaptic
specializations.
There are a number of interesting future directions that come out of this
work.

One of the most intriguing results from these studies was that

simultaneous knockdown of both ephrin-B1 and ephrin-B2 does not further
reduce synapse number, but does increase the amount of syntenin-1 at synaptic
sites. However, the differences between the ephrin-B1 and ephrin-B2 signaling
pathways were never identified. Therefore, I hypothesize that ephrin-B1 and
ephrin-B2 are members of distinct signaling pathways for formation of
presynaptic specializations and cannot compensate for the loss of the other.
One way to test this hypothesis would be to generate double knockout mice for
both ephrin-B1 and ephrin-B2 and then perform immunostaining experiments
comparing the number of presynaptic specializations between homozygous and
heterozygous animals. However, both ephrin-B1-/- and ephrin-B2-/- null mice are
embryonic lethal.

Therefore, I would need to breed together the conditional

knockout lines for both ephrin-B1 and ephrin-B2. I could then directly inject Crerecombinase into these double conditional knockout mice to delete efnb1 and
efnb2 gene expression.

Brains from these animals could sectioned and

immunostained for presynaptic marker SV2, postsynaptic marker SynGAP, and
syntenin-1. Based on our knockdown experiments using ephrin-B1 and ephrinB2 shRNAs (Chapter 2), I would expect that double knockout mice would not
have fewer synapses than animals lacking either ephrin-B1 or ephrin-B2.
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However, synaptic syntenin-1 levels should be reduced in the double knockout
mice compared to mice lacking either ephrin-B1 or ephrin-B2.
Another interesting future direction would be to follow-up on our
observation that ephrin-B2 is expressed in glial cells. These data leads to the
intriguing hypothesis that ephrin-B2 might be involved in neuron-glial
communication at synapses (Filosa et al., 2009; Murai and Pasquale, 2011;
Zhuang et al., 2010).

Glial glutamate transporters are known to modulate

synaptic transmission by clearing glutamate from the synaptic cleft (Tzingounis
and Wadiche, 2007). At the CA3-CA1 synapse, the loss of presynaptic ephrinA3 caused deficits in synaptic plasticity and overexpression of ephrin-A3 in
astrocytes reduced levels of glutamate transporters (Filosa et al., 2009).
Therefore, I hypothesize that ephrin-B2 would be a regulator of glial glutamate
transporters in the cerebral cortex. To test this hypothesis, cortical lysates from
wild-type and conditional ephrin-B2 knockout mice could be probed for levels of
the glial glutamate/aspartate transporter (GLAST) and glutamate transporter
subtype-1 (GLT-1). Based on the findings of (Filosa et al., 2009), I would expect
an upregulation in either GLAST or GLT-1 proteins in mice where ephrin-B2 gene
expression was removed. Alternatively, ephrin-B2 constructs could be generated
with a GFAP promoter for overexpression studies in cortical neuron culture and
density of presynaptic specializations could be assessed. I would expect that
glial over-expression of ephrin-B2 would increase density of presynaptic
specializations.
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Role of the EphB-NMDAR interaction at mature synapses
Prior to the work presented in Chapter 3 of this thesis, it was shown that
EphBs directly bind NMDA-type glutamate receptors in an unknown region of
their extracellular domains (Dalva et al., 2000). The EphB-NMDAR interaction is
dependent on binding of ephrin-B ligand, but does not require activation of the
EphB intracellular kinase (Dalva et al., 2000). The EphB-NMDAR interaction
changes cellular signaling by causing changes in Ca2+ influx, phosphorylation of
NMDARs by Src kinases, and changes in NMDAR-dependent gene transcription
(Takasu et al., 2002). Furthermore, EphBs are required for synapse formation
early in neuronal development (DIV7-14), but not after DIV21 (Kayser et al.,
2008). Late in neuronal development (DIV14-23), EphBs specifically regulate the
expression levels, Ca2+-dependent desensitization, and synaptic currents of
NR2B-containing NMDARs (Nolt et al., 2011). However, for the EphB-NMDAR
interaction; the specific binding domain, mechanism, and pharmacological agents
that modulate the interaction remained unknown.
We have identified a single amino acid, tyrosine residue 504, in the
extracellular domain of EphB2 that is necessary and sufficient for the EphBNMDAR interaction to occur. Presynaptic ephrin-B binding to EphB2 leads to
Y504 phosphorylation, which is required to induce the EphB-NMDAR interaction.
Furthermore, the EphB-NMDAR interaction stabilizes both receptor proteins on
the plasma membrane and blocks their internalization. We also show that late in
neuronal development, mutations at Y504 affect synaptic regulation and function
including; synaptic currents and gene transcription of NR2B-containing NMDARs.
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Finally, I have identified a non-membrane permeable extracellular kinase inhibitor
k-252b, which inhibits the EphB-NMDAR interaction.
This work moves the fields of EphB receptor biology, synapse maturation
and function, and potentially treatment for synaptopathies forward in several
important ways. In the sections below, I will specifically discuss how this work
resolves between different receptor fates at the plasma membrane (including a
model summarizing EphB2 Y504 in terms of receptor trafficking and the EphBNMDAR interaction), how the EphB-NMDAR interaction can be targeted to treat
neuronal disease, and future directions for this work.

EphB Receptor Fates at the Plasma Membrane
Ephrin-B binding to EphB receptors regulates a diverse number of
receptor trafficking events from cleavage by γ-secretase / MMP system (Lin et
al., 2008; Litterst et al., 2007; Xu et al., 2009), internalization by clathrin-mediated
mechanisms (Andersson, ; Irie et al., 2005; Nishimura et al., 2006; Pitulescu and
Adams, 2010), trans-endocytosis of the receptor-ligand complex (Marston et al.,
2003; Zimmer et al., 2003), to EphB ubiquitination and degradation by the
proteasome (Fasen et al., 2008; Margolis et al., 2010), or direct binding to NMDA
receptors (Dalva et al., 2000; Takasu et al., 2002). However, what differentiates
between these trafficking events at the plasma membrane is a major gap in the
literature.

One intriguing idea from this thesis work (Chapter 3), is that

extracellular phosphorylation at Y504 might direct EphBs towards internalization
and NMDAR binding, but away from cleavage events. Interestingly, it appears in
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an environment without NMDARs present like HEK293T cells (Chapter 3); a
negative charge at Y504 is a signal for receptor internalization and subsequent
degradation.

In this system, I was unable to detect the EphB2 receptor

ectodomain in the supernatant (S.I.S-C and M.B.D., unpublished observations).
However, in cortical neuron cultures where endogenous NMDAR are widely
expressed or HEK293T cells over-expressing NMDARs, a negative charge at
Y504 acts as a signal to promote the EphB-NMDAR interaction stabilizing both
proteins at the plasma membrane and therefore inhibiting their internalization
(Chapter 3).
These observations are summarized into a working model (Figure 4.1) to
explain the role of extracellular phosphorylation of EphB2 on EphB receptor
internalization and NMDAR density at the plasma membrane. Briefly, ephrin-B
binding to EphB2 receptors at the plasma membrane leads to extracellular
phosphorylation of Y504 and activation of the EphB kinase domain (including
intracellular phosphorylation at Y662). Next, comes the main decision point for
this signaling pathway, which depends on whether NMDARs are closely localized
to EphB receptors after ligand binding and extracellular phosphorylation at Y504.
Once EphB receptors are phosphorylated and unbound to NMDARs, (Figure 4.1
bottom) they are internalized by clathrin-mediated mechanisms, and degraded
through ubiquitin-dependent mechanisms in the proteasome (Fasen et al., 2008;
Margolis et al., 2010).

However, if NMDARs are present (Figure 4.1 top),

phosphorylated EphBs bind NMDARs blocking internalization of both proteins.
The EphB-NMDAR interaction starts a number of signaling events including
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src-mediated phosphorylation of NR2B-containing NMDARs (Takasu et al.,
2002), trafficking of more NR2B-containing receptors to synaptic sites, increased
NMDAR currents, calcium influx (Nolt et al., 2011; Takasu et al., 2002), and
changes in gene expression.
A number of intriguing future directions arise from the observation that
when NMDARs are absent, EphBs that are phosphorylated at Y504 are rapidly
degraded. First, one attractive hypothesis is that phosphorylation at Y504 may
allow for the developmental switch between axon guidance and synapse
formation. The role of EphB/ephrin-B signaling is well established in both of
these processes, but involves different molecular mechanisms.

During axon

guidance (DIV0-7), ephrin-Bs act as repulsive cues. Upon binding ephrin-Bs,
EphB activation leads to receptor internalization and eventually growth cone
collapse (Fasen et al., 2008; Marston et al., 2003; Zimmer et al., 2003).

In

contrast, at DIV7-14, EphB activation is not repulsive anymore but acts as an
adhesion molecule promoting synapse formation (Kayser et al., 2008).

This

switch in EphB function could result from differences in NMDAR expression.
Thus, low NMDAR expression such as seen in growth cones (Wang et al., 2011)
would induce ephrin-B-dependent internalizations of EphBs and growth cone
collapse; whereas higher levels of NMDARs, as observed in dendritic filopodia,
would favor EphB-NMDAR interaction, and EphB-NMDAR retention at the
surface.
One way to test the hypothesis that ephrin-B-dependent phosphorylation
at EphB Y504 promotes growth cone collapse is to make retinal explants cultures
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from retinal ganglion cell (RGC) neurons which endogenously express EphBs
(Petros et al., 2010). Then, growth cone collapse could be assessed using live
imaging or immunostaining after bath pretreatment with ephrin-B2 or Fc-control
in the presence or absence of k-252b the broad spectrum, membrane
impermeable, extracellular kinase inhibitor. If phosphorylation at Y504 is critical
to ephrin-B-mediated growth cone collapse, then collapse should be blocked by
k-252b treatment. Similarly, I would expect that over-expression of Y504F
mutants would prevent growth cone collapse.
To assess the hypothesis that the presence of NMDARs blocks repulsion
through Y504, RGC explants could be transfected with EphB2 WT and Y504
mutant constructs in the presence or absence of NR1/2B constructs. I would
predict that because binding NMDARs stabilizes EphBs that over-expression of
NR1/2B receptors would block growth cone collapse. We have shown in Chapter
3 that over-expression of Y504F mutant receptors decreases synaptic currents
and NMDARs at postsynaptic specializations. Alternatively, it is also possible
that the change from repulsive signaling during axon guidance at growth cones,
to stabilization during synaptogenesis at dendritic filopodia is mediated by
intracellular signaling events through different GEFs. Rho-GEF Vav2 is required
for internalization during growth cone collapse (Cowan et al., 2005); whereas
Rho-GEF intersectin-1 (Irie and Yamaguchi, 2002), Rac-GEF Tiam1 (Tolias et
al., 2007), and Rho/Rac1-GEF Kalirin-7 (Penzes et al., 2003) help EphBs
associate with NMDAR at synaptic sites to form dendritic spine synapses.
Unfortunately, the differences in signaling mechanisms amongst GEFs remains
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poorly understood.

However, shRNAs could be generated against each

individual GEF, and co-expressed with EphB WT and Y504 mutant constructs in
cultured cortical neurons.

Then dendritic filopodia motility and density of

postsynaptic specializations could be assessed as previously described in
(Kayser et al., 2008).

Targeting the EphB-NMDAR interaction to treat CNS disease
A number of recent reports have specifically implicated the EphB-NMDAR
interaction as a critical regulator of the deleterious effects of both Alzheimer’s
disease and neuropathic pain. In this thesis (Chapter 3), I have identified a
specific amino acid (Y504) that mediates the EphB-NMDAR interaction and a
pharmacological agent (k-252b) that blocks this interaction. Therefore, the most
exciting future direction for this thesis work is to test whether modulating EphB2
Y504 phosphorylation and the EphB-NMDAR interaction with k-252b can
ameliorate either of these devastating diseases. While EphBs are not required
for localization of NMDARs or NR2B-conatining NMDARs at all synaptic sites,
our data suggests they are at a substantial fraction (~50%) of mature synapses
(Kayser et al., 2006; Nolt et al., 2011). Here, I will discuss future directions to
test the hypothesis that EphB2 Y504 is a critical regulator of Alzheimer’s disease
and neuropathic pain.
A strong link has emerged between EphBs and Alzheimer’s disease (AD)
through Amyloid-β (Aβ) including in vitro, in vivo, and clinical reports (Chen et
al.). Furthermore, EphB2 expression levels are reduced in AD patients (Simon et
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al., 2009). Aβ appears to bind directly to EphB2 in its extracellular FnIII domains
(which contains Y504) promoting EphB receptor degradation (Cisse et al., 2011).
Thus, viral overexpression of EphB2 can rescue LTP, NMDAR current deficits,
and cognitive abilities in a mouse model of AD (Cisse et al., 2011). Therefore, it
is intriguing to propose that EphB2, and modulation of the EphB-NMDAR
interaction through phosphorylation at Y504 could yield a therapeutic target for
Alzheimer’s disease.
Based on the work of Cisse et al., (2011), it has been suggested that
EphB binding directly to Aβ is a critical event to AD progression. First, it would
be important to test the hypothesis that Y504 is the binding domain for EphBs
and Aβ. This hypothesis could be tested in vitro using the human amyloid-beta
(hAβ) protein precursor mouse model of AD (Cisse et al., 2011; Simon et al.,
2009) and performing co-immunoprecipitation experiments.

Cortical neurons

from the hAPP mouse could be cultured, and then infected with EphB2-YFP WT,
Y504E, and Y504F lentiviruses (Chapter 3). Over-expressed EphB2 receptors
could be pulled down using an anti-GFP antibody, and then probed with an
antibody against Aβ. Furthermore, these blots could be stripped and reprobed
with anti-NMDAR antibodies to see if the EphB-NMDAR interaction is affected. If
EphB2 Y504 is the binding domain for Aβ-binding, one would expect that due to
the change in charge, EphB2 Y504E mutants would have decreased Aβ-binding,
and more EphB-NMDAR interactions.

Next, it would be important to see if

infection of the EphB-YFP lentiviruses into the hAPP mice could rescue the
deficits in LTP, NMDAR currents, and behavior as described by (Cisse et al.,
154

2011). If Y504 is the critical residue for EphB-Aβ-binding, I would expect that
infection of EphB2 Y504F receptors would not rescue the deficits in hAPP mice
because it would preferentially bind Aβ over NMDARs. However, it is possible
that the Aβ-binding domain is not located at Y504, but somewhere else in the
FnIII repeat domains.

If Y504 were not the Aβ-binding domain, it would be

interesting to see if the other extracellular phosphorylation site identified by our
mass spectrometry experiments (Y481) is involved in this process.
In addition to a role of EphB in AD, a robust literature links EphB1/ephrinB signaling to regulate neuropathic pain in the spinal cord and periphery through
modulation of NMDAR signaling.

Specifically, EphB1 and ephrin-Bs are

upregulated in the spinal cord and periphery after injury (Kobayashi et al., 2007;
Song et al., 2008a; Song et al., 2008b). The upregulation of EphB1/ephrin-Bs
leads to hyperexcitable NMDARs with lower LTP thresholds (Battaglia et al.,
2003; Cao et al., 2008; Guan et al., 2010; Ruan et al., 2010; Slack et al., 2008;
Song et al., 2008b) and NR2B phosphorylation by src kinase (Battaglia et al.,
2003; Slack et al., 2008; Song et al., 2008b). Therefore, it is hypothesized that
the EphB-NMDAR interaction plays a critical role in the enhancement of pain
sensitivity. EphB1 Y502 is the structurally homologous interaction domain on
EphB1 that should modulate NMDAR binding. Based on our findings that k-252b
is necessary and sufficient to block the EphB-NMDAR interaction, I hypothesize
that k-252b injection could ameliorate neuropathic pain. To test this hypothesis,
hyperalgesia could be induced by intrathecal injection of ephrin-B2-Fc (Battaglia
et al., 2003; Slack et al., 2008; Song et al., 2008b) in the presence or absence of
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k-252b pre-injection.

Thermal hyperalgesia or mechanical allodynia models

could be used to assess the behavioral affects of k-252b on pain, and the EphBNMDAR interaction could be assessed biochemically in spinal tissues from
injected rats. If EphB1 Y502 phosphorylation is required for neuropathic pain,
then k-252b should block the induction of neuropathic pain mediated by ephrinBs by inhibiting the EphB-NMDAR interaction in behavioral and biochemical
assays.
Alternatively, if we knew the kinase that phosphorylates Y504, antagonism
of that receptor would also have large therapeutic potential because it may have
fewer side effects than k-252b. While no extracellular tyrosine kinases have
been reported, extracellular serine/threonine kinases have been found in
numerous cell types including neurons (Chen et al., 1996; Fujii et al., 2000;
Kumar et al., 2011; Redegeld et al., 1999). Three soluble FGFR splice variants
have been reported with kinase domains intact, but lacking transmembrane
domains (Johnston et al., 1995; Katoh et al., 1992; Sturla et al., 2003). Another
possibility is known extracellular kinase Casein Kinase 2 (CK2) (Bohana-Kashtan
et al., 2005; Maik-Rachline et al., 2005; Nguyen et al., 2008; Zimina et al., 2007)
which has been reported to phosphorylate tyrosine residues in addition to its
known function on serine/threonine residues (St-Denis and Litchfield, 2009).
There a few different ways to determine which kinase phosphorylates
EphB2 Y504. A first approach, currently being taken by Dr. Kenji Hanamura a
postdoc in the laboratory, is to use pharmacological inhibitors of known tyrosine
kinases to find ones that inhibit phosphorylation of Y504, but not other
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intracellular phospho-tyrosine residues. Then, effective inhibitors could be used
to see if they can block the EphB-NMDAR interaction.

Using a variety of

inhibitors would narrow down the list to a few known kinases.

Then, these

kinases could be tested individually in in vitro kinase assays and in neuron
culture for the EphB-NMDAR interaction. Preliminary experiments suggest that
PD161570 an FGFR antagonist; and PD166285 an antagonist of FGFR, PDGFR,
and src kinases blocks phosphorylation of EphB2 at Y504 (K.H., S.I.S-C, and
M.B.D., unpublished observations). To build on the first approach, Dr. Hanamura
is also performing an in vitro kinase assay with only the extracellular domain of
EphB2 (EphB2-Fc). Commercially available soluble receptor tyrosine kinases
like FGFRs, CK2, EphB, EGFR, and other RTKs are combined in the presence
or absence of ATP. The EphB2-Fc is then immunoprecipitated using anti-human
IgG antibodies and lysates are probed using the anti-EphB2 pY504 antibody.
A final approach based on mass spectrometry (similar to Y504
identification) would express EphB2 TR (extracellular domain only) constructs in
cell lines. Then, the cells could be treated with ephrin-B2 ligand to induce Y504
phosphorylation.

Next,

a

chemical

cross-linking

reagent

like

Dithiobis(succinimidyl propionate) (DSP) (Sinz, 2006; Wiseman et al., 2009) or
formaldehyde (Sutherland et al., 2008) could be used to crosslink kinase and
substrate.

This cross-linking would need to be done at different timepoints

including 5, 7.5, 15, and 30 minutes to makes sure to catch receptor and kinase
together. Then, phospho-tyrosine residues could be immunoprecipitated using
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PY99, and tryptic peptides identified could be bioinformatically linked to known
tyrosine kinases (Sinz, 2006).

Conclusion
The work presented in this thesis has strived to understand basic
mechanisms of EphB receptor biology with the goal of understanding how to
better understand synaptopathies.

These findings move the field of EphB

receptor biology, synapse formation, and synapse maturation forward in four
important ways.

First, the mechanisms for EphB-dependent presynaptic

signalling have been elucidated from ephrin-B adhesion molecule to vesicles of
glutamate. Second, this dissertation is the first report of extracellular tyrosine
phosphorylation of any protein, and a significant advance for the field of EphB
receptor biology by revealing new signalling mechanisms. Thirdly, it has shown
a single residue that is necessary and sufficient for the EphB-NMDAR interaction
to occur. Finally, a novel mechanism of extracellular tyrosine phosphorylation for
regulating protein-protein interactions has emerged with the potential to treat
diseases of the central nervous system and beyond. Future studies will address
which specific tyrosine kinase is responsible for this extracellular phosphorylation
event and whether inhibiting this phosphorylation event, using k-252b, to block
the EphB-NMDAR interaction could have therapeutic potential for treating
neuropathic pain.

Also, potentiating the EphB-NMDAR interactions could be

protective against Alzheimer’s disease.

158

Therefore, it is hoped that this

dissertation research moves the field of synapse formation and EphB receptor
biology towards the goal of treating human disease.
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Abstract
Dynamic regulation of the localization and function of NMDA receptors
(NMDARs) is critical for synaptic development and function. The composition and
localization of NMDAR subunits at synapses are tightly regulated and can
influence the ability of individual synapses to undergo long-lasting changes in
response to stimuli. Here, we examine mechanisms by which EphB2, a receptor
tyrosine kinase that binds and phosphorylates NMDARs, controls NMDAR
subunit localization and function at synapses. We find that, in mature neurons,
EphB2 expression levels regulate the amount of NMDARs at synapses, and
EphB activation decreases Ca2+-dependent desensitization of NR2B-containing
NMDARs. EphBs are required for enhanced localization of NR2B-containing
NMDARs at synapses of mature neurons; triple EphB knockout mice lacking
EphB1–3 exhibit homeostatic upregulation of NMDAR surface expression and
loss of proper targeting to synaptic sites. These findings demonstrate that, in the
mature nervous system, EphBs are key regulators of the synaptic localization of
NMDARs.
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Introduction
The NMDA receptor (NMDAR) is essential for neuronal development and
function, synaptic plasticity, and adaptive responses to sensory experience (CullCandy and Leszkiewicz, 2004; Lau and Zukin, 2007; Perez-Otano and Ehlers,
2005). These functions require glutamate-dependent calcium influx into neurons
through the NMDAR. The NMDAR is a heteromeric protein complex of two
obligate NR1 subunits and typically two NR2 subunits, which each convey
distinct functional properties to the receptor (Cull-Candy and Leszkiewicz, 2004).
NR2A is the principal subunit at mature cortical and hippocampal synapses.
Although NR2B subunits are more prevalent at these synapses during
development, they are still expressed in the mature brain (Monyer et al., 1994;
Sheng et al., 1994; Tovar and Westbrook, 1999). NR2B-containing NMDARs
have a slower inactivation rate and longer decay times compared with NR2A
subunits (Cull-Candy and Leszkiewicz, 2004). Thus, synapses with higher
proportions of NR2B can integrate synaptic currents across broader time
intervals than those with more NR2A. In addition, NR2B-containing NMDA
receptors carry more Ca2+ current per unit charge (Sobczyk et al., 2005), are
preferentially tethered to the plasticity protein CaMKII (calcium/calmodulindependent protein kinase II) (Barria and Malinow, 2005), and exhibit a lower
threshold to undergo potentiation of synaptic responses (Philpot et al., 2007;
Philpot and Zukin, 2010). Thus, understanding the molecular mechanisms that
direct trafficking of NR2B subunits to and from synapses will provide insights into
synaptic plasticity.
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NMDARs are recruited to and retained at synapses through well studied
mechanisms (Chen and Roche, 2007; Kim and Sheng, 2004; Lau and Zukin,
2007, including postsynaptic density-95/Discs large/zona occludens-1 (PDZ)
binding domain interactions and phosphorylation of the receptor itself
{Prybylowski, 2005 #112; Perez-Otano and Ehlers, 2005). Activation of EphB
leads to a Src kinase-dependent phosphorylation of the NR2B subunit at three
tyrosine residues (Antion et al., 2010; Takasu et al., 2002). One of these
residues, Y1472, is important for regulating NMDAR surface and synaptic
localization (Salter and Kalia, 2004), suggesting that EphBs might play a role in
the synaptic targeting/retention of NMDARs.
The EphB family of receptor tyrosine kinases is enriched at excitatory
synapses and is important during synapse and spine formation and maintenance
(Aoto and Chen, 2007; Klein, 2009; Shi et al., 2009; Tolias et al., 2007). Triple
knock-out mice lacking EphB1–3 have fewer excitatory synapses (Henkemeyer
et al., 2003; Kayser et al., 2006), whereas animals lacking only EphB2 have
reduced NMDAR content at synapses (Henderson et al., 2001). In addition to
modulating NMDAR-mediated calcium influx, activation of EphBs leads to a
direct association between EphB and the NMDAR NR1 subunit (Dalva et al.,
2000); EphBs also associate with and regulate trafficking of AMPA receptors
(AMPARs) (Irie et al., 2005; Kayser et al., 2006). We examined whether EphBs
impact synaptic NMDAR function and contribute to subunit-specific synaptic
localization of NMDARs. We find that expression levels of EphB2 control the
amount of NMDAR at synapses, and that EphB2 kinase activity regulates the
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calcium inactivation rate of NR2B-containing NMDARs. EphB2 activation also
preferentially targets and stabilizes NR2B-containing NMDARs at synapses.
These results suggest that EphBs may be important regulators of NMDAR
targeting, subunit composition, and function at mature synapses.
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Materials and Methods

Cell culture and transfection. Dissociated cortical neurons were prepared from
embryonic day 17 (E17) to E18 rats of either sex and cultured as described
previously (Kayser et al., 2006). Briefly, neurons were cultured in Neurobasal
(Invitrogen), B27 supplement (Invitrogen), glutamine (Sigma-Aldrich), and
penicillin–streptomycin (Sigma-Aldrich) on poly-d-lysine (BD Biosciences or
Sigma-Aldrich) and laminin (BD Biosciences)-coated glass coverslips (12 mm;
Bellco Glass) in 24-well plates (Corning Life Sciences). Cells were plated at
150,000 per well and maintained in a humidified incubator with 5% CO2 at 37°C.
Neurons were transfected with Lipofectamine 2000 (Invitrogen) at 14 d in vitro
(DIV) using methods described previously (Kayser et al., 2008).

HEK-293 cell culture and transfection. HEK-293 cells were maintained as
described (Lin et al., 2004). For transfection, HEK-293 cells were plated at a
density of 1 × 106 cells per milliliter on 12 mm glass coverslips coated with polyd-lysine (10 μg/ml) in 24-well culture plates and transfected with NR1, NR2A, or
NR2B and green fluorescent protein (GFP) or EphB2-YFP plasmid (1 μg of
plasmid cDNA per 12 mm coverslips in 1:1:1 ratio) using the calcium phosphate
method according to the manufacturer's protocol (Invitrogen). For the EphB2-KD
experiment, we transfected YFP-NR1, NR2B, and EphB2-KD into HEK-293 cells
in 1:1:1 ratio.
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Immunocytochemistry. Cultures were fixed in 4% paraformaldehyde/2%
sucrose for 8 min at room temperature. Cells were washed three times in PBS
and blocked and permeabilized in 1% ovalbumin (Sigma-Aldrich)/0.2% coldwater
fish scale gelatin (Sigma-Aldrich)/0.1% saponin (Sigma-Aldrich) for 1 h at room
temperature. Antibody incubations were conducted overnight at 4°C for primary
antibody and 1 h at room temperature in secondary antibody diluted in blocking
reagents. Antibodies used were as follows: chicken anti-GFP (Millipore; 1:2500),
guinea pig anti-VGlut1 (Millipore Bioscience Research Reagents; 1:5000), and
mouse anti-NR1 (Millipore Bioscience Research Reagents; 1:1000). Cy2, Cy3,
and Cy5 secondary antibodies were obtained from Jackson ImmunoResearch
and used at 1:250.

cDNA and short hairpin RNA constructs. EphB2 short hairpin RNA (shRNA)
was described previously (Kayser et al., 2006). The EphB2 rescue construct was
generated and described previously (Kayser et al., 2006; Kayser et al., 2008).
Full-length FLAG-tagged EphB2 and FLAG-tagged kinase inactive EphB2 were
described previously (Dalva et al., 2000).

Imaging and analysis. Images of primary neuronal cultures were acquired by
confocal scanning microscopy (Leica) using methods described previously
(Kayser et al., 2006; Kayser et al., 2008). Briefly, all images were acquired using
a 63×, numerical aperture 1.4, oil-immersion objective with z-steps of 0.5 μm and
subsequently analyzed with custom-designed NIH ImageJ macros blind to
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experimental condition. Images were collected from at least three independent
experiments. For puncta analysis, images were converted from maximum
projections to binary scale, and puncta were identified as continuous groups of
pixels corresponding to 0.5–7.5 μm2. Colocalization between puncta was defined
as >1 pixel overlap between channels. To determine amount of NR1 at the
synapse, images were collected for each condition with the same gain values.
Intensity of NR1 staining at the synapse was then calculated for each condition.
Amounts for each condition were normalized to the maximum intensity observed
from all three conditions.

Electrophysiology. Whole-cell recordings were made from 21–23 DIV rat
cortical neurons. Coverslips were moved into a recording chamber and bathed in
a HEPES-buffered artificial CSF (ACSF) solution (in mm: 140 NaCl, 5 KCl, 2
CaCl2, 20 glucose, and 10 HEPES, pH 7.2). GFP-positive pyramidal neurons
were chosen for recording. The internal solution contained the following (in mm):
125 CsGlu, 5 EGTA, 2 MgCl2, 1 CsCl2, 2 K2-ATP, 10 HEPES, and 0.42 Na-GTP,
pH 7.2. Pipettes were pulled to a 6–9 MΩ resistance, and recordings were made
for 2–5 min at −65 mV before bath application of APV. After application of APV,
the cell was again recorded for 2–5 min. For experiments conducted at +50 mV,
similar recording conditions were used except that coverslips were moved into a
recording chamber and bathed in a HEPES-buffered ACSF solution (in mm: 140
NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 20 glucose, and 10 HEPES, pH 7.2). Tetrodotoxin
(TTX) and picrotoxin were used at 1 and 10 μm, respectively (Sigma-Aldrich).
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Bicuculline was used at 50–100 μm, APV was used at 10 μm, and (αR,βS)-α-(4hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate (Ro256981) was used at 1–2 μm (Tocris Bioscience). All data were collected at 5 kHz
and filtered at 1 kHz; events were detected in Clampfit 9.2 (Molecular Devices).
Event analysis and statistics were performed using Matlab (The MathWorks) and
Clampfit software (Molecular Devices). Decay time was calculated as the time
from peak amplitude of the current to 30% of the peak amplitude.

Whole-cell recording from HEK-293 cells. Electrophysiological recordings
were performed 1–2 d after transfection. Once whole-cell-recording configuration
was obtained, NMDA plus glycine was applied several times for 5 s periods
separated by

25 s recovery intervals. Rapid agonist application was achieved

by placing cells in a laminar solution stream that was delivered from a multibarrel
array fed by gravity. Currents activated by NMDA (300 μm) in the presence of
glycine (10 μm) were recorded in the whole-cell mode at a holding potential of
−60 mV, filtered at 2 Hz, and digitized on-line at 1 kHz. Importantly, we did not
observe an increase in desensitization during the few minutes of recording.
Electrodes with open-tip resistances of 2–5 MΩ were used. Data were acquired
and analyzed using pClamp 9 software and AxoPatch-1D amplifier (Molecular
Devices). The internal pipette solution was composed of the following (in mm):
145 KCl, 4 Mg-ATP, 10 HEPES, and 5.5 EGTA, adjusted to pH 7.25 with KOH.
External solution contained the following (in mm): 145 NaCl, 5.4 KCl, 2 CaCl2, 11
glucose, and 10 HEPES, adjusted to pH 7.3 with NaOH.
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Cultured neuron biotinylation. After treatment with clustered ephrin-B2-Fc or
Fc control, cortical neuron cultures were placed on ice and rinsed twice with icecold rinsing solution (PBS, pH 7.5, containing 0.1 mm CaCl2 and 1 mm MgCl2).
Clustering of ephrin-B2-Fc and human-Fc control proteins (R&D Systems) was
achieved by incubation with anti-human IgG (Jackson ImmunoResearch) using
methods described previously (Dalva et al., 2000). Cells were incubated in
rinsing solution containing 1 mg/ml Sulfo-NHS-SS-Biotin (Pierce Protein
Research Products; Thermo Fisher Scientific) with gentle agitation at 4°C for 30
min. Cells were then washed in quenching solution (rinsing solution with 100 mm
glycine) and incubated in this solution with gentle agitation at 4°C for 30 min to
quench unbound biotin. Cells were washed in rinsing solution, and then agitated
at 4°C for 60 min using radioimmunoprecipitation assay (RIPA) buffer containing
protease inhibitors for cell lysis. Cell lysates were harvested and centrifuged at
13,000 rpm for 20 min at 4°C. Aliquots were taken for total lysate fraction, for
Bradford protein assay analysis (Bio-Rad), and for incubation with monomeric
avidin agarose (Pierce Protein Research Products; Thermo Fisher Scientific) at
25°C for 60 min. After incubation, lysates were centrifuged at 13,000 rpm for 15
min, and the supernatant (intracellular fraction) was removed. The 4× sample
solubilizing buffer was added to the total and intracellular fractions. Avidin beads
were then washed three times with RIPA buffer, before incubation in 2×
solubilizing buffer at 37°C for 30 min. Samples were then centrifuged for 5 min at
14,000 rpm, and the supernatant (surface fraction) was extracted. Five to 10 μg
169

of surface and total lysate fraction were subjected to SDS-PAGE and Western
blot analysis. Experiments were excluded from additional analysis if Western
blots of the biotinylated fractions were positive for the cytosolic protein β-actin.
Band intensities were quantified by densitometric analysis using NIH ImageJ
software, and comparisons were made between total and biotin labeled fractions.

Biotinylation assay for surface NMDARs from slices. Hippocampal or cortical
slices were prepared from postnatal day 21 (P21) to P28 mice of either sex. After
washing twice in ice-cold ACSF, slices were incubated in 1 mg/ml NHS-SS-biotin
(Pierce) for 30 min at 4°C to biotinylate surface proteins as described previously
(Huang et al., 2009). After removing nonspecifically bound NHS-SS-biotin, the
tissue was homogenized and sonicated in PBS-based lysis buffer containing
protease and phosphatase inhibitors (in mm: 1 EDTA, 1 EGTA, and 1% Triton X100, 0.1% SDS, pH 7.4), followed by end-to-end rotating for 30 min at 4°C. After
centrifugation at 13,000 rpm for 30 min at 4°C, the supernatant was incubated
with Neutravidin beads (Thermo Fisher Scientific) to capture biotinylated surface
proteins. After washing three times with lysis buffer, the surface proteins were
eluted with protein sample buffer containing DTT and subjected to Western
blotting. Membranes were probed with polyclonal anti-NR2A (1:1000; Millipore),
with monoclonal anti-NR2B (1:2000; Millipore), monoclonal anti-NR1 (1:2000;
54.1; a generous gift from J. Morrison, Mount Sinai School of Medicine, New
York, NY), and with anti-β-actin (1:5000; Sigma-Aldrich). Samples with actin
labeling in the surface fraction were excluded from additional analysis.
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Membranes were stripped with Restore reagent (Thermo Fisher Scientific) to
reprobe the membranes with a different antibody. Band intensities were
quantified by densitometric analysis using NIH ImageJ software.

Synaptosome preparation. This protocol was adapted from previous work
(Blackstone et al., 1992; Lau et al., 1996). Briefly, whole brains from male and
female P30 wild type (WT), EphB double knock-out (DKO), and triple knock-out
(TKO) mice were homogenized in HEPES-buffered sucrose [0.32 m sucrose, 4
mm HEPES, pH 7.4, and protease inhibitor mixture (Sigma-Aldrich)]. The nuclear
fraction was removed from the homogenate by centrifugation at 1000 × g for 15
min. The resulting supernatant (S1) was then centrifuged at 10,000 × g for 15
min to yield the crude membrane fraction (P1). The P1 pellet was resuspended in
10 vol of HEPES-buffered sucrose and spun again at 10,000 × g for 15 min to
yield washed crude synaptosomal fraction (P2). The P2 fraction was layered onto
4 ml of 1.2 m sucrose containing protease inhibitors (Sigma-Aldrich) and
centrifuged at 230,000 × g for 15 min. The interface was collected and diluted
into final volume of 6 ml with HEPES-buffered 0.32 m sucrose and layered onto
0.8 m sucrose containing protease inhibitors. The sample was centrifuged at
230,000 × g for 15 min to obtain a pure synaptosomal (Syn) pellet. The
intensities of glutamate receptors from each fraction were determined by
densitometric analysis using ImageJ software. The raw intensities were then
normalized to actin intensities in each fraction. The relative levels of synaptic
versus membrane-associated glutamate receptors were calculated by taking a
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ratio of normalized synaptic fraction values (Syn) to normalized crude membrane
fraction values (P1). Statistical significance was assessed by ANOVA.
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Results
Early in development, the EphB receptor couples filopodia motility to
synaptogenesis (Kayser et al., 2008). As neurons and synapses mature, EphB is
no longer required to maintain normal numbers of established synapses (Kayser
et al., 2008). However, EphB2 is still highly expressed in the adult nervous
system (Bouvier et al., 2008), suggesting that it likely has an active role in mature
neurons. We examined the impact of EphB2 on NMDAR surface and synaptic
localization in the mature nervous system. We used an shRNA that targets
EphB2 and has been extensively characterized previously in the following ways:
(1) it has no detectable effects on neurons from EphB1-3 triple knock-out mice;
(2) it causes selective inhibition of EphB2-dependent synapse formation; (3) it
knocks down EphB2 expression with high efficacy in neurons and non-neuronal
cells; and (4) the effects of expressing it can be reversed with expression of
EphB2 constructs rendered insensitive to the shRNA by the introduction of silent
mutations (Kayser et al., 2006; Kayser et al., 2008). Previous work using this
shRNA has shown that knockdown of EphB2 in cortical neurons at either 3 or 10
DIV leads to a robust decrease in synapse number at 21 DIV, whereas later
knockdown of EphB2 from 14–21 or 14–24 DIV has no effect on synapse number
(Kayser et al., 2008). Importantly, knockdown at each of these times leads to
similar decreases in EphB2 expression.
To selectively determine how changes in EphB2 expression later in
neuronal development affect NMDAR localization in mature neurons, we first
used immunohistochemical methods in cultured cortical neurons. Neurons were
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transfected with enhanced green fluorescent protein (eGFP) and shRNA vector
(control), EphB2.1 shRNA, or EphB2.1 shRNA with rescue at 14 DIV. We
rescued EphB2 knockdown with a shRNA-insensitive EphB2 construct—an
approach that generates functional overexpression (McClelland et al., 2010;
McClelland et al., 2009). We used this approach to control the amount of EphB2
expressed in neurons. At 21 DIV, neurons were processed to determine the
amount of NR1 labeling at synapses. In these experiments, we focused on NR1
immunolabeling because (1) this subunit is present in all NMDARs (Cull-Candy
and Leszkiewicz, 2004), (2) EphB directly binds NR1 through an interaction
involving extracellular domains (Dalva et al., 2000), and (3) the anti-NR1
antibody most reliably colocalizes with other presynaptic and postsynaptic
marker proteins (data not shown). Synapses were defined as locations where
NR1 puncta (red) colocalized with GFP-positive dendrites (green) within <1 μm of
anti-vGlut1-positive puncta (blue) (Figure 5.1A-C). We determined the size and
intensity of NMDAR staining at each synapse. Although there were no effects on
the size of the NMDAR puncta, functional overexpression and knockdown of
EphB2 did alter the amount of NMDAR localized at synapses as measured by
the normalized intensity of synaptic puncta. We plotted the cumulative probability
distribution of the amount of NMDAR staining at synaptic sites and found that
knockdown of endogenous EphB2 caused a decrease in the amount of NR1 at
synapses, whereas functional overexpression of EphB2 in the context of EphB2
knockdown resulted in a marked increase in synaptic NR1 (Figure 5.1D)
[Kolmogorov–Smirnov (K-S) test, p < 0.001]. More specifically, EphB2
174

knockdown caused a preferential reduction in the number of synapses with large
amounts of NR1. Conversely, functional overexpression of EphB2 resulted in a
preferential increase in the number of synapses with smaller amounts of NR1.
We next determined whether there were any differences between the effects of
EphB2 manipulation on shaft and spine synapses. Analysis revealed that EphB2
knockdown or overexpression resulted in similar changes in the amount of
NMDAR content at both shaft and spine synapses (Figure 5.1E, F) (K-S test, p <
0.001). Consistent with the role of EphB2 in control of dendritic spine shape in
mature neurons, changes in the amount of NR1 at spine synapses were larger
after EphB2 overexpression than the changes seen at shaft synapses. Together,
these results suggest a role for EphB2 in directing or maintaining NMDARs at
mature synapses.
To examine the functional significance of these immunohistochemical
findings, we next measured spontaneous miniature EPSC (mEPSC) frequency in
cultured cortical neurons at 21 DIV after endogenous EphB2 knockdown with or
without expression of our EphB2 rescue construct at 14 DIV. As expected from
previous work (Kayser et al., 2008), knockdown or functional overexpression of
EphB2 at 14–21 DIV resulted in no change in mEPSC frequency (Figure 5.2A,
C), confirming that EphBs are not likely to be important for the maintenance of
overall excitatory synapse number in mature neurons. To determine whether
modulation of EphB2 expression levels impacts synaptic receptor content, we
studied mEPSC amplitude. To isolate glutamatergic mEPSCs, whole-cell patchclamp recordings were conducted in Mg2+-free solutions to increase NMDAR175

mediated currents in the presence of tetrodotoxin and blockers of GABAergic
channels (see Materials and Methods). Although neither knockdown nor
functional overexpression of EphB2 changed excitatory synapse number,
functional overexpression of EphB2 did result in a significant increase in mEPSC
amplitude (Figure 5.2B, D, E) (control, −15.45 ± 0.14 pA; EphB2, −22.79 ± 0.37;
K-S test, p < 0.001). Similar changes in mEPSC amplitude were found in an
independent series of experiments in which we overexpressed wild-type EphB2
without knockdown, in the presence of the endogenous protein (Figure 5.3). The
small size of the NMDAR-dependent component of mEPSCs in cultured neurons
(2–3 pA) prevents reliable isolation of this current alone. Therefore, to examine
whether EphB-dependent changes in mEPSC amplitude are attributable to
increased recruitment of NMDARs to synapses, we recorded from neurons in the
presence or absence of the NMDAR antagonist APV (50–100 μm), applied via
the bath perfusate. We found that NMDAR blockade significantly reduced
mEPSC amplitude in all conditions (control, EphB2.1 shRNA, or functional
EphB2 overexpression). To estimate the average NMDAR component of the
mEPSC, we measured the difference between mean mEPSC amplitude before
and after APV blockade. The estimated NMDAR component was

60% larger

than control when EphB2 was functionally overexpressed [control, 3.13 pA;
EphB2 overexpression (OE), 4.98 pA] (Figure 5.2B, D), indicating that the level
of EphB2 expression might determine the amount of NMDARs at synapses.
These findings were confirmed by cumulative probability histograms of mEPSC
amplitude demonstrating that functional overexpression of EphB2 results in an
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increase in the NMDAR-dependent component of mEPSCs (Figure 5.2E).
Functional overexpression of EphB2 also appeared to increase the AMPARdependent component of mEPSCs, assessed by measuring mEPSCs in the
presence of APV for all three conditions. These findings are consistent with
previous work showing that EphB2 can regulate AMPAR retention in the
recycling pool through its PDZ binding domain (Kayser et al., 2006). Although
there appears to be a change in the AMPAR component, we focused on the role
of EphB2 in the regulation of the NMDAR in this study because of the importance
of this interaction in human disease (Cisse et al., 2011).
NMDARs contribute significantly to the decay component of synaptic
currents, and thus measuring changes in these currents provides a sensitive
measure for the presence of these channels at synapses. We found that,
compared with controls, the average decay time (from peak to 30% amplitude) in
neurons where EphB2 was functionally overexpressed was significantly longer,
whereas knockdown of EphB2 resulted in a significant shortening of the average
decay time. After blocking NMDARs with the antagonist APV, significantly shorter
decay times were seen for all conditions (Figure 5.3C) (control, 5.88 ± 0.06 ms;
control plus APV, 4.66 ± 0.05; EphB2.1 shRNA, 5.60 ± 0.06; EphB2.1 plus APV,
4.96 ± 0.06; functional EphB2 OE, 7.32 ± 0.10; functional EphB2 OE plus APV,
6.17 ± 0.08; ANOVA, p < 0.001). To further examine these data, we plotted
cumulative probability distributions of the decay times for mEPSCs in control,
knockdown, and functional overexpression conditions that represent all the
measured decay times in our data set (Figure 5.3D, E). We found that before
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blocking NMDARs with the antagonist APV, control and EphB2-overexpressing
cells exhibit a larger proportion of mEPSCs with longer decay times, whereas
EphB2 knockdown substantially reduces the fraction of events with longer decay
times (Figure 5.3C-E). Specifically, in neurons expressing EphB2 shRNA,
of events have decay times of >10 ms; in control neurons,
group; in neurons overexpressing EphB2,

5%

10% fall into this

15% of events have decay times of

>10 ms (Figure 5.3D, E). The difference between decay times in the control and
EphB2 knockdown conditions were mostly eliminated by pharmacologic NMDAR
blockade. Interestingly, the decay times of mEPSCs recorded from neurons
functionally overexpressing EphB2 were longer than those of events in control or
EphB2 knockdown neurons even in the presence of NMDAR blockade. These
effects are most consistent with a change in AMPAR subunit composition at
synapses, although additional work will be needed to determine whether this is
the case. Regardless, our findings indicate that EphB2 expression levels might
bidirectionally modulate the synaptic localization of NMDARs.
To further examine the role of EphB2 in the control of NMDAR trafficking,
we recorded from neurons held at +50 mV to remove Mg2+ voltage-dependent
blockade of the NMDAR. In these experiments, we overexpressed EphB2 alone,
without expression of shRNAs targeting EphB2. Consistent with our findings from
functional overexpression of EphB2 in the presence of EphB2 shRNA (Figure
5.2), overexpression of EphB2 without knockdown resulted in a significant
increase in mEPSC amplitude, whereas knockdown resulted in a reduction in
mEPSC amplitude (control, 12.35 ± 0.23 pA, n = 957 events/9 neurons; EphB2
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shRNA, 11.53 ± 0.19 pA, n = 1189/11; EphB2 OE, 15.44 ± 0.29 pA, n = 795/5;
ANOVA, p < 0.01). To isolate the NMDAR component, neurons were held at +50
mV in the presence of TTX (1 μm), bicuculline (50 μm), and picrotoxin (10 μm).
Using established methods (Myme et al., 2003), we examined the NMDAR
component of mEPSCs by taking the average current 10–15 ms after the initial
rise phase of each mEPSC (a time when the AMPAR-dependent current has
already decayed). We found that knockdown of EphB2 resulted in a significant
decrease in the NMDAR-dependent component of the mEPSCs, whereas
overexpression of EphB2 resulted in a significant increase (Figure 5.3F, G)
(control, 2.09 ± 0.13 pA, n = 368 events/6 cells; EphB2 shRNAi, 1.74 ± 0.11 pA,
n = 744/11; OE, 2.83 ± 0.08 pA, n = 1247/9; ANOVA, p < 0.01). To test whether
the effects of EphB2 overexpression might be linked to the recruitment of a
specific NMDAR subunit, we treated neurons with an NR2B-selective NMDA
receptor antagonist, Ro25-6981 (1–2 μm), and measured the percentage change
in mEPSC amplitude. The NMDAR-dependent component of mEPSCs was
reduced significantly ( 25%) by the selective antagonist in neurons transfected
with EphB2 compared with control transfected neurons (control, n = 5 cells;
EphB2 OE, n = 5 cells; ANOVA, p < 0.03) (data not shown), suggesting that
EphB2 overexpression increases the amount of NR2B-containing NMDARs
found at synapses. We also conducted analysis of the decay times of mEPSCs
recorded at +50 mV. Consistent with the effects observed at −65 mV, we found
that EphB2 knockdown reduces the decay time, whereas overexpression of
EphB2 causes a marked increase in the decay time of mEPSCs (control, 6.36 ±
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0.19; EphB2.1 shRNA, 5.52 ± 0.14; EphB2 OE, 7.35 ± 0.16; ANOVA, p < 0.001)
(data not shown). Together, our experiments demonstrate that, in mature
neurons, EphB2 expression levels regulate the localization of NMDARs at
synapses and their contribution to synaptic currents.
We investigated whether EphB signaling might modulate NMDAR function
and localization in a subunit-specific manner. Activation of endogenous EphB
receptors with soluble ephrin-B ligand results in an interaction between EphBs
and NMDARs followed by phosphorylation of the NR2B subunit and increased
NMDAR-dependent Ca2+ influx (Takasu et al., 2002). The mechanism through
which this increased calcium influx occurs is unknown. To both test whether this
functional modification is subunit specific and determine the underlying
mechanism, we coexpressed EphB2 with NR1-1a and either NR2A or NR2B
subunits in HEK-293 cells (Zukin and Bennett, 1995). We examined whether the
EphB–NMDAR interaction specifically alters NMDAR channel function by
recording NMDA-evoked currents from transfected HEK-293 cells using the
whole-cell patch-clamp method described in detail previously (Skeberdis et al.,
2006; Zheng et al., 1997). Briefly, in control cells held at −60 mV, application of
NMDA (300 μm) with glycine (10 μm) for 5 s by laminar flow elicited an inward
current that rapidly declined to a steady-state value (Legendre et al., 1993;
Skeberdis et al., 2006; Tong et al., 1995; Zheng et al., 1997; Zorumski et al.,
1989). Measurements were made from the average of two to three trials per cell.
In cells transfected with EphB2, NR1-1a, and NR2B, the peak amplitude was not
significantly altered but the desensitization/inactivation in the NMDA response
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was greatly reduced (Figure 5.4A). These effects required EphB kinase activity,
as NMDAR currents in HEK-293 cells cotransfected with a kinase-dead form of
EphB2 were normal. The absence of an effect with the kinase-dead mutant is not
simply attributable to a disrupted interaction between EphB and NMDARs, as
previous work has shown this mutant and the NMDAR still interact through their
extracellular domains (Dalva et al., 2000). In cells transfected with EphB2, NR11a, and NR2A, we found no significant difference in NMDA-evoked currents
compared with control cells transfected with only NR1 and NR2A (Figure 5.4B).
These

results

suggest

that

EphB2

preferentially

modulates

desensitization/inactivation of NMDARs containing NR2B subunits, and that the
enhanced Ca2+ influx through NMDARs occurs by altering the kinetics of the
channel in a kinase-dependent manner.
Activation of EphBs results in phosphorylation of the NR2B subunit at
Y1472 (Takasu et al., 2002), which in turn controls the internalization and
localization of NR2B-containing NMDARs (Chen and Roche, 2007; Lavezzari et
al., 2003; Prybylowski et al., 2005). Given the subunit-specific modulation of Ca2+
desensitization/inactivation in NR2B-containing NMDARs by EphB2,

we

examined whether EphB2 activation might preferentially control NR2B surface
localization. We studied NMDAR subunit trafficking/localization with surface
biotinylation experiments in cultured cortical neurons after treatment with control
or activated ephrin-B2 at different times during development. Biotinylated surface
proteins were pulled down and the fraction of the total protein labeled with biotin
determined by Western blot analysis. Only samples lacking detectable actin in
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the biotinylated fraction were included for additional analysis. We conducted
these experiments at 7, 14, and 21 DIV—times when cultured cortical neurons
have just entered a period of rapid EphB-dependent synapse addition (7 DIV),
just ended the period of rapid synapse addition (14 DIV), or when synapses have
matured (21 DIV) (Kayser et al., 2006). At each time point, NR2B was found on
the cell surface under control conditions (Figure 5.5). We then asked whether 45
min to 1 h of ephrin-B2 treatment might alter the surface localization of the
NMDAR. We compared the fraction of total NR2B with biotin before and after
ephrin-B2 treatment. At 7 DIV, ephrin-B2 treatment failed to induce a significant
increase in the surface localization of NR2B. In contrast, at 14 and 21 DIV, when
EphB is no longer required for synapse addition or to maintain normal numbers
of functional synapses, ephrin-B2 treatment induced a significant increase in
NR2B surface expression (Figure 5.5). These results show that activation of
EphB2 increases NR2B on the cell surface of neurons and confirm that EphB2
undergoes an age-dependent change in the control of NR2B trafficking.
To determine whether EphB also controls the localization of specific
NMDAR subunits in organized neural tissue, we examined the surface
expression of the NMDAR in acute brain slices from TKO mice lacking EphB1–3.
We chose to examine TKO animals because the presence of any EphB family
members often masks the effects of genetic loss of one or two EphBs
{Henkemeyer, 2003 #32; Kayser, 2006 #7. Indeed, throughout our experiments,
we failed to detect effects on NMDAR localization in DKO mice lacking EphB1
and 3, which maintain normal EphB2 function (Figures 5.6-5.9). To investigate if
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the trafficking and localization of NMDARs is disrupted after the loss of EphB
expression, we made hippocampal or cortical brain slices from wild-type, DKO, or
TKO mice. The brain slices were then incubated live with Sulfo-NHS-SS-biotin
(Pierce Protein Research Products; Thermo Fisher Scientific) on ice, and tissue
was processed to determine the surface fraction of the NMDAR using methods
similar to those for the cultured cortical neurons.
Cortical and hippocampal brain slices were collected and labeled in
parallel. Surprisingly, surface and total expression of the NR2B subunit of the
NMDAR was increased significantly in TKO mice compared with controls (Figure
5.6A, E-G). NR2A and NR1 expression were unchanged in cortex in the absence
of EphBs, although the variability in this data set was large for NR1 (Figure 5.6AD, Figure 5.8). These findings were not mirrored in hippocampus, where total
NR2A levels were reduced and surface NR2B increased in TKO compared with
WT (Figure 5.7); surface levels of NR1 were also significantly reduced in
hippocampus of TKO mice (Figure 5.8). These effects suggest that the role of
EphBs may differ between different brain regions and that the interaction
between EphBs and NMDARs is more complex than simple recruitment or
retention of NMDARs on the cell surface, in which case we would expect NR2B
surface localization to be decreased in the absence of EphBs.
One possible explanation for the paradoxical increase in NR2B total and
surface expression in the absence EphBs is that homeostatic mechanisms lead
to upregulated expression and surface delivery because of a specific deficiency
of NR2B at synapses. EphBs are localized to the postsynaptic complex at mature
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synapses, and we have shown that increased expression or activation of EphB2
increases the amount of NR2B on the cell surface and NMDARs at the synapse
in vitro (Figures 5.1-5.3). Thus, we tested whether EphBs might help to direct
NMDARs to synaptic sites in vivo. Using fractionation experiments, we compared
the normalized amount of NMDAR found in the crude membrane fraction (P1)
and at synaptosomes (Syn) from EphB DKO, TKO, and control WT mice by
quantifying the amount of specific proteins by Western blot. The P1 fraction is
enriched for all membranes, whereas the synaptosomal fraction is enriched for
synaptic components. As expected, synaptic proteins such as NR1, GluR1, PSD95, and EphB2 were enriched in the Syn versus the P1 fraction from WT mice
(Figure 5.9A). We then asked whether loss of the EphB proteins would disrupt
the synaptic localization of the NMDAR. In the DKO mice lacking EphB1 and 3,
NR2B expression and synaptic localization did not differ from wild-type animals,
and we did not detect changes in the other synaptic proteins examined.
However, TKO brains showed a significant decrease in the fraction of NR2B
subunits at synapses (Figure 5.9A, D). Interestingly, there was also reduced
localization of NR2A subunits at synapses in TKO brains (Figure 5.9A, C).
Consistent with the direct nature of the EphB–NMDAR interaction, the loss of
EphBs did not alter the localization of other synaptic components such as PSD95 and GluR2 (Figure 5.9A, E). Together with the biotinylation experiments,
these findings suggest that EphBs direct the NR2B subunit to synaptic sites, and
in the absence of EphBs, neurons unsuccessfully attempt to compensate,
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resulting in increased overall expression and nonsynaptic surface expression of
the NR2B subunit.
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Discussion
Multiple mechanisms contribute to the tightly regulated yet dynamic
control of NMDAR trafficking. Here, we provide evidence that the EphB2 receptor
tyrosine kinase is also an important regulator of synaptic NMDAR localization,
but preferentially at mature contacts. Our results indicate that expression levels
of EphB2 in mature cells can determine NMDAR content at synapses without
impacting synapse number. We also find that EphB2 kinase activity specifically
reduces the temporal decline of the NR2B subunit-mediated currents, resulting in
prolonged currents and increased Ca2+ influx. In the absence of EphBs, total
NR2B abundance and surface NR2B expression is increased, whereas synaptic
expression is decreased, indicating mistargeting of this subunit without EphB
signaling. These findings extend previous work demonstrating that EphB2 binds,
clusters, and increases Ca2+ flux through NMDARs in young neurons {Dalva,
2000 #9; Takasu, 2002 #8}, and suggest that the EphB–NMDAR interaction is
significant throughout multiple phases of development and particularly in the
mature brain.
We find an age-dependent change in how EphBs modulate NMDAR
activity. Early in development, EphBs are essential for the formation of normal
numbers of excitatory synaptic connections made on dendritic spines (Kayser et
al., 2008). During this time period, activation of EphB does not appear to
increase recruitment of NR2B subunits to the cell surface. As neurons mature,
EphBs are no longer required to maintain normal numbers of functional excitatory
synapses but function to control the number of NMDARs localized to synaptic
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sites. These results begin to answer the question posed by in vitro work
indicating distinct mechanisms of NMDAR recruitment at differing neuronal ages
(Bresler et al., 2004; Washbourne et al., 2002). Moreover, our data indicate that
EphB specifically regulates trafficking of NR2B subunits in mature neurons,
although our results do not exclude the possibility that EphBs play some role in
NR1 and NR2A localization as well. Localization of the NR2B subunit of the
NMDAR is of particular interest, as the proportion of NR2B-containing receptors
can affect NMDAR channel open time and Ca2+ flux. Recent work has shown that
phosphorylation of NR2B by casein kinase 2 (CK2) at a distinct site from EphBdependent phosphorylation leads to NR2B endocytosis and increased NR2A
expression (Sanz-Clemente et al.). The interplay between CK2 and EphB2
activity on NR2B, leading to endocytosis or retention, respectively, would be a
sensitive mechanism for determining NR2B content at synapses. Functional
consequences of increased NR2B content at synapses in certain areas of brain
are known to include improved performance on memory tasks and enhanced
visuocortical plasticity (Philpot et al., 2007; Tang et al., 1999). During normal
development, the ratio of NR2A/NR2B at synapses increases over time ((Sheng
et al., 1994), raising the threshold for long-lasting changes in synaptic strength in
response to external stimuli (Philpot et al., 2007). Given that EphBs serve to
drive NR2B into synapses only later in development, one interpretation of our
data is that EphBs define mature synapses with a relatively low NR2A/NR2B
ratio. These inputs would remain more plastic in the adult brain, with a lower
threshold for long-term potentiation (LTP). Consistent with this role for EphBs in
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maintaining or generating plastic synapses, EphB2 knock-out mice have reduced
LTP, long-term depression (LTD), and quality of performance in the Morris water
maze (Grunwald et al., 2001; Henderson et al., 2001). Although one feature of
mature neurons by virtue of a higher NR2A/NR2B ratio is an increased selectivity
for specific stimuli, it is clear that, even in the adult CNS, some inputs remain
remarkably malleable (Holtmaat and Svoboda, 2009). Future work will need to
specifically examine whether and how EphBs contribute to this sustained
plasticity.
Two likely mechanisms mediating EphB-dependent control of synaptic
localization of NMDARs are the direct EphB–NMDAR interaction and EphBdependent phosphorylation of NR2B. We showed previously that ephrin-B
activation of EphB2 results in the direct interaction of the NMDAR with EphB2
and the phosphorylation of three tyrosine residues on the NMDAR (Dalva et al.,
2000; Takasu et al., 2002). One of the phosphorylated residues, Y1472, has
since been shown to be important for the synaptic localization and retention of
NMDARs, acting to prevent binding of AP-2 that in turn targets proteins for
internalization by clathrin-mediated endocytosis (Chen and Roche, 2007;
Lavezzari et al., 2003). Notably, there is a significant reduction in the level of
NR2B phosphorylated at Y1472 found at synapses in EphB TKO brains
compared with controls (data not shown). Although the magnitude of this change
is matched by the decrease in total NR2B at synapses in TKOs, these data are
consistent with a model in which EphB2 regulates retention of the NMDAR at
synapses by phosphorylating the NR2B subunit at Y1472. In the absence of
188

EphBs, more NR2B is endocytosed, triggering the homeostatic drive of neurons
to deliver more NR2B to synapses. This drive appears to fail in the absence of
EphBs, as NR2B total and surface expression increase without effective synaptic
delivery. Thus, the EphB–NMDAR interaction likely has a role in synaptic
targeting of NMDARs in addition to retention. The loss of EphBs also results in
decreased NR2A at synapses. This effect could be attributable to the direct
interaction between EphB2 and the NMDAR or to the previously described
phosphorylation of the NR2A subunit. Importantly, we cannot rule out a role for
the direct EphB–NMDAR interaction in the synaptic localization of the NMDAR. In
fact, the EphB–NMDAR interaction is likely to be central to the ability of EphB2 to
specifically phosphorylate NR2 subunits, making it difficult to distinguish effects
of the physical interaction and kinase activation.
Although EphBs are important for the proper localization of NMDARs to
synapses, they are not essential for all NMDARs to localize properly, nor for all
facets of NR2B trafficking. These conclusions are consistent with the observation
that EphBs direct formation of a subset of excitatory synapses (Kayser et al.,
2006) and our new findings that EphBs control a substantial fraction ( 50%) of
NMDAR localization to mature contacts. Although additional research is needed
to characterize the significance of this subpopulation, loss of EphB2 causes
abnormal LTP and LTD in mouse hippocampus (Grunwald et al., 2001;
Henderson et al., 2001), suggesting a functionally important role. Other proteins
are undoubtedly required in these events as well, however, and synaptic
transmission still occurs. For example, neuroligins (NLGs) cluster NMDARs and
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signal to regulate excitatory synapse maturation (Chih et al., 2005; Graf et al.,
2004); more recent work suggests that loss of NLG1 results in reduced NMDAR
expression and NMDAR-mediated synaptic transmission in hippocampus
(Chubykin et al., 2007). These findings are similar to those for EphBs and
suggest that both EphBs and NLGs, and very likely others, impact NMDAR
localization at synaptic sites.
In addition to the effects that we observe on NMDAR localization and
function, our analysis of mEPSCs reveals a change in the AMPAR-dependent
component of synaptic currents (Figures 5.2, 5.3). This finding is consistent with
previous work showing that EphB2 activation can increase the surface
localization of the AMPAR via PDZ domain-dependent interactions (Irie et al.,
2005; Kayser et al., 2006). However, our biotinylation and fractionation
experiments in EphB TKO mice failed to detect changes in the localization of the
GluR2 subunit of the AMPAR compared with controls. Thus, it appears possible
that, although EphB2 overexpression results in increased AMPAR-dependent
currents at synapses, mice lacking EphBs fail to show changes in the synaptic
localization of GluR2. EphBs are therefore unlikely to regulate AMPAR function
by simply controlling the overall amount of AMPARs at synapses. EphB2
associates with AMPAR-interacting proteins PICK1 and GRIP (Torres et al.,
1998), which are important for trafficking of specific AMPAR subunits to
synapses (Gardner et al., 2005; Liu and Cull-Candy, 2005). As with NMDARs,
different AMPAR subunit combinations confer distinct channel properties (Greger
and Esteban, 2007; Isaac et al., 2007). Thus, one interesting possibility is that
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the EphB2-dependent changes in AMPAR current we observe (Figures 5.2, 5.3)
are attributable to modulation of AMPAR subunit ratios at synapses rather than
changes in overall AMPAR content. Additional work will be needed to determine
the mechanisms by which EphBs regulate AMPAR synaptic currents.
In addition to their role in the localization of NMDARs, EphBs modulate
NMDAR-mediated

calcium

flux

through

Src

family

kinase-dependent

phosphorylation of NR2B. This enhanced calcium influx is likely mediated by a
reduction in the rate of calcium-dependent inactivation in NMDAR channels that
contain the NR2B subunit, although in our current analysis we cannot rule out a
role for glycine-independent desensitization. Importantly, the effects of EphB2
appear selective for NR2B, as a similar change in time course is not found in
NMDAR channels containing the NR2A subunit. Yet previous work has
suggested

that

ephrin-B

activation

of

EphB

may

increase

tyrosine

phosphorylation of not only NR2B subunits but also NR2A subunits (Grunwald et
al., 2001; Takasu et al., 2002). The functional significance of EphB2/NR2A
interactions has yet to be extensively examined, but given that EphB2 does bind
to NR2A (Dalva et al., 2000), future investigation into whether EphBs modulate
NR2A function will be of interest.
The expression level of EphBs has recently been shown to be
downregulated in models of Alzheimer's disease (Simon et al., 2009), and
phosphorylation of NMDARs is reduced in brains of Alzheimer's disease patients
relative to controls (Sze et al., 2001). One intriguing possibility is that the late
function of EphBs in synaptic localization of NMDARs may be relevant to
191

neurodegenerative diseases. Consistent with this hypothesis, both ephrin-Bs and
EphBs undergo posttranslational modification via γ-secretase activity (Litterst et
al., 2007; Tomita et al., 2006), and overexpression of EphB2 has recently been
shown to rescue cognitive defects in a mouse model of Alzheimer's disease
(Cisse et al., 2011). Additional work will be needed to determine how EphBs and
their ligands are linked to Alzheimer's and other diseases, but the recruitment to
and modulation of NMDARs at synapses is likely a key part of any potential role.
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Figure Legends.

Figure 5.1. EphB2 regulates localization of NMDAR receptors to synapses
in mature cortical neurons. A–C, Confocal microscopy maximum projection
images of cultured cortical neurons at 21 DIV expressing eGFP and shRNA
vector (control), EphB2.1 shRNA, or EphB2.1 shRNA plus “rescue” EphB2
(functional EphB2 OE), immunostained for GFP (green), NR1 (red), and the
presynaptic marker vGlut (blue). The magnified sections (top) of high-contrast
image with arrows show spine (yellow arrows) and shaft (white arrows)
synapses, defined as the locations where NR1, GFP, and vGlut immunostaining
colocalize. The bottom panels show same region with anti-NR1 staining in red.
D–F, Cumulative probability histograms of synaptic NR1, NR1 at spine synapses,
and NR1 at shaft synapses. Functional EphB2 OE using a rescue construct in
the context of endogenous EphB2 knockdown caused a significant increase in
the amount of NR1 colocalizing with vGlut, whereas knockdown of EphB2
resulted in a decrease (Kolmogorov–Smirnov test, p < 0.001). Amount of NR1 for
each condition is normalized to the maximum intensity observed from all three
conditions. Control, n = 27 cells, 432 synapses; EphB2.1 shRNA, n = 27, 359;
functional EphB2 OE, n = 21, 319.

Figure 5.2. EphB2 expression regulates mEPSC amplitude but not
frequency in mature cortical neurons. Whole-cell patch-clamp recordings were
made from 21–23 DIV cultured rat cortical neurons expressing eGFP and
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shRNAi vector (control; blue), EphB2 shRNA (EphB2.1 shRNA; red), or EphB2.1
shRNA plus “rescue” EphB2 (functional EphB2 OE; green). Recordings were at
−65 mV in Mg2+-free solution. A, Example whole-cell patch-clamp recordings
from cortical neurons in each condition; functional EphB2 OE neurons (row 3)
show occasional miniature synaptic events at higher amplitude (left) that are
blocked by the NMDAR antagonist APV (right). B, Mean traces of mEPSCs after
NMDAR blockade with APV. Control: n = 5 cells without APV, 2298 mEPSCs; n =
5 cells with APV, 2490 mEPSCs; EphB2 shRNA: n = 5 cells without APV, 2528
mEPSCs; n = 5 cells with APV, 2040 mEPSCs. Functional EphB2 OE: n = 3 cells
without APV, 1037 mEPSCs; n = 3 cells with APV, 1052 mEPSCs. C, No change
in mEPSC frequency was observed for any condition (ANOVA, p > 0.05). D,
Quantification of mean mEPSC amplitude before and after application of 50–100
μm APV. An increase in mEPSC amplitude was observed with functional
overexpression of EphB2, whereas NMDAR blockade with APV significantly
reduced mEPSC amplitude for all conditions (ANOVA, *p < 0.01, **p < 0.001). E,
Cumulative probability histograms of mEPSC amplitude for each condition. Error
bars indicate SEM.

Figure 5.3. EphB2 regulates synaptic localization of functional NMDARs in
mature cortical neurons. Whole-cell patch-clamp recordings were made from
21–23 DIV cultured rat cortical neurons expressing eGFP and shRNA vector
(control; blue), EphB2 shRNA (EphB2.1 shRNA; red), or EphB2 shRNA plus
“rescue” EphB2 (functional EphB2 OE; green) (A–E). A, Mean traces of EPSCs
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for each condition. B, Sample trace of whole-cell patch-clamp recording
illustrating decay time. Decay time was calculated as the time from peak
amplitude of the current to 30% of the peak amplitude, indicated by the arrows.
C, Quantification of average decay time for each condition. D, E, Cumulative
probability histograms of mEPSC decay times for each condition, plotted together
(D) and individually for clarity (E). Control/EphB2.1 shRNA, p < 0.05; EphB2.1
shRNA/functional EphB2 OE, p < 0.0001; without APV/with APV, p < 0.0001 for
all conditions; control with APV/functional EphB2 OE with APV, p < 0.0001;
EphB2.1 shRNA with APV/functional EphB2 OE with APV, p < 0.0001; K-S tests;
N as in Figure 5.1. These findings indicate that the slow NMDAR component of
mEPSCs is reduced by EphB2 knockdown (EphB2.1 shRNA) and increased
when EphB2 is functionally overexpressed (EphB2.1 shRNA plus “rescue”
EphB2). F, Whole-cell patch-clamp recordings were made from 21–23 DIV
cultured rat cortical neurons expressing eGFP and vector (control; blue),
EphB2.1 shRNA (red), or EphB2 (EphB2 OE; green). Normalized amplitude plot
of the mean mEPSCs recorded at +50 mV in control, EphB2 shRNA, and EphB2
OE neurons. G, Quantification of NMDAR component of the mEPSCs recorded
at +50 mV in the presence of Mg2+ (control, n = 368 events/6 cells; EphB2
shRNAi, n = 744/11; EphB2 OE, n = 1247/9). *p < 0.05, **p < 0.001, ANOVA.
Error bars indicate SEM.

Figure 5.4. EphB2 attenuates Ca2+-dependent desensitization of NR2B- but
not NR2A-containing NMDARs. A, Top, NMDA-elicited currents recorded from
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HEK-293 cells expressing NR1-1a/NR2B receptors in the absence (left) or
presence of EphB2 (center), or the kinase-dead mutant EphB2-KD (right).
Recordings at −60 mV in Mg2+-free solution. Bottom, Summary data showing
peak current, steady-state current, and Ca2+-dependent desensitization of NMDA
current (quantified as 1 − steady-state current/peak current × 100) (n = 8, 9, and
7 for cells in the absence of cotransfected EphB2, presence of EphB2, or EphB2KD, respectively). B, Top, NMDA-elicited currents recorded from HEK-293 cells
expressing NR1-1a/NR2A receptors in the absence (left) or presence (right) of
EphB2. Bottom, Summary data showing peak current, steady-state current, and
Ca2+-dependent desensitization of NMDA current [n = 10 and 8 cells (3
independent experiments) in the absence or presence of EphB2, respectively]. *p
< 0.05, **p < 0.01. Error bars indicate SEM.

Figure 5.5. Ephrin-B2 activation of EphB2 increases NR2B surface
localization. A–C, Cortical neurons at 7 DIV (A), 14 DIV (B), or 21 DIV (C) were
treated for 45 min with control Fc (C) or activated ephrin-B2-Fc (eB2).
Biotinylated (surface) and total NR2B protein was visualized by immunoblotting
with specific antibodies (top gels). β-Actin was used as a loading control for total
protein (bottom gels). Absence of actin in surface (biotinylated) gels indicates
validity of surface labeling. Representative immunoblots show no actin
immunolabeling in the biotinylated surface fraction. The bottom bar graphs show
the ratio of amount of surface NR2B to total NR2B at 7 DIV (n = 5 experiments),
14 DIV (n = 6 experiments), or 21 DIV (n = 6 experiments). Ephrin-B2-Fc versus
196

Fc (control) conditions were analyzed by an unpaired t test. *p < 0.05. Error bars
indicate SEM.

Figure 5.6. Surface and total NR2B expression levels are increased in the
cortex of EphB1−/−, 2−/−, 3−/− TKO mice. A, Representative Western blots
depicting NR2A and NR2B surface expression (left) and total expression (right) in
WT, EphB1−/−, 3−/− DKO, and TKO mice. B–D, Quantification of NR2A surface,
total, and surface/total expression. E–G, Quantification of NR2B surface, total,
and surface/total expression. Values were normalized to DKO (n = 6, 9, and 7
animals for WT, DKO, and TKO, respectively). *p < 0.05, **p < 0.01. Error bars
indicate SEM.

Figure 5.7. NR2B surface expression is increased and total NR2A levels are
decreased in the hippocampus of TKO mice. A, Left, Representative Western
blots depicting NR2A and NR2B surface expression in WT, EphB DKO, and
EphB TKO mice. Right, Western blots showing total expression of NR2A and
NR2B in WT, EphB DKO, and EphB TKO mice. Actin was used as a loading
control in total protein fraction and as a control for surface staining in surface
fraction. B, Quantification of NR2A and NR2B surface, total, and surface/total
expression. Values are normalized to DKO (n = 6, 9, and 7 animals for WT, DKO,
and TKO, respectively). *p < 0.05, **p < 0.01, ANOVA. Error bars indicate SEM.
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Figure 5.8. NR1 surface expression is decreased in hippocampus of TKO
mice. Top left, Western blot illustrating surface and total NR1 expression in
cortex of WT, EphB DKO, and EphB TKO mice. Top right, Western blot depicting
surface and total NR1 levels in hippocampus of WT, EphB DKO, and EphB TKO
mice. Actin is shown as a loading control in total protein fraction and as a control
for surface staining in surface fraction. Below, Quantification of NR1 surface,
total, and surface/total levels in cortex and hippocampus of WT, EphB DKO, and
EphB TKO mice. Values are normalized to WT (n = 2 animals each for WT, DKO,
and TKO, samples were then divided and labeled with two independent
reactions). *p < 0.05, ANOVA. Error bars indicate SEM.

Figure 5.9. EphB TKO brains exhibit reduced synaptic expression of NR2A
and NR2B. A, Lysates from brains of WT, EphB DKO, and EphB TKO animals
were fractionated to isolate supernatant (S1), crude membrane (P1), and pure
synaptosome (Syn) fractions. Western blots were probed with indicated
antibodies and show enrichment of glutamate receptor subunits in the
synaptosome fraction of all animals. PSD-95 and EphB2 are enriched in the
same fraction. B–E, Syn/P1 ratio was used to compare synaptic versus
nonsynaptic expression of NMDA and GluR2 glutamate receptors subunits.
Compared with the WT and EphB DKO brains, EphB TKO animals exhibit
reduced synaptic expression of NR2A (C) and NR2B (D) subunits of the NMDAR.
There is no change in synaptic expression the GluR2 subunit (E) of AMPA

198

receptors between different genotypes. ANOVA, *p < 0.005; n = 3 animals for
each condition. Error bars indicate SEM.
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